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Abstract 
The thesis describes synthetic studies directed towards the total synthesis of 
14,15-anhydrovirginiamycin M2, a streptogramin antibiotic of the virginiamycin 
family. This novel natural product shows pronounced antibacterial activity against a 
wide range of potentially lethal bacteria. The Introduction summarises the main 
therapeutic uses, isolation, structural determination, biosynthesis, and mode of action 
of the virginiamycins. Also included is a review of synthetic approaches which have 
been described to access these and similar streptogramin antibiotics by other research 
groups. A review of the intramolecular Stille coupling reaction within organic 
synthesis incorporating the most prominent examples of its use over the past ten years 
in the synthesis of natural products is also presented. 
The Discussion part of the thesis contains details of our synthetic studies on 
suitable model systems, including: a study of conjugated triene formation via Stille 
chemistry; peptidic bond formation; and special reference to the problems involved in 
the synthesis of the 2,4-disubstituted oxazole contained within the virginiamycins. The 
studies culminate with a description of the first total synthesis of 14,15- 
anhydrovirginiamycin M2, which proved identical to the natural product obtained from 
a Streptomyces fermentation process. 
A full description of the experimental work carried out, and spectroscopic data 
for all compounds synthesised, is contained in an Experimental section. 
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1. INTRODUCTION 
1.1 Virginiamycin: A General Introduction. 
The virginiamycins, and other related compounds of the streptogramin family 
such as madumycin (2) and griseoviridin (3) (Figure 1), which are produced as 
secondary metabolites by a wide range of Streptoinyces and Actinoplanes, have been 
known since the later half of the 1950's. Their mode of action and their pharmacology 
have been studied extensively since their isolation, but up until the last fifteen years 
there had been relatively few synthetic studies undertaken on these molecules. Their 
unique biological properties as effective antibiotics has led to their continued use in 
General Practice for over thirty years, especially in the treatment of Staphylococcal 
infections, and in the agricultural industry as a growth promoter. Despite its 
effectiveness, virginiamycin* and other related compounds, although finding some 
alternative therapeutic uses have not become more widespread due to their poor water 
solubility and difficulties associated with their assay in the blood. However the 
increase in the incidence of resistant strains of Staphylococcal infections in hospitals 
during the late 1970's, and in particular those strains showing multiple resistance to the 
more commonly used antibiotics, has prompted interest in these compounds once more. 
It is surprising that even today virginiamycin is still one of the most effective antibiotics 
available for the treatment of Staphylococcal infections, and at present is one of the few 
antibiotics effective in the treatment of the new deadly multiple resistant strain of 
Tuberculosis. 
*Where 
virginiamycin is used without a suffix this refers to the mixture of virginiamycin M and S as 
isolated from the fermentation broth. 
1 
0 
O 
kN 
OH 
0 
N 
O 
Virginiamycin Mi (1) 
O 
N OH 
OO 0 
H 
Madumycin 1 (2) 
O 
N OH 
s 
p OH 
QHH 
O 
Griseoviridin (3) 
Figure 1 
Virginiamycin was first isolated from cultures of the soil organism 
Streptomyces Pristinaespiralis by Preud'homme et al in 1955.1 Annual demands for 
virginiamycin haven risen dramatically over the past twenty years and production is 
currently in the hundreds of tons per annum. To accommodate such huge demands 
virginiamycin is produced by fermentation of specially selected high yielding strains of 
Streptomyces Pristinaespiralis. 
As a treatment for staphylococcal infection virginiamycin has several distinct 
advantages over the other MLS (Macrolides-Lincosamides-Streptogramins) antibiotics 
currently used. Virginiamycin shows a low number of incidents of resistant strains of 
Staphylococcus (only 2-3%, including those isolated in hospital environments), 2 good 
general tolerance, a low incidence of allergic reactions associated with their use, and 
good activity against strains of Staphylococcus that show resistance to the more 
commonly used antibiotics (30% of isolated hospital strains of the bacteria show 
2 
resistance to erythromycin and/or methicillin, and penicillin is inactive against 90% of 
the Staphylococcus strains isolated) 
.3 
Since 1980 the use of virginiamycin has been extended to the treatment of not 
only Staphylococcal infection but also the more persistent sexually transmitted diseases 
such as Mycoplasma, Nasseria and Chimydia, 4 and also to the treatment of lung 
infections such as Pneumococcus, Legionnella and Haemophilus. 5 More recently 
studies have found these compounds to be potent gastrin and cholecystokinin 
antagonists. Cholecystokinin antagonists are useful as analgesics and in the treatment 
and prevention of gastrointestinal disorders, and disorders of the central nervous and 
appetite regulatory systems. Gastrin antagonist block the receptors for gastrin therefore 
acting as agents in the treatments of ulcers, tumours and other gastrointestinal 
disorders. 6 
Apart from its therapeutic applications the other main use of virginiamycin is as 
a growth promoter, thus making virginiamycin an important food additive in the animal 
farming industry.? Studies of young pigs fed on an artificial milk diet containing 
virginiamycin, with the emphasis of results purely on the nutritional effects and not any 
underlying clinically associated effects, have shown an increase of 10% in the growth 
rate and 7% in feed conversion. 8 These results were attributed to the following 
identified effects: a change in the distribution of intestinal flora giving rise to a new 
equilibrium of Gram positive flora; a decrease in the microbial production of lactic acid, 
volatile fatty acids, ammonia and amines thereby reducing the toxic effects of these 
breakdown compounds; a saving and optimal availability of glucose and amino acids 
resulting in less wastage; a reduction in the pass through rate of the intestine resulting in 
the increased absorption of protein, fat and carbohydrates; and a direct influence on the 
permeability of the intestinal mucosa. The experiments also showed no sign of 
destruction of the intestinal flora but only changes in the ratio of the different bacterial 
species present. These results have also been found in the case of poultry, and studies 
with other animals have shown virginiamycin to be beneficial in most cases. The 
overall effect of these conditions reduces the metabolism of the bacteria, thus increasing 
3 
the amount of nutrients available for the animal. This property has allowed the use of 
low protein diets, a method for cutting costs in the farming of animal that is becoming 
ever more prevalent. 
The isolated virginiamycin obtained from the fermentation broth comprises two 
groups of synergistic components: 30-40% virginiamycin S (4)- a group B 
streptogramin Figure 2; and 60-70% virginiamycin M (1)- a group A 
streptogramin. 9 Antibiotics of the streptogramin family are an association of two 
groups of compounds: group A streptogramins are polyunsaturated macrolactones; and 
the group B streptogramins are peptidic macrolactones (depsipeptides). Both groups 
contain members differing slightly in substituents, functional moieties and amino acid 
residues. 
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1.2 The Mode of Action and Biological Activity of Virginiamycin. 
Virginiamycin inhibits the multiplication of some procaryotic cells, but has no 
effect on the growth of most eucaryotic cells. It is active against a wide range of Gram 
positive bacteria (especially Staphylococcus) and has also been shown to affect some 
Gram negative bacteria such as Haemophilus. The two components of virginiamycin, 
virginiamycin M and virginiamycin S, are synergistic, i. e. the activity of the mixture is 
ten-fold that of the sum of the activities of the individual components. Virginiamycin S 
is active at about 2 mgL-1 on approximately 70% of the isolated strains of 
Staphylococcus, and virginiamycin M is active at about 1 mgL-t on approximately 80% 
of the isolated strains of Staphylococcus. Each component on its own is bacteriostatic, 
i. e. they prevent the multiplication of the bacterial cells. However, the mixture of both 
of the components has an activity of about 0.1 mgL-t on approximately 97-98% of the 
isolated strains of Staphylococcus, including the multiple resistant strains of 
Staphylococcus aureus. This synergistic behaviour not only increases the spectrum of 
activity and potency of virginiamycin, but renders the mixture bactericidal, i. e. the 
mixture reduces the number of bacterial cells present. '° 
The mode of action of virginiamycin and related compounds has been 
extensively studied. 9' 11 The bacteriostatic activity of the single components can be 
explained as a consequence of cessation of protein synthesis within the bacterial cell, an 
effect produced almost immediately after incubation with the compound. Each 
component binds to the 50S ribosomal subunit arresting protein synthesis by 
preventing the elongation mechanism during the reading of the messenger RNA by the 
ribosome. Thus production of both RNA and DNA in the bacterium is prevented. This 
effect however is reversible unless both components are present. Virginiamycin S 
binds reversibly to the ribosome in a stoichiometric ratio, whereas virginiamycin M 
binds irreversibly when present stoichiometrically. However explanation of the 
bactericidal property of the mixture is still unclear at present. It has also been shown 
that virginiamycin S facilitates the transport of potassium ions across the cell 
5 
membrane, the presence of which has been shown to be essential for the irreversible 
binding of virginiamycin M to the ribosome. 12 
1.3 The Structure of Virginiamycin M. 
Natural virginiamycin M is a mixture of two main components: virginiamycin 
M1 (1) has a dehydroproline ring and constitutes 90-97% of the mixture; and 
virginiamycin M2 (5) containing a fully saturated (D)-proline ring and is present in 3- 
10% depending on the conditions of fermentation. In addition to these two main forms 
of virginiamycin M, several other analogues have also been isolated from various 
strains of Streptomyces, with all three compounds (6)-(8) having also been isolated in 
the fully saturated proline ring forms. 13 Figure 3. 
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The occurrence of both analogues (6) and (7) can be rationalised by the dehydration of 
the secondary alcohol of virginiamycin Mi with analogue (8) presumably resulting 
from a reductive elimination of the secondary alcohol. As before the occurrence of 
these analogues, and the relative percentages in which they are produced, is dependent 
on the conditions of fermentation and the strain of Streptomyces used. 
With a variety of organisms producing various analogues of virginiamycin Ma 
number of different names arose for these compounds. We have used the name 
virginiamycin M, but alternatively this compound can also be referrdd to as 
pristinamycin II, streptogramin A, mikamycin A, ostreogrycin A, synergistin A and 
vernamycin A. To avoid confusion Chemical Abstracts have adopted a numbering 
system that is now recognised by all research groups working on these compounds, 
and it is this method of numbering that shall be used throughout this thesis. Figure 4. 
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The structure of virginiamycin M1 was partially elucidated by Preud'homme et 
al in the laboratories of Rhone-Poulenc in the mid 1960's by the use of classical 
degradation and chemical analysis. lb, is Final structural elucidation was not achieved 
until a few years later by Delpierre et al using spectroscopic methods in conjunction 
with classical chemical analysis. 14 The configuration of the molecule was determined 
in 1974 by Durant et al using X-ray crystallography. Is 
7 
Conformational studies of the crystal structure using computer graphic 
examination has shown the molecule to be fairly compact, with the macrocycle folded 
in two and held by weak hydrogen bonding between the hydrogen at N-8 and 0-38 (a 
distance of 2.6A). The three oxygen atoms 0-34,0-35 and 0-36 are all arranged 
towards one side of the molecule producing a predominately hydrophilic side to the 
molecule. The methyl groups, double bonds and the oxazole nucleus are all arranged 
towards the opposite side of the molecule forming the lipophilic portion of the 
molecule. Further nmr studies, both 1H and 13C, including quantitative NOE 
measurements, indicate the conformation in solution to be very close to that of the 
crystal structure. 16 
1.4 The Biosynthesis of the Virginiamycin M System. 
The biosynthesis of virginiamycin MI (1) has been studied by Kingston et a117 
using feeding experiments with 13C labelled precursors incorporated into the PDT 30 
strain of Streptomyces virginiea. The studies identified six substrates directly used in 
the biosynthetic pathway, i. e. acetate, valine, methyl methionine, serine, proline, and 
glycine. The majority of the virginiamycin M skeleton was found to derive from acetate 
units from the polyketide chain indicated by the incorporation of both 1-13C acetate and 
2-13C acetate at C-5, 
-7, -12, -14, -16, -18, and C-4, -6, -11, -13, -15, -17 
respectively. In addition to this the experiments indicated that C-33, the vinylic methyl 
group, was also derived from an acetate unit via a hitherto unrecognised pathway. The 
authors reasoned that the method by which the C-33 methyl was incorporated was via 
the ß-hydroxy acid (10), formed by an aldol condensation of an acetate unit, 
presumably as malonyl coenzyme A, to a preformed polyketide chain (9). The ß- 
hydroxy acid (10) then undergoes decarboxylation and dehydration, with reduction of 
the carbonyl group to give the allylic alcohol system (11) of virginiamycin M1. 
Figure 5. 
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Incorporation of labelled valine at C-3, 
-29, -30, and -31 clearly indicated that 
the isopropyl group in virginiamycin M originated from valine. C-32, the adjacent 
methyl group, derives from methyl methionine via the normal recognised pathway for 
methyl incorporation involving methyl methionine. 
The subunit of the virginiamycin M system of most interest is the 2,4- 
disubstituted oxazole ring. In the case of berninamycin18, an antibiotic containing a 
2,4-disubstituted oxazole with a methyl in the 5-position, the oxazole was found to 
originate from threonine. It was therefore reasoned that the oxazole in virginiamycin 
could conceivably originate from serine. Incorporation studies using labelled serine 
gave 13C enrichment at C-20 in virginiamycin M indicating serine as the source for the 
oxazole. The pathway proposed for the conversion of serine into the oxazole is thought 
to proceed via the corresponding ß-hydroxy amide (12). Figure 6. 
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The remaining two nitrogen atoms within the system were found to originate 
from proline itself, and glycine to give the N-8, C-9 and C-10. Combining this 
information, and the information gained from other studies, the authors proposed 
precursors for the biosynthesis of the virginiamycin M skeleton as illustrated in Figure 
7. 
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1.5 Synthetic Approaches to the Virginiamycins and Related Group A 
Streptogramin Antibiotics. 
The importance of the virginiamycins as potent antibiotics, coupled with their 
interesting structural features, have led to these compounds receiving increased 
attention from synthetic chemists over the past twenty years. One of the pioneers in the 
search for a synthetic route to virginiamycin M, madumycin, and griseoviridin (Figure 
1), compounds of great similarity, has been A. I. Meyers from Colorado. His work 
over the past fifteen years culminated in one of the first syntheses of these group A 
streptogramin antibiotics, that of madumycin II (13). 19 This work was published 
simultaneously with the completion of our own studies. The approach used by Meyers 
et at relied on a macrolactamisation between C-7 and N-8, using BOP-Cl to effect the 
cyclisation to form the 23-membered ring system. Their route proceeds along a 
convergent synthesis of two fragments resulting from the initial disconnection between 
C-7 and N-8, as mentioned for the cyclisation, and between C-22 and N-23, as the 
amide bond formation step to afford the cyclisation precursor. Figure 8. 
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Meyers' synthesis of the left-hand fragment (14) utilised the chiral oxazolidinone 
developed by Evans to form the syn adduct (16). 20 The adduct (16) was 
transformed into the Weinreb amide (17) before being reduced to the unstable aldol 
(18) with DIBAL-H. The aldol (18) was converted to the a, ß-unsaturated silyl ester 
(19) in 72% yield using a Horner-Emmons-Wadsworth modified olefination before 
coupling the free hydroxyl group of (19) to N-Boc-D-alanine in a quantitative yield. 
Final removal of the Boc protecting group yielded the free amine (14). Scheme 1. 
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Fragment (15) was synthesised from the Weinreb amide (20) by treatment with 
allylmagnesium bromide to give the allyl ketone. Scheme 2. Stereoselective 
reduction of the allyl ketone to the syn 1,3-alcohol with LiAlH4 and lithium iodide 
followed by TBS protection yielded the allyl alcohol (21) in 98% yield. Ozonolysis of 
the double bond in (21) gave the aldehyde (22). The aldehyde (22) was then 
oxidised to the carboxylic acid (23) which was then coupled to (S)-serine methyl ester, 
via the mixed anhydride, to give the hydroxyamide (24) in 93% yield. Treatment of 
the hydroxyamide (24) with Burgess reagent afforded the oxazoline (25), in 69% 
yield, which was then oxidised to the oxazole (26) in 81 % yield using a Cu(I)-Cu(II) 
peroxide reagent. The TBS protection of (26) was removed with TBAF to give the 
free alcohol which underwent smooth conversion to the stereochemically pure 1,3- 
mesityldioxane (27) in 74% yield on treatment with 1,3,5-mesitylformaldehyde and 
catalytic camphorsulphonic acid. Oxidation of the primary alcohol (27) to the 
aldehyde (28) using S02. py, DMSO and triethylamine, followed by Wittig olefination 
with a-formylethylidenetriphenylphosphorane gave the E-a, ß-unsaturated aldehyde 
(29) in 62% yield. Chain extension of the aldehyde was achieved by treatment with 
vinyl triphenylphosphonium bromide in the presence of potassium phthalimide to give 
the EE-diene-amide (30). Hydrolysis of the methyl ester with lithium iodide in 
pyridine finally gave the carboxylic acid (15) in 58% yield. 
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During the course of their synthetic studies Meyers et al published an alternative route 
to fragment (15). 21 This method utilised Cornforth's method of oxazole synthesis, 
but with an additional twist. In Comforth's synthesis of 2-methyl-4-carboxyoxazole 
14 
ethyl ester the unstable potassium enolate (31) is cyclised to the oxazole directly, using 
hot glacial acetic acid. Meyers however, deprotonated the potassium enolate (31) with 
t-butyllithium, and then added the aldehyde (33) to the resulting anion before cyclising 
with boron trifluoride etherate to give the diastereomeric mixture of the oxazole (34). 
This method enabled Meyers to elaborate the 2-methyl group into a suitable side-chain 
before forming the oxazole ring. This method also had the advantage of forming the 
oxazole ring directly, without the need for the oxidation of the oxazoline to the oxazole, 
a reaction which at that tithe was usually achieved using nickel peroxide in very poor 
yields. The oxazole (34) was then carried through to fragment (15) in accordance 
with the method described previously. Scheme 3. 
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Fragments (14) and (15) were coupled together using DCC to give the amide 
(35) in 63% yield. Scheme 4. After removal of the phthalimide protecting group 
with methylamine in ethanol-benzene, and removal of the silyl protecting group with 
. 
TBAF, the amino acid was cyclised with BOP-Cl and Hünig's base to give the 
15 
protected madumycin in 32% yield. Finally hydrolysis of the dioxane ring with 
trifluoroacetic acid gave madumycin 11 (13). 
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Scheme 4 
Published simultaneously with Meyers' synthesis was an independent total 
synthesis of (-) virginiamycin M2 by Schlessinger et a122 Schlessinger's approach to 
the virginiamycin system relied on a macrolactamisation between C-22 and N-23 using 
the Mukaiyama amide coupling conditions? 3 Disconnection of virginiamycin M2 (5) 
in accordance with this methodology, and further disconnection between C-7 and N-8, 
provided the two main fragments (36) and (39). Figure 9. Further disconnection of 
fragment (36) gave the 2-bromomethyloxazole (38) and the polyunsaturated aminal 
16 
chain (37). Disconnection of fragment (39) at the ester linkage gave the protected 
proline (41) and the a, p-unsaturated hydroxy acid (40). 
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Schlessinger's synthesis of fragment (39), used a stereoselective lactonisation 
reaction 24 Thus, the lithium enolate of the vinylogous urethane (42) was reacted with 
isobutyraldehyde to give the lactone (43) in 87% yield (96% de). Scheme 5. 
Dissolving metal reduction of the lactone (43) gave the amino lactol (44) which was 
then oxidatively eliminated with m-CPBA and pyridine to give the moderately unstable 
aldol (45). The aldol (45) was immediately esterified with N-Troc-D-proline using 
DCC and DMAP to give the ester (46) in 92% yield. Oxidation of. the aldehyde (46) 
17 
under Lindgrin's conditions with sodium chlorite and sulphamic acid gave the acid 
(47) in 88% yield. 
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Reagents: i, LDA, isobutyraldehyde, TIIF; ii, Li, NH3, t-BuOii; iii, m-CPBA, THF, py; iv, 
N-Troc-D-proline, DCC, DMAP; v, NaCIO2, NH2SO311, THE-HZO. 
Scheme 5 
The polyunsaturated aminal (37) was also synthesised from a vinylogous urethane. 
Thus, alkylation of the lithium enolate of urethane (48) with isopropyl bromoacetate 
gave the ester (49) in 93% yield. Scheme 6. The ester (49) was selectively 
hydrolysed to the primary alcohol and then protected as the TBS ether (50). Reduction 
of the lactone (50) under the Birch conditions afforded the amino lactol, which was 
oxidatively eliminated to give the aldol and then protected as the TBDPS ether (51). 
Olefination of the aldehyde (51) with cyanomethyl diisopropylphosphonate under the 
Horner-Emmons conditions, and reduction of the nitrile group with aluminium hydride, 
gave the allylic amine (52). 
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A1H3, THF. 
Scheme 6 
Acid (47) and amine (52) were coupled using the Mukaiyama coupling conditions to 
afford the amide in 89% yield. Deprotection of the primary alcohol and subsequent 
oxidation with Dess-Martin's periodinane gave the aldehyde (53). Scheme 7. 
Treatment of the aldehyde (53) and the 2-bromomethyloxazole (38) under the 
Reformatsky conditions, using zinc dust and diethylaluminium chloride, gave a 
diastereomeric mixture of secondary alcohols which were protected as the TES ether 
(54) in 55% yield (2 steps). Removal of the Troc amine protecting group with zinc, 
followed by selective hydrolysis of the methyl ester with lithium hydroxide, gave the 
cyclisation precursor. Cyclisation of the precursor under the Mukaiyama conditions 
gave the protected macrocycle in 48% yield (3 steps). Final removal of the TES 
protection and oxidation of the resultant alcohol to the ketone, followed by removal of 
the TBDPS alcohol protecting group, gave (-) virginiamycin M2 (5). 
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Scheme 7 
Another eminent chemist who has dedicated much time into studying methods 
of synthesising the virginiamycin M system is Helquist. Although having not 
published a total synthesis of these systems to date, Helquist et at. have published 
numerous papers describing their work involved in the syntheses of group A 
streptogramin antibiotics 25 Their approach to madumycin once again relies on a 
macrolactamisation between C-7 and N-8 as the final cyclisation step. Figure 10. 
Further disconnection between C-22 and N-23 yielded the two main fragments (55) 
and (58). Fragment (55) was further disconnected to the hydroxy ester (56) and 
protected alanine (57). Fragment (58) was disconnected to the aminal (59) and the 2- 
20 
bromomethyloxazole (60). 
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Helquist et al reported the synthesis of fragment (56) by two routes 26 The first of 
their routes began with the conversion of ethyl levulinate (61) into the butyrolactone 
(62) by firstly alkylating with isobutylmagnesium bromide and then cyclising under 
strong acidic conditions to the lactone (62) in 56% yield (2 steps). Scheme 8. The 
lactone (62) was then converted to the cyclopentenone by treatment with 
orthophosphoric acid and phosphorous pentoxide in 96% yield. The cyclopentenone 
was then stereoselectively hydrogenated under Paquette's conditions to give the 
cyclopentanone (63) in 83% yield in a 44: 1 ratio of the syn: anti isomers. Baeyer- 
Villiger oxidation of (63) with m-CPBA gave the valerolactone (64). The lactone 
21 
(64) was then ring opened with lithium hydroxide and the resulting alcohol protected 
as the TBS ether (65). Treatment of (65) with LDA and phenylselenyl bromide, 
followed by oxidative work-up with hydrogen peroxide, gave the a, ß-unsaturated ester 
(56). The second route described by Helquist et at used the more conventional chiral 
oxazolidinethione to introduce the two adjacent chiral alkyl groups via a chiral aldol 
reaction. 
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Scheme 8 
Helquist et al synthesised fragment (58) from ethyl 3-methyl-2-butenoate (66). 27 
Scheme 9. Thus, treatment of the ester (66) with NBS in carbon tetrachloride 
followed by the addition of triethylphosphonate gave a 1: 1 E: Z mixture of the 
phosphonate (67) in 70% yield. Horner-Wadsworth-Emmons condensation with N- 
Boc glycinal gave the diene (68) in 68% yield. The ester (68) was reduced to the 
alcohol with DIBAL-H and then oxidised under the Swern conditions to the aldehyde 
(69) in 90% yield (2 steps). Stereoselective aidol condensation with the lithium 
22 
enolate of (S)-N-acetyl-4-isopropyl-2-oxazolidinone gave a 3: 1 mixture of 
diastereoisomers of the alcohol (70). After removing the unwanted minor isomer the 
alcohol (70) was converted into the Weinreb amide. The free alcohol was protected as 
the TBDPS ether and the Weinreb amide was then reduced to the corresponding 
aldehyde (71) with DIBAL-H in 60% yield (3 steps). Reaction of the aldehyde (71) 
with the 2-bromo-methyloxazole (60) under the Reformatsky conditions gave the 
secondary alcohol, which was then oxidised under the Swern conditions to give the 
ketone in 50% yield (2 steps). Finally treatment with TBAF in THE yielded fragment 
(58). 
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At the time of publication the remaining coupling reactions in the total synthesis of 
madumycin had not been completed. However Helquist et al had reported the coupling 
of the free hydroxyl of fragment (56) to N-Boc-alanine, and the subsequent coupling 
of the free amine of this fragment (55) to an analogue of fragment (58) using EDC, 
HOBt, and triethylamine, to give the amide (72). Scheme 10. 
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Scheme 10 
There have been several other research groups around the world working to 
solve the synthesis of this group of macrocyclic Group A Streptogramin antibiotics, 
including both Fujita28 and Ganem, 29 who provide practical solutions to the synthesis 
of the 2,4"disubstituted oxazole fragment. However it has been Meyers, Schlessinger 
and Helquist who have provided the most notable contributions to the synthesis of this 
group of compounds over the past fifteen years. 
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1.6 Our Approach to the Synthesis of Virginiamycin M1: The Stille 
Reaction and its use in the Synthesis of Ring Systems. 
The structure of virginiamycin M1 (1) presents us with an interesting synthetic 
challenge. As has already been discussed in some detail within the review of previous 
approaches to these systems, the main bond linkages of the molecule at which we could 
disconnect would result in either a macrolactonisation or a macrolactamisation to afford 
the macrocyclic ring. A portion of the ring however which has received little attention 
up until now is the E, E-1,3-diene system, a subunit present in a number of macrolides 
which have become of considerable interest in our research group over the past few 
years. Figure 11 
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Figure 11 
This interesting approach to the synthesis of virginiamycin Mi relies on the formation 
of a single bond between two spe centres, which would need to be accomplished under 
relatively mild conditions in the presence of a wide range of functional groups. Up 
until recent years there were very few examples of this type of reaction known, with the 
exception of the Ulmann diaryl synthesis34 and the tandem Michael addition- 
elimination reaction. However with the introduction of transition metal mediated 
carbon-carbon bond forming reactions, and in particular those of the Group 10 
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elements such as nickel and palladium, a wide range of carbon-carbon coupling 
methods have become available. Some of the more notable of these include the Heck 
reaction31, the Suzuki reaction32 and the Stille reaction33. These reactions in 
particular have provided valuable answers to the problems inherent in the coupling of 
alkenes, allenes, allyl, benzyl, aryl and heteroaryl groups within organic synthesis. 
Typical organometallic species which have been used in such coupling reactions include 
the organoborane, 34 the organomagnesium, 3S the organozirconium36 and the 
organozinc reagents, 37 but among the most versatile and widely used organom'etallic 
species must be the organostannane reagents, especially when used in conjunction with 
palladium in the Stille reaction. Figure 12. 
R1-X + R2-SnR33 
Pd(O) 
R'-R2 + R33SnX 
where R1, R2 = allyl, vinyl, aryl etc 
R3 
= alkyl or phenyl 
X= halogen or triflate 
Figure 12 
The popularity of organostannanes is in the main due to their ease of preparation and 
purification, and their stability towards many reagents including water and oxygen. 
Coupled with their high reactivity towards palladium transmetallation and their poor 
ability to transfer a second group, such as alkyl groups, lends the organostannanes 
admirably to the Stille reaction. 
The proposed catalytic cycle involved in the Stille reaction presumes the active 
species to be the 14 electron Pd(O) species L2Pd° 33c Figure 13. This undergoes 
oxidative addition with the electrophilic species RI-X to generate the 16 electron square 
planar complex L2Pd°R1X, which then undergoes transmetallation with the 
organostannane R2SnR33 to give the complex R'LPd°LR2. This complex undergoes 
26 
facile "syn-anti" isomerisation to give the syn complex L2Pd°R'R2. Reductive 
elimination of RI-R2 finally leaves the active species L2Pd° to continue in the cycle. 
R'-R2 
Reductive 
elimination 
rL 
'R_Pd-L 
R2 
Isomerisation. 
L2Pd° 
L 
1R-Pd-X 
L 
R2SnR33 
L 
'R-Pd-R 
L 
Transmetalladon 
Rag SnX 
Figure 13 
R'-X 
Oxidative 
addition 
The transmetallation step from tin to palladium has long been established as the rate 
determining step, and as a result numerous studies have been undertaken to find 
suitable conditions to increase the rate at which this process will occur. The overall 
results of these studies identified that addition of lithium chloride or copper salts 
increase the reaction rate and the yields 38 The same can be said of using ligands with 
poor donor ability such as triphenylarsine or tri(2-furyl)phoshine leading to vast 
increases in rate over the ligand originally used, triphenylphosphine 39 
The Stille reaction has proved to be a powerful tool in the formation of single 
bonds between two spe centres and as such has received much attention as an 
intermolecular coupling reaction. However it is the intramolecular coupling reactions 
which have shown the Stille reaction to be unparalleled in the area of medium- and 
macrocyclic ring formation. 
The first example of an intramolecular Stille coupling reaction was described by 
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Piers et al in 1985.40 Piers et al successfully cyclised the substituted cyclohexene 
(73), containing a vinyl stannane and a vinyl triflate, to the diene containing 6,5-ring 
system (74). Scheme 11. 
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Scheme 11 
(74) 
This strategy was successfully used by Piers et al in their total synthesis of the 
diterpenoid marine natural product (+/-)-(14S)-dolasta-l-(15)-7,9-trien-14-o1 (77), 41 
where the key annulation step involved the intramolecular Stille cyclisation of the vinyl 
triflate (75) to the bicycle (76), which was then elaborated to give the natural product 
(77). Scheme 12. 
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More recently Piers et al have also used the Stille coupling reaction in the stereospecific 
synthesis of small ring cyclobutane carboxylates (78). 42 Scheme 13. 
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Scheme 13 
Bradely and Durst have used an identical strategy to form the 2-benzylidene 
benzocyclobutenol (80) via the cyclisation of the aromatic bromide (79). 43 Scheme 
14. 
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The first use of a sp2-sp2 coupling reaction in the formation of macrolide rings was 
pioneered by Stille in 1987.44 Stille et al cyclised (81), containing the vinyl tin and 
vinyl triflate groups at the ends of the ester chain, under palladium (0) catalysis, to give 
the macrolactone (82). Scheme 15. 
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The yield of the macrolactone (82) was found to be insensitive to the ring size with the 
formation of all ring sizes from 12-membered through to 21-membered proceeding in 
around 60% yield, and as predicted, no sign of double bond isomerisation. As also 
expected the rate of cyclisation was shown to be slowest in the case of the 12- 
membered ring. 
This work was further developed by Stille for the synthesis of large ring keto- 
lactones (84A) by palladium catalysed carbonylative couplings of the esters (83). 4s 
Scheme 16. 
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Scheme 16 
With this novel method identified as an effective route into a wide variety of 
macrolide products, many research groups around the world subsequently applied the 
Stille cyclisation reactions to the synthesis of natural products. 
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One of the first groups to utilise this method was that of Stille himself in the 
simple, yet elegant, synthesis of the macrolide (S)-zearalenone (87). 46 Scheme 17. 
After obtaining low yields during this cyclisation Stille found that the best 
macrocyclisation yields were achieved by using a polymer supported palladium 
catalyst. It was noted by the authors that if the iodide and stannane groups in (85) 
were interchanged, the only product isolated was the dehalogenated starting material. 
The explanation for this outcome was due to the electron withdrawing effect of the 
ortho ester deactivating the tin group towards transmetallation, an observation in 
accordance with the fact that the rate-determining step is the transmetallation from tin to 
palladium. 
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Scheme 17 
The strategy was further used by Stille et al in the total synthesis of (+/-)- 
jatrophone (89). 47 The key macrocycle forming step was achieved by the 
carbonylative coupling of the vinyl triflate and vinyl stannane contained within the 
compound (88). Scheme 18. 
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Pattenden and Thom furthered the use of this method of cyclisation with their approach 
to the polyene macrolactam ring in the antibiotic leinamycin (92). 48 Thus, treatment 
of the E-vinyl stannane and Z-vinyl bromide containing precursor (90) using 
tetrakis(triphenylarsine) palladium (0) (the catalyst developed by Farina39), in refluxing 
THF, produced the macrolactam (91) in 37% yield with complete retention of 
geometries of the double bond unit participating in the coupling reaction. Scheme 19. 
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Another advocate of the Stille reaction, Barrett et al, completed the total 
synthesis of the C2 symmetric pentacyclic diamine papuamine I (94), isolated from the 
marine sponge Halicona. 49 The macrocyclisation of the E-vinyl stannane precursor 
(93) under palladium (0) catalysis, followed by deprotection and formation of the 
hydrochloride salt, gave papuamine 1 (94). Scheme 20. 
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Baldwin et al have used the intramolecular Stille coupling reaction in the formation of 
a, ß-unsaturated lactones (96). This cyclisation used the reactive chloroformates (95) 
to oxidatively add to the palladium, instead of the more commonly used halides. so 
Scheme 21. 
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Surprisingly Baldwin found that when the chloroformates of the type (97) were treated 
under the same cyclisation conditions, a precursor to the larger ring a, ß-unsaturated 
lactones, the cyclised material (98) was never isolated. Scheme 22. 
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However Baldwin et al did accomplish the intramolecular palladium cross coupling 
reaction to give the y-oxo-a, ß-unsaturated macrolactones (100) directly by subjecting 
the precursor (99) to the carbonylative coupling conditions to give varying yields (15- 
70%) of the macrocycle (100). Unfortunately the smaller chain length precursor (n = 
3) yielded only the dimer. si Scheme 23. 
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Shortly after Baldwin's publications Hodgson et al published an efficient 
medium ring cyclisation approach to the germacranes. 52 Thus, the E-vinyl stannane 
(101) was cyclised to the dienone (102) using what has now become the catalyst of 
choice, Farina's Pd(AsPh3)4, in an outstanding 96% yield. Scheme 24. 
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Although conventional thought would suggest that both stannanes and halides 
i 
containing spa-bonded hydrogen atoms would favour ß-elimination in place of 
cyclisation, this observation does not include the allyl species. This reasoning was 
explored by Pattenden and Boden in their palladium mediated intramolecular spe-spa 
coupling approach to the amphidinolides, and in particular amphidinolide A (105). -53 
Hence, the vinyl stannane-allylic chloride precursor (103) underwent smooth and 
efficient coupling with Pd(AsPh3)4 to give the macrocyclic E-1,4-diene (104) in 38% 
yield with only very small amounts of the geometric isomers being isolated. Scheme 
25. 
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One of the most inspiring examples of the Stille cyclisation in natural product 
synthesis must be the total synthesis of rapamycin (108) by Nicolaou et al published in 
1993.54 Their strategy uses a `stitching' protocol to incorporate ethene-distannane into 
the molecule via a `one-pot' intermolecular and intramolecular Stille coupling reaction. 
Thus, treatment of both the distannane (106) and the diiodide (107) with Pd2 and 
Hünig's base in a mixture of DMF and THE gave rapamycin (108) in 28% yield along 
with 30% recovered starting material and 30% of the uncyclised vinyl iodide-vinyl 
stannane product. This later 
'compound 
was cyclised in the standard fashion to yield 
rapamycin (108) in 60%. Scheme 26. 
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A slightly more standard intramolecular spe-spe coupling reaction was used by A. B. 
Smith et al in their synthesis of rapamycin. ss Their strategy proceeded via the vinyl 
bromide-vinyl stannane precursor traditionally used in Stille coupling reactions. 
Another interesting and elegant example of the use of the `stitching' approach to 
cyclisation is that of Danishefsky et al in their synthesis of the enediyne unit present in 
dynaemicin A (111). 56 Thus, the bis(iodideacetylene) (109) was coupled with the Z- 
ethenedistannane to yield the conjugated enediyne (110) in a remarkable 80% yield. 
Scheme 27. The authors noted that the epoxide in the molecule was necessary for 
cyclisation to occur, with its replacement by a double bond resulting in the reaction 
stopping after the intermolecular reaction had occurred. 
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Another example of this powerful cyclisation method, is the synthesis of 
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macrolactin A (119) by Boyce and Pattenden. 57 The synthesis of the three 
geometrically constrained diene units present in macrolactin A was achieved by the use 
of two Stille coupling reactions and one Suzuki coupling reaction. Schemes 28 and 
29. The formation of the first of these units used an intermolecular Stille coupling 
reaction. Thus, the vinyl stannane (113) was coupled, under Stille conditions using 
Pd(II)OAc2 and triphenylarsine, to the vinyl iodide (112), to give the EE-diene (114) 
in an excellent 94% yield. Further elaboration of the diene (114) through to the Z- 
vinyl iodide (115), and subsequent Suzuki coupling of this iodide (115) to the 
boronic acid (116), using palladium (0) and thallium (I), 58 gave the second of the 
diene units, the E. Z-diene (117). Scheme 28. Finally, after further elaboration of 
the diene (117) to the vinyl stannane-vinyl iodide (118), the synthesis of the final 
diene unit, and hence the cyclisation of the precursor, was achieved by treatment with 
the Farina catalyst, Pd(AsPh3)4, to give the protected form of macrolactin A (119) in 
58% yield. Scheme 29 
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In addition to the previously mentioned examples, Critcher and Pattenden have 
more recently published the Stille mediated synthesis of the bis-lactone core of the 
antifungal agent pateamine (122). 59 The key step in this synthesis once again was an 
intramolecular Stille coupling reaction between the Z-vinyl stannane and E-vinyliodide 
precursor (120), to give the bis-lactone (121) in 72% in the presence of Farina's 
catalyst. Scheme 30. 
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This brief review of the Stille reaction as a strategy for the synthesis of polyene 
fragments, especially within ring systems, provides overwhelming evidence for the 
importance of this reaction within the area of total synthesis. The stereo- and chemo- 
selectivity of the reaction, coupled to the ease of synthesis of its precursors, make this 
reaction one of the most important synthetic methods developed within the past 15 
years. The improvements in reaction rate and yield resulting from the immense amount 
of synthetic and mechanistic studies carried out into the catalysts used and' their ligands, 
and the addition of salts to the reaction, only add further support to the importance of 
the Stille reaction in contemporary synthesis. 
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2. RESULTS and DISCUSSION 
2.1 Initial Disconnections 
As discussed earlier in the Introduction, the main approaches to the 
virginiamycin system have been concentrated on producing the macrocyclic ring via a 
macrolactonisation or a macrolactamisation. Our attention was drawn to the polyene 
portion of virginiamycin M2 with the intention of using an intramolecular Stille 
cyclisation for its construction as our cyclisation step. Work within the Pattenden 
research group, including the synthesis of the macrolide portion of the natural product 
leinamycin by Pattenden and Thom48 using an intramolecular spe-spe Stille reaction, 
gave good precedent for this strategy. Thus, if we disconnect between C-11 and C- 12 
in (5) we obtain the cyclisation precursor (123), where X and Y are the halide and 
trialkylstannane associated with the Stille coupling. Figure 14 
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Disconnection of the precursor (123) at the ester and amide linkages, between C-1 and 
0-2, and between C-22 and N-23, then gave us three main fragments: (i) fragment 
(124), the unsaturated hydroxyamide containing the two adjacent chiral alkyl groups; 
(ii) fragment (125), the 2,4-disubstituted oxazole fragment; (iii) fragment (126), the 
commercially available amino acid (R)-proline. Figure 15. 
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Fragment (124) has received much attention over the past ten years, with 
particular interest being given to the corresponding ethyl ester (127). Figure 16. 
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This particular ethyl ester (127) has been synthesised by a number of different 
research groups, using a variety of strategies. Helquist26 and Ganem29 used different 
achiral starting materials and methods to produce a common intermediate, whereas 
Uguen, 60 Schlessinger, 24 and Meyers2° have all used chiral auxiliaries to introduce 
the two adjacent chiral centres in (127). For our synthesis we decided to exploit the 
method published by Meyers et al utilising the Evans' chiral oxazolidinone (128). 
Scheme 31. 
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Thus, (4S)-(-)-isopropyloxazolidin-2-one (128) was first treated with n- 
butyllithium and propionyl chloride, in THE at -78°C, to give the amide (129) in 95% 
yield. The amide (129) was next treated with di-n-butylboron triflate and Hiinigs base 
to form the corresponding Z-enolate, which was then reacted at -78°C, in CH2C12, with 
isobutyraldehyde to give the hydroxyamide (16) in 80% yield, with a >95% ee 
(measured by nmr) after recrystallisation. (It was interesting to note that the specific 
rotation obtained for our product did not match that of the published value. Over 
repeated measurements we obtained readings between +27.0° to +28.0° (c 3.9 in 
CHC13) whereas Meyers quotes values of -8.2° (c 4.7 in CHC13); however all values 
obtained for subsequent compounds were identical to those obtained by Meyers. We 
can only assume that the value quoted may be that of one of the other isomers produced 
by the authors). The hydroxyamide (16) was then cleaved reductively to the aldol 
(18) using Red-Al at 
-50°C. Wadsworth-Emmons olefination of the aldol (18) using 
triethyl phosphonoacetate, in THE at -78°C, yielded the E-a, ß-unsaturated ethyl ester 
(127) in 60% (2 steps) which proved identical to that synthesised by Meyers 20 
2.2 Work on a Model System for Virginiamycin M2. 
Initial studies, aimed at determining if our strategy utilising the Stille reaction 
could be applied to the synthesis of the virginiamycin system, were carried out on a 
model system containing the basic 23-membered macrocyclic ring. For the synthesis of 
such a model it was decided to remove the two adjacent chiral alkyl groups at C-3 and 
C-4 and to also have a diastereomeric mixture about the hydroxy group at C-14. It was 
also decided to replace the unnatural (R)-proline with the more readily available (S)- 
proline. These modifications had the advantage of removing the need for expensive 
chiral auxiliaries and amino acids in our initial studies. We therefore proposed to 
synthesise the macrocycle (130) as a suitable model system for our initial studies in the 
synthesis of the virginiamycin system. Figure 17. 
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Disconnecting (130) between C-11 and C-12 for our cyclisation step using a 
Stille coupling, and then again between C-I and 0-2 and between C-22 and N-23, we 
once again obtain three main fragments. Figure 18. Fragment (134) is the 
commercially available natural amino acid (S)-proline, fragment (133) is the racemic 
form of fragment (125) (Figure 15), and fragment (132) is the a, ß-unsaturated 
amide equivalent to the chiral fragment (124) (Figure 15). 
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With our model system and its three component fragments identified we then 
proceeded with our synthesis of the cyclisation precursor (131). 
2.2.1 Synthesis of the Left-hand Fragment (132) of the Model System 
(130). 
At this point it was necessary to determine which fragment would contain the 
vinyl halide and which the vinyl stannane, i. e. designate groups X and Y in (132) and 
(133). There exists in the literature numerous methods for the synthesis of vinyl 
halides and vinyl stannanes. In the case of vinyl halides their syntheses can be 
61__ 
- 
." achieved by Wittig type reactions such as the chromium mediated Takai reaction, 
elimination of HX from the 1,2-dihalide formed from the alkene, 62 and substitution of 
vinyl species such as aluminates, 3 silicates64 and zirconates 6S In the case of vinyl 
stannanes there exist fewer options. The most common methods for introducing vinyl 
stannanes are either by transmetallation of vinyl organometallic species, or by radical 
additions to triple bonds 66 However none of these methods are of use if stereo- and 
regio-control are poor. After consideration it was decided to attempt to form the vinyl 
stannane on fragment (132) and to this end we chose Boc protected propargylamine 
(135) to ascertain the required conditions. A number of different conditions were tried 
to effect a radical hydrostannation of the protected propargylamine (135) with tri-n- 
butyltin hydride, including thermal and photolytic methods, but all attempts resulted in 
inseparable mixtures of a- and ß-products. 66 Figure 19. 
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Reginato et a167 reported that protected propargylamines could be hydrostannated to 
give the E-ß-product (136) exclusively and in good yields by using the high order 
cuprate Bu3Sn(Bu)Cu(CN)Li2 (139) developed by Lipshutz. 68 Figure 20. 
Bu3Sn(Bu)Cu(CN)Li2 
BocHN BocHN SnBu3 
(139) (135) (136) 75% >95% trans 
Figure 20 
It was proposed that the excellent regiocontrol arose from the stabilisation of complex 
(140), Figure 21, by the additional co-ordination of the copper atom to the 
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nitrogen of the carbamate, since without this additional co-ordination the reverse 
transition state (141) is observed. Having found a high yielding and highly selective 
method for the production of the vinyl stannane portion (143) of our left-hand 
fragment (132), we proceeded with the synthesis. 
BocHN Bu3Sn(Bu)Cu(CN)Li2 BocHN T- 
(139) Cu-SnBu3 (135) 
Bu Li+ 
BocHN BocHN 
Cu-- Bu3S 
-----Cu 
CN CN i Li L 
(140) ' (141) 
Favoured stabilised complex 
Figure 21 
Disconnecting fragment (132) at the amide linkage we realise the two 
fragments, (142), an a, ß-unsaturated ester, and (143), the free amine corresponding 
to the protected vinyl stannane (136). Figure 22. Fragment (142) was synthesised 
in its protected form in three steps starting from commercially available 3-butenol 
(144) utilising Wadsworth-Emmons chemistry. 69 Scheme 32. 
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Thus, 3-butenol (144) was first protected using TBDMS-C1 and imidazole in 
dry DMF to give the silyl ether (145) in an excellent 98% yield 7° Scheme 32. The 
terminal double bond in (145) was next cleaved to the aldehyde (146) using ozone, at 
-78°C, in dry CH2C12 with triphenylphosphine work-up. The aldehyde (146) was 
carried through without further purification into a Wadsworth-Emmons olefination 
reaction, using potassium t-butoxide and triethyl phosphonoacetate in dry THF, at 
-78°C, to give the ester (147) in 70% yield (2 steps). 
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Scheme 32 
With the ester (147) in hand our attention was now drawn to the deprotection 
of the amine (136). The Boc group is usually cleaved under acidic conditions and can 
be removed using a variety of inorganic, organic, and Lewis acids 71 However the 
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carbon-tin bond is known to readily undergo cleavage under these conditions and we 
found the Boc protection could not be removed without concomitant 
protiodestannylation. We therefore decided it would be advantageous to couple 
propargylamine to the ester (147) before attempting hydrostannylation, since a greater 
range of transformations could be performed on the acetylene than could be on the less 
robust vinyl stannane. General methods of converting the ester (147) into the N- 
propargylamide (148) such as direct activation of the ester with cyanide or by 
hydrolysis of the ester and mixed anhydride formation, only led to decomposition or 
recovery of the ester (147). However this problem was overcome by using Weinreb's 
method of amide formation employing trimethylaluminium to activate the amine. 72 The 
increased nucleophilicity of the nitrogen in the resultant highly reactive amino- 
aluminium species allows smooth addition into the ester carbonyl under relatively mild 
conditions giving the corresponding amide cleanly and in good yields. Scheme 33. 
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Thus, propargylamine was treated with trimethylaluminium, at 0°C in dry 
CH2C12 under scrupulously dry conditions, to form the active amino-aluminium 
species. Addition of the ester (147) to the mixture at reflux gave the amide (148) 
cleanly, in 75% yield. With the amide (148) in hand we began to look at the 
hydrostannylation of the terminal triple bond. It was at this point that we realised the 
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problems we would later encounter when removing the silyl protecting group. 
Removal of a TBDMS group is normally achieved by treatment with either acid or a 
fluoride ion source, both of which would cause decomposition of the vinyl stannane. 73 
It became apparent that the hydroxyl protecting group would have to be changed before 
we could proceed with the hydrostannation, and to this end we decided to replace the 
TBDMS group with an acetyl group, as this could be removed by treatment with a mild 
base such as potassium carbonate. Thus the TBDMS group of (148) was removed 
with pTSA in methanol and CH2C12 to give the alcohol (149) in 75% yield. The 
alcohol (149) was acetylated with acetyl chloride and pyridine in CH2C12 to give the 
acetoxyamide (150) in 80% yield. The amide (150) was then hydrostannylated using 
the high order cuprate (139), in dry THF, to give the stannane (151) in 70% yield. 
The acetyl protection was removed by stirring with potassium carbonate in wet MeOH 
to give the alcohol (132) in 98% yield. Scheme 34. 
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2.2.2 Synthesis of the Right-hand Fragment (133) of the Model System 
(130). 
With the left-hand fragment (132) in hand our attention was drawn to what 
could be regarded as the more synthetically challenging fragment, (133). Figure 23. 
HOZCý N Br 
O OH 0 
(133) 
Figure 23 
As already shown in the Introduction, the halide of choice would ideally have 
been the iodide, as this has been shown to react at a faster rate in Stille couplings74 
However, vinyl iodides are inherently less stable than vinyl bromides and vinyl 
chlorides. From the synthetic point of view ideally we would choose to synthesise the 
vinyl chloride, as this would allow us to perform a greater variety of transformations in 
its presence due to its relative stability. But the vinyl chlorides are known to react 
sluggishly in Stille couplings, even in the relatively easier intermolecular and medium 
ring intramolecular cases. Therefore as a compromise between the two extremes it was 
decided to synthesise the vinyl bromide, which had been shown to be fairly reactive in 
the Stille reaction, and to be relatively stable under general synthetic conditions. 
Looking at fragment (133) a number of important questions arose which had to 
be considered before embarking on a synthesis. Firstly there is the synthesis of the 
2,4-disubstituted"1.3-oxazole. This is an interesting synthetic challenge due to the 
substitution pattern of the oxazole, leaving only a few synthetic alternatives open for 
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utilisation. In natural products containing oxazole rings the 2,4-disubstituted oxazoles 
are among the most prevalent. This is thought to be due to the precursor for the 
biosynthesis to the 2,4-disubstituted oxazole rings having been identified as the 
naturally occurring amino acid serine 75 Figure 5. This makes routes starting from 
serine residues an obvious area for consideration. Another question that arises is 
whether to have the whole or part of the side chain (in the 2-substituent) in place before 
forming the oxazole ring or whether to form the ring first and construct the side chain 
afterwards. Finally there is the question of synthesising the side chain and its 
trisubstituted double bond. 
Over the past 20 years there have been many reported solutions to the problem 
of synthesising 2,4-disubstituted oxazoles. These syntheses can be divided into two 
main approaches. Firstly there are the methods which cyclise a serine-based precursor 
to the corresponding oxazoline and then use one of a number of oxidants to oxidise to 
the oxazole. An example of this method is Pattenden's synthesis of the trisoxazole 
fragment of the ulapualides. 76 Secondly there are the methods which involve 
cyclisation to give the oxazole ring directly without involving the oxazoline 
intermediates. Notably in this later group is the work of Das, who used caesium 
carbonate to effect the cyclisation of an amido vinyl bromide in his synthesis of 
thrombaxane A2 receptor antagonists. 77 The work of Wipf, who uses a mixture of 
triphenylphosphine, iodine, and triethylamine to effect the cyclisation of an amido 
aldehyde. 78 The work of Helquist, who forms 2-bromomethyloxazol-4- 
ethylcarboxylate using the Cornforth method, 79 using the bromide as a handle to 
elaborate the side chain in the 2-position using Reformatsky chemistry. 25 And finally 
the work of Meyers, who once again uses Cornforth's method of oxazole synthesis but 
with the addition of the side chain at the enolate stage before effecting the cyclisation to 
the oxazole. 21 Figure 24. 
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The method published by Das et al can be used in the presence of a wide variety 
of functionality, and so it was decided to attempt to use this methodology in our 
synthesis. Disconnection of fragment (133) between C-14 and C-15 led us back to 
fragment (152) which under the Das protocol would result from the amido vinyl 
bromide (154). Figure 25. The remaining fragment (153) could come from the 
oxidation of the alcohol (155) which was synthesised by Corey et al in their synthesis 
of maytansine. 80 In our hands the synthesis of the vinyl bromide (154) proceeded 
smoothly until the final bromination step. Scheme 35. 
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Thus, ethyl acetoacetate (156) was protected as its dithiolane acetal (157) using 1,3- 
propanedithiol and chlorotrimethylsilane in 90% yield. 81 The ester was then 
hydrolysed with lithium hydroxide to give the acid (158) in 90% yield. Coupling of 
the acid (158) with the serine methyl ester using DCC and DMAP next gave the 
hydroxyamide (159) in a 70% yield. The alcohol (159) was transformed into the 
chloroamide (160), in 85% yield, using N-chlorosuccinimide and 
triphenylphosphine. 82 The alkene (161) was obtained by elimination of the 
chloroamide (160) using DBU in 90% yield. Although many reaction conditions were 
tried, including NBS, py. HBrBr2 and Br2/Et3N, bromination of the alkene (161) was 
never achieved; under all the conditions complete decomposition of the starting alkene 
resulted without any of the desired vinyl bromide (162) being isolated. 
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Since we had the chloroamide (160) in hand, it was decided to remove the 
dithiane protection and effect a cyclisation to the oxazoline (164) using silver 
triflate, 83 and then to oxidise the resulting oxazoline (164) to the corresponding 
oxazole (165) using nickel peroxide. 84 Scheme 36. Thus, the chloroamide (160) 
was treated with mercuric perchlorate iri THE to first give the keto-amide (163) in 40% 
yield. 85 The amide was then cyclised to the oxazoline (164) using silver triflate, in 
benzene, in 70% yield. Attempts to oxidise the oxazoline to the oxazole (165) using 
nickel peroxide only led to complete loss of starting material. This may have been due 
to the carbonyl group of the side chain leading to additional coordination to the already 
oxazoline bound nickel peroxide. The coordination of nickel peroxide to oxazolines 
and the resulting oxazole products has long been a problem in these oxidations, often 
leading to poor and variable yields. 
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The lack of oxidants for the oxidation of oxazolines to oxazoles at the time forced us to 
consider alternative routes to our system. To this end we turned our attention to the 
work of Helquist. 25 If we look at fragment (133) with the aim of utilising Helquist's 
methodology we require a disconnection of fragment (133) between C-16 and C-17. 
Figure 25. 
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Fragment (167), the 2-bromomethyloxazole, was synthesised from the 2- 
methyloxazole (173) obtained using the methodology developed by Cornforth. 79 
Scheme 37. 
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Thus, glycine ethyl ester hydrochloride (170) was condensed with ethyl acetimidate 
hydrochloride (169) to give the imino ether (171) in 65% yield. The imino ether 
(171) was then treated with potassium t-butoxide and ethyl formate to give the 
potassium enolate (172), which was cyclised to the oxazole (173) with hot glacial 
acetic acid in 90% yield without isolation (2 steps). Bromination of the oxazole (173) 
with N-bromosuccinimide and AIBN in carbon tetrachloride provided the bromo 
oxazole (60) in 50% yield. 86 
In our initial studies we repeated the work of Helquist starting with the straight- 
chain aldehyde hexanal (174) using a variety of differently activated zinc powders to 
ascertain which would give us the best results with our bromo oxazole (60). We 
found that the reaction only gave the desired product (175) when sulphuric acid 
activated zinc powder was used, albeit in an optimised 35% yield. Having gained some 
insight into the reaction using hexanal, we then moved to a more synthetically useful 
aldehyde (176), containing a silyl ether to give us a handle into our desired target 
58 
compound. This aldehyde had been reported by Heiquist to participate in the 
Reformatsky reaction. However in our hands this aldehyde (176) would not react to 
give the oxazole (177) under all conditions tried, and so we moved our attention to the 
alternative aldehyde, (178). Scheme 38. 
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In the case of 4-pentenal (178), we once again obtained an optimised 35% yield of the 
desired oxazole (179) when using sulphuric acid activated zinc powder. The terminal 
double bond in (179) was cleaved to the aldehyde (180) using osmium tetroxide and 
sodium periodate. 87 Scheme 39. The'aldehyde (180) was shown by nmr analysis 
to exist as a 9: 1 mixture of the aldehyde and its lactol tautomer (181). It was hoped to 
transform the aldehyde (180) to the corresponding E-vinyl bromide (183) using the 
Takai proceedure. 61 This method, analogous to a Wittig olefination, uses an 
intermediate formed from chromium(II)bromide and bromoform, instead of a 
phosphonium ylide. Although the aldehyde (180) reacted with methyl 
(triphenylphosphoranylidene) acetate in a Wittig reaction to give the a, ß-unsaturated 
ester (182) in 90% yield, under the Takai conditions the desired vinyl bromide (183) 
was never obtained. 
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Scheme 39 
Having already synthesised the 2-methyloxazole (173) for use in above 
synthetic route, it was decided to look at the direct deprotonation of the 2-methyl group, 
and to attempt the addition of a suitable electrophile. It has been well documented that 
deprotonation of oxazole (173) occurs at the 5-position of the ring rather than at the 
methyl group-89 This can be attributed to the carboxylate group in the 4-position 
stabilising the 5-lithium intermediate via intramolecular chelation. To overcome this 
problem three main approaches have been employed by the various research groups 
working in this area. Firstly we could increase the acidity of the methyl protons of the 
2-methyl group. This approach has been used by Fujita et at, who used a 
phenylsulphone group on the methyl to induce deprotonation of the methylene protons 
exclusively, which the authors removed later in the synthesis with aluminium 
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amalgam 28 The second approach is to block the 5-position on the ring with a suitable 
protecting group which can be removed easily at a later stage. To this end Ganern et al 
used a trimethylsilyl group to block the 5-position, and later removed this with caesium 
fluoride. 29 The other alternative is to reduce the carboxylate group to the 
corresponding alcohol, and to protect this with a bulky protecting group such as the 
TBDMS group. Scheme 40. 
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Scheme 40 
Having attempted the first two approaches without great success it was decided 
to reduce the carboxylate group to the corresponding alcohol (184). Thus, the 
oxazole (173) was first reduced to the corresponding alcohol (184) using DIBAL-H, 
in CH2C12 at 0°C, in 60% yield. The alcohol (184) was then protected with t- 
butyldimethysilyl chloride and imidazole to give the silyl ether (185) in 90% yield. 
Deprotonation of oxazole (185) with n-butyllithium at 
-78°C in dry THE and stirring 
for 15 min at 
-78°C before addition of deuterium oxide, and then allowing the solution 
to warm to room temperature, gave 90% deuterium incorporation in the 2-methyl 
group, and 10% deuterium incorporation in the 5-position of the ring (by IH nmr 
analysis). The degree of incorporation of deuterium in the 5-position increased with the 
time at which the anion was left at 
-78°C before adding the deuterium oxide, suggesting 
deprotonation must first occur at the kinetically favoured 2-methyl position, and then 
with time forms the more thermodynamically stable anion at the 5-position. The 
thermodynamic anion is further stabilised by the so called ß-effect, a direct result of 
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chelation of the lithium atom by the oxygen atom of the ether. Figure 26. 
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Having shown deprotonation of the 2-methyl group of the oxazole (185) could 
be achieved, we embarked on the synthesis of a suitable fragment to act as an 
electrophile to yield the desired chain in the 2-position. Looking back at fragment 
(133) we ideally required a fragment which would give us the ketone directly without 
the need for further manipulation. Figure 27. 
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One of the most useful synthons in the direct production of ketones is the Weinreb 
amide. 89 Weinreb found that by treating an N-methoxy-N-methylamide with 
62 
nucleophilic species, and in particular lithium species and Grignard reagents, the 
corresponding ketone was obtained directly. The N-methoxy-N-methylamide 
possesses this useful synthetic ability due to the chelation of the oxygen atom of the N- 
methoxy group to the lithium atom of the adduct forming a stable 5-membered 
intermediate (187). This intermediate then breaks down on addition of a proton 
source, such as ammonium chloride or water, to give the desired ketone and N, O- 
dimethylhydroxylamine. Figure 28. 
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The formation of the stable intermediate only occurs when the metal ions used are 
lithium or magnesium, as their small atomic radii, 1.52 A and 1.6 A respectively, 
enables them to form the stable 5-membered ring. Larger alkali metals ions such as 
sodium and potassium, with atomic radii of 1.85 A and 2.31 A respectively, are too 
large to form the stable 5-membered ring. 
The synthesis of the vinyl bromide aldehyde (153) followed Corey's method 
as mentioned earlier. 80 Scheme 41. Thus, E-crotyl alcohol (188) was first treated 
with bromine in carbon tetrachloride at 
-20°C to give the erythro dibromide (189) in 
98% yield. The dibromide (189) was then treated at 
-78°C with 2 equivalents of LDA 
to give the alcohol (155) in 50% yield. The alcohol (155) was finally oxidised to the 
aldehyde (153) using activated manganese dioxide in CH2C12 in 70% yield. 
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Our next task was to couple the aldehyde (153) to the N-methoxy-N- 
methylacetamide (191), and to then protect the resultant secondary hydroxyl group. 
Scheme 42. 
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Scheme 42 
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Thus, N, O-dimethylhydroxylamine hydrochloride was first acetylated using acetyl 
chloride and pyridine in CH2C12, at 0°C, to give N-methoxy-N-methylacetamide (191) 
in 80% yield. The next step was to deprotonate the acetamide (191). Due to the 
inherent stability of the intermediates formed by Weinreb amides and lithium ions we 
found that attempts to deprotonate with lithium bases such as n-BuLi and LDA gave no 
products on addition of electrophiles. To overcome this problem we found it necessary 
to use a base containing a larger metal ion, i. e. potassium, to achieve deprotonation and 
smooth coupling. Thus, the amide (191) 'was treated with potassium 
hexamethyldisilazide at 
-78°C in THF, and addition of the aldehyde (153) gave the 
hydroxyamide (192) in 60% yield. The secondary hydroxyl group in (192) was 
protected as the methoxymethyl ether (193), using MOM-Cl and Hünigs base at reflux 
in dry CH2C12, in 70% yield. Attempts to add the anion of the oxazole (185) into the 
Weinreb amide (193) to give the corresponding ketone (194), only gave starting 
materials. Scheme 43. Numerous bases were used to form the oxazole anion 
including n-BuLi, t-BuLi, LDA, LiHMDS, KHMDS, and NaHMDS, at a variety of 
temperatures, and in a variety of solvents, all of which failed to yield the desired 
product. The lack of reactivity of the anion of oxazole (185) towards Weinreb amides 
was found to be a problem even with simple Weinreb amides such as the acetamide 
(191). 
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However earlier studies had shown that the anion of the oxazole (185) would react 
with aldehydes such as acetaldehyde and isobutyraldehyde to give the corresponding 
secondary alcohols. It was therefore decided to utilise the other useful property of the 
Weinreb amides, i. e. their ease of reduction to the corresponding aldehyde. 90 
Treatment of Weinreb amides with excess DIBAL-H or LiAlH4 had been reported, in 
most cases, to give the corresponding aldehydes directly in good yields. However in 
the case of amide (193), only the fully conjugated aldehyde (196) was isolated, a 
result of the simultaneous elimination of the protected hydroxyl group, without 
isolation of any of the desired aldehyde (195). Scheme 44. 
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Rather than seeking an alternative route to obtain the intended aldehyde (195) 
we noted that certain members of the virginiamycin family, e. g. (6) and (7), contained 
conjugated triene systems corresponding to the aldehyde (196), instead of the 
aldehyde (195) in the case of (5). Figure 29. Combining the trienol system of (7) 
with our proposed model system (130) revealed a revised target macrocycle (197) to 
act as our model system. Figure 30. 
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Disconnection of the cyclisation precursor (198) led us to the left-hand 
14 
fragment (132) and L-proline (134) as before, together with the new right-hand 
fragment (199). Figure 31. 
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Disconnection of fragment (199) between C-16 and C-17, as with fragment (133), 
led us to the 2-methyloxazole (186) and the conjugated aldehyde (196), previously 
obtained in the reduction of the Weinreb amide (193). Figure 32. 
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Following the success obtained in the depronation studies of the oxazole (185) 
it was decided to employ this methodology in the synthesis of fragment (199). Thus, 
the oxazole (185) was deprotonated using n-BuLi, in THF, at -78°C. After addition of 
the aldehyde (196) the hydroxyoxazole (200) was obtained in 40% yield. Scheme 
45. 
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At this point it was interesting to note that the unprotected oxazole (184) also gave the 
same regiocontrol and yield as the protected oxazole (185) and so subsequent reactions 
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were carried out using the unprotected oxazole, thus removing the need for the 
protection and deprotection steps. 
The route by which the aldehyde (196) was obtained was altered to a more 
conventional route, replacing the N-methoxy-N-methylamide group with an ester. 
Scheme 46. Thus, the aldehyde (153) was transformed into the EE-diene ester 
(201) using triethyl phosphonoacetate under the Wadsworth-Emmons olefination 
conditions in 70% yield. Reduction of the ester (201) to the alcohol (202) was next 
achieved using DIBAL-H in CH2C12 at 
-78°C in 97% yield. 'the alcohol (202) was 
then oxidised to the aldehyde (196) in 80% yield using activated manganese dioxide in 
CH2C12. The aldehyde (196) was finally coupled to the unprotected oxazole (184) 
using n-BuLi in THE at 
-78°C, leading to the diol (203) in 40% yield. 
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Oxidation of the primary allylic alcohol in (203) to the hydroxy aldehyde (205) was 
achieved using activated manganese dioxide in 30-70% yields. Attempts to 
simultaneously oxidise both the primary and secondary allylic alcohols with activated 
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manganese dioxide, barium manganate and Dess-Martin periodinane, to give the right- 
hand fragment (204), only gave the hydroxy aldehyde (205). Scheme 47. We 
reasoned that the secondary hydroxyl group would require longer reaction times or 
more forcing conditions to give the corresponding keto aldehyde (204). Subjecting 
the diol (203) to excess reagents for long periods predominately gave the products of 
the retro-aldol reaction, as well as oxidation of the primary hydroxyl group. It should 
also be noted that the outcome of the manganese dioxide and barium manganate 
oxidations were highly dependent on the qualities of the oxidants used, with some 
batches giving sluggish oxidation and other more active batches giving only the retro- 
aldol products. To overcome this problem we found it necessary to use 10 equivalents 
of activated manganese dioxide (as supplied by Aldrich) which was filtered off when 
the reaction was seen to be about 50% complete by tic. The aldehyde (205) was then 
oxidised to the corresponding carboxylic acid (199) using buffered sodium chlorite 
solution and 2-methyl-2-butene in t-butanol and water in 90% yield as a hygroscopic 
solid. 91 Other oxidants such as potassium permanganate, PCC, PDC, TPAP and 
Ru04 all resulted in complete loss of starting material and no sign of oxidation 
products. 
Br p-- N Br HO N 
>00000, 
O OH 
(203) (204) 
i 30%-70% 
O., N Br ii 1102C N Br 
OH 90% O OH 0 
00000 
(205) (199) 
Reagents: i, Mn02, C112C12; ii, NaC1O2, K112P04,2-methyl-2-butene, 1120, tIuOII. 
Scheme 47 
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2.2.3 Peptidic Coupling Reactions of Fragments (132) and (199) to 
Proline. 
With the fragments (132) and (199) in hand it became necessary to ascertain 
the conditions required for the coupling of these two fragments to proline to afford the 
cyclisation precursor (198). To model the amide bond formation between the oxazole 
acid (199) and proline, our first studies were carried out using the 2-methyloxazole 
acid (186) instead of the synthetically valuable oxazole acid (199). The acid (186) 
was obtained by hydrolysis of the oxazole ethyl ester (173) using lithium hydroxide in 
wet THE in 60% yield. Scheme 48. 
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In the virginiamycin M family the members containing a fully saturated proline rings all 
contain the unnatural D- (or R-) proline, which is rather more expensive than the more 
readily available L- (or S-) proline. It was therefore decided to use the less expensive 
L-proline for all of our model studies as this was deemed to have little or no effect on 
the information we would obtain concerning reaction conditions. In our initial studies 
we coupled the oxazole acid (186) to L-proline methyl ester (206) using DCC and 
DMAP in dry CH2C12 to give the amide (207) in 70% yield. Scheme 49. 
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The nmr spectra of the amide (207) indicated that the amide existed as a 1: 1 
mixture of rotamers 92 This phenomenon although causing no problems synthetically, 
did lead to complicated nmr spectra, especially when the molecules became more 
complicated as in the case of our later molecules. Figure 33. 
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The ester group of the amide (207) was next hydrolysed to the acid (208) 
using lithium hydroxide in wet THE in 85% yield. The acid (208) was then coupled 
to fragment (132) using EDC, DMAP and DMAP. HC1 in dry CH2C12 to give the ester 
(209) in 55% yield. 93 Scheme 50. 
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Having ascertained coupling conditions which would be tolerated by the fragile 
vinyl stannane moiety present in fragment (132), we attempted to use the same route 
with the right-hand fragment (199). The reaction of the acid (199) with L-proline 
methyl ester (206) using DCC and DMAP proved very slow and low yielding, and so 
it was decided to changed the reagents to EDC, HOBt and Et3N as these conditions had 
been shown to give better results in some cases. Thus, the acid (199) was coupled to 
L-proline methyl ester (206) using EDC, HOBt and triethylamine in dry CH2C12, to 
give the amide (210) in 70% yield. Scheme 51. 
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Attempts to hydrolyse the methyl ester group of amide (210) using basic conditions 
led to complete decomposition of the molecule with none of the desired acid (211) 
being isolated. It was thought that under the basic conditions of the hydrolysis the side 
chain in the 2-position of (210) may have undergone a retro-aldol elimination. It was 
hoped that by changing the base-labile methyl ester to the acid-labile methoxymethyl 
ester, that the acid (211) would be obtained without decomposition. Thus, L-proline 
(206) was esterified with chloromethylmethyl ether and triethylamine in dry CH2CI2 to 
give L-proline methoxymethyl ester (212) in 90% yield. The general lability of the 
methoxymethyl ester in (212) led to some decomposition on exposure to flash 
chromatography and therefore the proline (212) was used without further purification. 
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To determine if the MOM ester group would withstand our coupling conditions, and to 
ascertain the degree of lability of the MOM ester to mild acidic conditions, the proline 
(212) was coupled to the 2-methyloxazole acid (186) using EDC, HOBt and Et3N in 
CH2C12, to give the amide (213) in 60% yield. Scheme 52. 
HO2C H MOMO2C MOMO2C O 
Y.. 
-5 
ib 11 NN 
90% 0 (212) (213) 
HO2C 0 
iii NN 
90% 1 ý%- 
0 
(208) 
Reagents: i, MOM-Cl, Et3N, CI12C12; ii, (186), EDC, 11O13t, Et3N, C112C12; iii, 2M IHC1, THE 
Scheme 52 
Treatment of the amide (213) with 2M HCl gave the acid (208), identical to that 
produced by base hydrolysis of the methyl ester (207), in 90% yield. The L-proline 
methoxymethyl ester (212) was then coupled to the oxazole acid (199), using EDC, 
HOBt and triethylamine in dry CH2C12, to give the amide (214) in 70% yield. 
However on treatment of the amide (214) with 2M HCl none of the desired acid 
(211) or starting material were isolated. Scheme 53. 
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Concurrently with this work we had been looking at the coupling of proline to 
the left-hand fragment (132) prior to coupling to the right-hand oxazole acid (199). 
For this strategy we required a base-labile group for protection of the nitrogen of the 
proline during the esterification with the left-hand fragment (132). This would allow 
its subsequent removal in the presence of the acid sensitive vinyl stannane mQiety, 
allowing us to continue with the subsequent coupling of the resulting fragment to the 
oxazole acid (199). To this end the 9-fluorenylmethyloxycarbonyl (Fmoc) group was 
chosen as this had been shown to be readily attached and removed under mild 
conditions (properties which have resulted in the Fmoc group becoming widely used as 
a protecting group in peptide synthesis). Thus, commercial N-Fmoc-L-proline (215) 
was coupled to the alcohol (132) using DCC and DMAP in dry CH2C12 to give the 
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amide (216) in 90% yield. The Fmoc protection in (216) was then removed by 
stirring at room temperature with 5 equivalents of piperidine in acetonitrile to yield the 
free amine (217) in 90% yield. Fragment (217) was then coupled to the oxazole acid 
(186) using EDC, HOBt and triethylamine in dry CH2C12, to give the amide (209), 
identical to that formed from fragments (132) and (208), in 60% yield. Scheme 54. 
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It was found that the coupling reactions using EDC and HOBt resulted in 
protiodestannylation of the vinyl stannane. This was thought to be due to the release of 
HCl from the EDC during the reaction. Therefore, when using EDC as its normally 
supplied salt form, an equimolar amount of triethylamine was used to neutralise any 
acid produced. 
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Having ascertained suitable conditions for the coupling of fragments (217) and 
(199) to proline, we proceeded with the formation of the cyclisation precursor. 
Scheme 55. 
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Thus the oxazole acid (199) was coupled to the amine (217) using EDC, HOBt, and 
triethylamine in dry CH2C12, to give the cyclisation precursor (198) in a 60% yield as 
a mixture of rotamers and diastereoisomers. 
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2.3 Stille Coupling Reactions 
Before attempting an intramolecular Stille cyclisation of the precursor (198) of 
the model system (197), we wanted to gain some insight into the coupling reaction 
between a E-vinyl stannane and a trisubstituted E-vinyl bromide to obtain a triene 
system. It was hoped that by coupling various bromides and stannanes fragments 
prepared throughout our synthetic work, we would obtain valuable information about 
the properties of the resultant triene systems. As already mentioned there have been a 
number of different palladium catalysts used in Stille coupling reactions. One catalyst 
which has shown excellent activity and functional group tolerance is 
tetrakis(triphenylarsine) palladium(O), as developed by Farina39, and which was 
decided to be a good starting point in our own studies. Thus, the vinyl stannane (151) 
was coupled with the vinyl bromide (201) in THF, at reflux, with 1% Pd(0)(Ph3As)4, 
to give the triene (218) in 60% yield. The triene (218) was obtained exclusively as 
the all E-isomer with no sign of double bond isomerisation (by nmr analysis). 
Scheme 56. 
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The reaction was repeated with the deprotected vinyl stannane (132) to ascertain if the 
reaction would tolerate the presence of a free hydroxyl group. The reaction proceeded 
as before to give the triene (219) in 70% yield, and once again showed no sign of 
double bond isomerisation. Scheme 57. Both of the trienes (218) and (219) 
however were found to be unstable at room temperature for more than a few hours, 
especially in the presence of light, making purification and characterisation difficult. 
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With these coupling reactions in hand, our attention moved to a closer representative of 
the triene system present in our model cyclisation. It was necessary to couple fragment 
(132) with fragment (203) to give the trienol present in (197), this would not only 
give us a greater understanding of the cyclisation, but also give us an indication of what 
the nmr spectra may look like for this trienol system. We also wanted to take the 
opportunity to move away from THF, as this had been shown to be a poor solvent in 
studies of intramolecular Stille cyclisation, an observation made during other studies of 
the Stille cyclisation method within the laboratories at Nottingham. We therefore 
decided to run the reaction between the bromide (203) and the stannane (132) in 
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DMF, a polar solvent which has been shown to promote reactions where non-polar 
THE had failed. Thus, the vinyl bromide (203) and the vinyl stannane (132) were 
coupled in DMF at 100°C, using 1% Pd(0)(Ph3As)4 as catalyst, to give the trienol 
(220) in 40% yield. Scheme 58. The lower yield in this case was attributed to the 
difficulty in purifying the triol (220) and its general instability as with the previous two 
triene systems (218) and (219). 
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The success of these three coupling reactions prompted us not to change the conditions 
any further, but instead to continue with the cyclisation of our model precursor (198) 
using DMF at 100°C and 1% Pd(0)(Ph3As)4 as catalyst. Scheme 59. 
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Thus, the model precursor (198) was added to a solution of 1% Pd(0)(Ph3As)4 in dry 
DMF and the mixture was heated at 100°C for 18 h. After careful purification the 
trienol macrocycle (197) was obtained in 40% yield. Although the macrocycle proved 
to be very unstable at room temperature, it could however be stored at 
-20°C in acid free 
CDC13 for several days. It was interesting to note that the rate and success of the Stille 
coupling reaction was dependent not only on the concentration of the precursor 
(intramolecular couplings being favoured by low concentrations), but more so by the 
concentration of the catalyst present. It was found that at concentrations of less than 
0.1 mM of catalyst gradual decomposition of the precursor occurred at a faster rate than 
the cyclisation to the macrocycle. 
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The successful macrocyclisation to the model system (197) had provided 
valuable evidence that the Stille methodology could be used to overcome the cyclisation 
difficulties experienced in the formation of the virginiamycin M series of compounds. 
It now remained to go back and modify our synthesis to introduce the features required 
for a total synthesis of members of the family of the virginiamycin M antibiotics. 
2.4 Synthesis of 14,15-Anhydro"16,37-diliydrovirginiamycin M2 
On examination of the virginiamycins (6A) and (7A), it is possible to identify 
the portion of the left-hand-side common to all the virginiamycin M compounds, i. e. 
ester (127), which we had previously synthesised using Meyers methodology. 20 We 
also possessed the right-hand oxazole acid (199), albeit in a racemic form, required for 
the synthesis of the virginiamycin (7A). Figure 34. Disconnecting (7A) according 
to our Stille protocol, followed by further disconnections as before, led us once again 
to the three main fragments: (i) fragment (222), the left-hand fragment contains the 
two adjacent chiral alkyl groups (to be incorporated using Meyers method); (ii) D- 
proline; (iii) the oxazole acid (199). Figure 35. 
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It was hoped that the same methodology could be employed in the conversion of the 
chiral ester (127) into fragment (222) as had been used in the synthesis of fragment 
(132) during the model studies. The chiral ester (127) was synthesised as described 
earlier in this discussion (Scheme 31). The protecting group chosen for the hydroxyl 
group in the ester (127) needed to withstand the conditions employed in the synthesis 
of the amide (224), namely the conditions used in Weinreb's method of amide 
formation, i. e. treatment with the trimethylaluminium species. It also needed to be 
removed easily in the presence of the acid-sensitive vinyl stannane moiety, i. e. it 
needed to be base-labile. Once again no one suitable protecting group could be found, 
and so we were forced to resort to a change of protecting group halfway through our 
synthesis. Thus, the hydroxyl group in the ester (127) was first protected as its 
methoxymethyl ether (223) using chloromethylmethyl ether and Htinig's base, in dry 
CH2C12 under reflux, in 85% yield. Scheme 60. The protected ester (223) was 
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converted into the propargylic amide (224) using Weinreb's method in dry CH2C12, in 
80% yield. 72 The MOM ether in (224) was then cleaved to the alcohol (225) using 
bromotrimethylsilane, in dry CH2C12 at 
-78°C, in 95% yield. The alcohol (225) was 
then reprotected as the acetate using acetyl chloride and pyridine in dry CH2C12 to give 
the ester (226) in 95% yield. Hydrostannylation of the ester (226), using the high 
order cuprate developed by Lipshutz, 68 gave the vinyl stannane (227) in 80% yield. 
The acetate protection in (227) was then removed using excess potassium hydroxide in 
wet methanol to give fragment (222) in 98% yield. 1 
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Scheme 60 
86 
The next step in the synthesis was to couple the N-protected D-proline to 
fragment (222). We decided to retain the Fmoc protection used in the synthesis of our 
model system, as this had been shown to work well, and was also commercially 
available. Meyers et al had reported coupling a Boc-protected alanine residue to the free 
alcohol of a system containing the (4R)-methyl-(5R)-hydroxy-6-methyl-2-pentenamide 
fragment (present in our system) using DCC and DMAP in dry CH2C12.20 However 
using these conditions with N-Fmoc-D-proline and the alcohol (222) only gave 5% 
yield of the desired ester, with mostly recovered starting material. It was noted that the 
acetylation of the alcohol (225) had taken considerably longer than the corresponding 
example without the two chiral alkyl groups. It was also noted that the cleavage of the 
acetyl group in (227) required several equivalents of potassium hydroxide at room 
temperature over several hours, whereas a normal non-hindered acetate hydrolysis 
usually occurs using potassium carbonate at 0°C. These observations, and the fact that 
on attempting to couple N-Fmoc-D-proline and the alcohol (222) only gave very low 
yields of product, led to the conclusion that the alcohol must be too hindered to allow 
the bulky N-Fmoc-D-proline to approach easily enough for the reaction between the 
acid and the alcohol to proceed at a reasonable rate. It was hoped that by using a less 
bulky protecting group for the proline nitrogen that a better yield may be obtained for 
the coupling. It was therefore decided to use a trifluoroacetyl group instead of the 
Fmoc group. Trifluoroacetamides had been shown to be easily cleaved by weak bases 
such as sodium carbonate, but this would cause problems if readily hydrolysed esters 
were also present in the molecule. In our case however the ester in (227) had already 
shown itself to be too hindered for easy hydrolysis, especially by weak bases such as 
sodium carbonate, and so would cause no problems when removing the TFA group. 
Thus, D-proline was protected as its trifluoroethylacetamide (228) using ethyl 
trifluoroacetate and triethylamine in dry methanol, in 95% yield. 94 The N-TFA-D- 
proline (228) was then coupled to fragment (222) using DCC and DMAP in the 
minimum of dry CH202, to give the ester (229) in 60% yield. Scheme 61. 
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The TFA protection in (229) was removed with sodium carbonate in wet methanol to 
give the amine (230) in 95% yield. The amine (230) was then coupled to the oxazole 
acid (199) using EDC, HOBt and triethylamine, to give the cyclisation precursor 
(231) in 60% yield. Scheme 62. 
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Cyclisation of (231) using 1% Pd(O)(Ph3As)4 in dry DMF at 100°C for 18 h finally 
gave 14,15-anhydro-16,37-dihydrovirginiamycin M2 in a 30% yield as a mixture of 
secondary hydroxyl epimers. Scheme 63. 
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The macrocycle (7A) proved to be unstable at room temperature for any length 
of time, which we felt was a major factor in the low to moderate yields obtained in the 
cyclisation. It was hoped that the racemic alcohol could be oxidised to the ketone to 
give 14,15-anhydrovirginiamycin M2 (6A), which had been reported to be relatively 
more stable at room temperature 95 Attempts to oxidise this alcohol before cyclisation 
had only led to decomposition of the precursor (231) with no indication of oxidation 
of the secondary alcohol. Attempts to oxidise the alcohol after cyclisation was hindered 
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by the instability of the macrocycle and the sheer lack of material on which to work. 
Oxidants tried included activated manganese dioxide, activated manganese dioxide on 
carbon, barium manganate, DDQ, 96 and bis(tributyltin)oxide/iodine, 97 all of which 
gave none of the desired ketone (6A). Scheme 64. 
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However oxidation was finally achieved using Dess-Martin's periodinane in dry 
CH2C12, to give 14,15-anhydrovirginiamycin M2 (6) in 60% yield 98 Verification that 
virginiamycin (6) had been synthesised was obtained by comparison of the 1H and 13C 
nmr spectra of a sample of natural 14,15-anhydrovirginiamycin M2 with our synthetic 
sample. 99 Further confirmation that the intramolecular Stille cyclisation had taken 
place was gained by reduction of the natural 14,15-anhydrovirginiamycin M2 to a 
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product identical to the synthetic 14,15-anhydro-16,37-dihydrovirginiamycin M2 (7) in 
all respects except diastereoisomeric ratio. 
The total synthesis of two members of the virginiamycin family, albeit if in a 
mixture of diastereoisomers in the case of (7), along with the model studies have 
shown the importance of the Stille reaction in the synthesis of polyunsaturated 
macrolide ring systems. The reaction's tolerance to a wide range of functional groups 
and the retention of alkene geometry in the product adds further credence to the 
versatility of the Stille reaction within natural product synthesis. 
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3. EXPERIMENTAL 
General Details 
- 
Melting point determinations were made on a Reichert Kofler 
micro hot-stage apparatus and are uncorrected. IR spectra were recorded on a Perkin- 
Elmer 1720 or 1600 Series FT-IR and were calibrated using a standard polystyrene 
film; the spectra were recorded as thin films. UV spectra were recorded as solutions in 
spectroscopic grade ethanol using a Philips PU 8720 or a Perkin-Elmer Lambda 16 
spectrophotometer. Specific rotations were measured at 25°C in chloroform on a Jasco 
DIP-370 polarimeter. Unless stated otherwise, solutions in deuteriochloroform were 
used for the determination of NMR spectra. Shifts are expressed in ppm downfield 
from Me4Si as internal standard. The IH and 13C nmr spectra were recorded on a 250 
MHz Bruker WM250,270 MHz Jeol EX-270,400 MHz Bruker AM400, or a 500 
MHz Bruker DRX500 instrument. Signals were singlets unless specified otherwise: 
i. e. d= doublet, t= triplet, q= quartet, quint. = quintet, sext = sextet, Sept = septet, 
oct = octet, m= multiplet, br = broad and combinations thereof. Assignments in the 
IH spectra were consistent with signal intensities, and in the 13C spectra with the 
results of the DEPT pulse sequence. Assignments were supported by 2D H-H and H- 
C COSY experiments where necessary. Mass spectra were recorded on an VG 
Autospec or a MM-701CF instrument, using electron impact ionisation at 70 eV unless 
stated otherwise. Microanalytical data were obtained on a Perkin-Elmer 240B elemental 
analyser. Flash chromatography was performed using Merck silica gel 60, and all 
solvents were redistilled before use. Light petroleum refers to the fraction b. p. 40-60 
°C. All reactions were monitored by TLC using Merck silica gel 60 F254 precoated 
aluminium plates. Organic extracts were dried over anhydrous magnesium sulfate prior 
to removal using a Büchi rotary evaporator. 
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4-(tert-Butyldimethylsilyloxy)butene (145). 100 
TBDMSO 
3-Butenol (17.20 cm3,0.2 mol) was added dropwise, over 30 min, to a stirred solution 
of t-butyldimethylchlorosilane (33.16 g, 0.22 mol) and imidazole (14.98 g, 0.22 mol) 
in dry DMF (100 cm3) at 0°C, and the mixture was then stirred overnight while 
allowing it to warm to room temperature. Water (500 cm3) was added and the mixture 
was then extracted with ether (3 x 200 cm3). The extracts were combined and washed 
with water (200 cm3) and the dried solution (MgSO4) was concentrated in vacuo to 
leave the crude silyl ether (37 g, 98%) as a colourless oil; Vm. (cm-1): 1674 (C=C) and 
835 (Si-O); SH (250 MHz CDC13): 5.82 (m, 1 H, CH2CI: CH2), 5.08 (m, 2 H, 
CH: Ct), 3.67 (t, J 6.8 Hz, OCtCH2), 2.28 (q, J 6.8 Hz, OCH2C ), 0.90 
(OSiC(C )3) and 0.06 (OSi(CH3)2); 6C (68.7 MHz CDC13): 135.4 (d), 116.3 (t), 
62.8 (t), 37.5 (t), 25.7 (q), 18.4 (s) and 
-5.3 (q); m/z (EI): 171 (10%, M+-CH3), 115 
(20, TBDMS+), 89 (60), 75 (95), 73 (100) and 57 (20, tBu). 
3-(tert-Butyldimethylsilyloxy)propanal (146). 101 
TBDMSO 
`0 
Ozone was bubbled through a solution of the silyl ether (145) (50 g, 0.2688 mol) in 
dry CH2C12 (500 cm3) at 
-78°C under an atmosphere of nitrogen. Once the mixture 
had turned blue, oxygen was bubbled through the mixture until the blue colouration had 
disappeared indicating the removal of the excess ozone. Triphenylphosphine (70.49 g, 
0.2688 mol) was added in one portion and the mixture was stirred for 1h while 
allowing it to warm to room temperature. The solvent was removed in vacuo and the 
residue was stirred with pentane (500 cm3) for 30 min. The solid precipitate was 
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filtered off and washed with pentane, and the filtrate was then concentrated in vacuo. 
The residue was stirred with pentane (500 cm3) once more and the precipitate filtered 
off. The filtrate was concentrated in vacuo to give the crude aldehyde (68 g) as a 
colourless oil. The aldehyde was carried through crude without further purification; 
Vm,, (cm-1): 1723 (aldehyde C=O) and 835 (Si-O); 81, (400 MHz CDC13): 9.81 (t, J 
2.5 Hz, CdiO), 4.00 (t, J 7.0 Hz, SiOCt), 2.62 (dt, J 2.5 and 7.0 Hz, CtCHO), 
0.92 (SiC(Ch)3) and 0.11 (Si(Cth)2); So (100 MHz CDCl3): 202.3 (d), 57.8 (t), 
46.9 (t), 26.2 (q), 18.6 (s) and 
-5.1 (q). 
(E)-Ethyl 5- (tert-bu tyldim ethylsilyloxy) 
. 
2-pen ten oate (147). 
0 
TBDMSOýOEt 
Triethyl phosphonoacetate (19.84 cm3,100 mmol) was added dropwise, over 30 mim, 
to a stirred suspension of potassium t-butoxide (11.22 g, 100 mmol) in dry THE (200 
cm3) at 0°C under an atmosphere of nitrogen and the mixture stirred at 0°C for 30 min. 
The mixture was then cooled to 
-78°C and the aldehyde (146) (18.8 g, 100 mmol) was 
added dropwise, over 20 min. The mixture was stirred overnight while allowing it to 
warm to room temperature. Water (25 cm3) was added and the mixture was extracted 
with ethyl acetate (3 x 50 cm3), and the extracts were then combined and washed with 
brine. The dried solution (MgSO4) was concentrated in vacuo and the residue was 
purified using flash chromatography (10% Et20 in petroleum ether) to give the ester 
(20.7 g, 80%) as a colourless oil; (Found: C, 60.6; H, 10.4%; M+, 258.1678. 
C13H26O3Si requires C, 60.4; H, 10.1%; M+, 258.1651); Vmax(cm-i): 1724 (C=O), 
1656 (C=C), 981 (trans-C=C-H), 837 and 777 (Si-O); 1 
, a,, 
(EtOH)/nm (c) 210 (16 
409); Sit (400 MHz CDC13): 6.95 (dt, J 15.7 and 7.1 Hz, COCH: C, j ), 5.87 (dt, J 
15.7 and 1.6 Hz, COCJ,: ), 4.2 (q, J 7.1 Hz, CH3CtO), 3.73 (t, J 7.1 Hz, 
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SiOCIL2)9 2.43 (app dq, J 1.6 and 7.1 Hz, CH2C1CH: ), 1.29 (t, J 7.1 Hz, 
C CH2O)9 0.89 (SiC(Cth)3) and 0.06 (Si(CH3)2); 3c (67.8 MHz CDC13): 166.7 
(s), 146.1 (d), 123.2 (d), 61.8 (t), 60.4 (t), 36.0 (t), 26.1 (q), 18.6 (s), 14.5 (q) and 
-5.1 (q); m/z (EI): 213 (7%, M+-OEt), 201 (36, M+-tBu), 145 (8), 133 (39), 103 (100) 
89 (76) and 73 (57). 
(E)-N-Propargyl-S-(tert-butyldimethylsilyloxy)-2-pentenamlde (148). 
0 
rJý\ TBDMSOý"VýA 
H \ý 
Trimethylaluminium 2M in CH2C12 (33.42 cm3,67.83 mmol) was added dropwise, 
over 20 min, to a stirred solution of propargylamine (4.65 cm3,67.83 mmol) in dry 
CH2C12 (200 cm3) at 0°C under an atmosphere of nitrogen in a scrupulously dried 
flask, and the mixture was then stirred for 30 min while allowing it to warm to room 
temperature. The mixture was heated to reflux and the ester (147) (10 g, 38.76 mmol) 
was added in one portion. The mixture was heated under reflux for 2 h, then cooled to 
0°C, and quenched cautiuosly with 1M HCl until no further reaction occurred. The 
mixture was diluted with water (50 cm3) and then extracted with CH2C12 (3 x 100 
cm3). The extracts were combined and washed with brine. The dried solution 
(MgSO4) was evaporated in vacuo and the residue was purified using flash 
chromatography (CH2C12) to give the amide (9.1 g, 88%) as a colourless oil; Vma,, (cm- 
c): 3310 (N-H), 1672 (amide C=O), 1632 (C=C), 1538 (amide dimer), 978 (trans 
C=C-H), 837 and 779 (Si-O); %.,,, (EtOH)/nm (e) 217 (38 016); 811 (400 MHz 
CDC13): 6.85 (dt, J 15.3 and 7.1 Nz, COCH: Cli), 5.85 (dt, J 15.3 and 1.6 Hz, 
COCLI), 5.63 (CONT. ), 4.12 (dd, J 2.5 and 5.3 Hz, CC NH), 3.71 (t, J 6.9 Hz, 
: CHCH2CILO), 2.41 (app dq, J 1.6 and 6.9 Hz, : CHCUiz), 2.24 (t, J 2.5 Hz, 
IICCCH2), 0.89 (SiC(Cth)3) and 0.05 (Si(Cth)2); Sc (67.8 MHz CDC13): 165.6 (s), 
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141.7 (d), 124.7 (d), 79.6 (d), 71.3 (s), 61.6 (t), 35.5 (t), 29.0 (t), 25.8 (q), 18.1 (s) 
and 
-5.4 (q); n/z (FAB): 268 (38%, MH+), 252 (10, M+-Me), 210 (38, M+-tBu), 155 
(38), 136 (6, M+-OTBDMS), 115 (6, TBDMSf) and 73 (100). 
(E)-N-Propargyl-S-hydroxypent-2-enamide (149). 
HO0 
p-Toluenesulphonic acid (1.4 g, 7.31 mmol) was added, in one portion, to a stirred 
solution of the amide (148) (9.76 g, 36.53 mmol) in a mixture of CH2C12 (92 cm3) 
and MeOH (8 cm3) and the mixture was then stirred overnight at room temperature. 
The mixture was washed with brine (5 cm3) and the dried solution (MgSO4) was then 
concentrated in vacuo. The residue was purified using flash chromatography (5% 
MeOH in CHZC12) to give the hydroxyamide (4.2 g, 75%) as a white solid m. p. 84- 
85°C (CH2C12); (Found: C, 62.4; H, 7.4; N, 9.4%; M+, 153.0788. C8Hi1N02 
requires C, 62.7; H, 7.2; N, 9.2%; M+, 153.0790); Vmax(cm-1). 3287 (0-H), 1667 
(amide C=0), 1632 (C=C), 1538 (amide dimer) and 983 (trans C=C-H); X,. ax 
(EtOH)/nm (c): 216 (18 850); 81, (400 MHz CDC13): 6.87 (dt, J 15.3 and 7.1 Hz, 
COCH: CJj), 5.90 (dt, J 15.3 and 1.4 Hz, COCU: ), 5.81 (NIA, 4.13 (dd, J 2.5 and 
5.3 Hz, NHCH2CCH), 3.77 (t, J 6.9 Hz, CH2OH), 2.46 (app dq, J 1.4 and 6.9 Hz, 
: CHCI-I2)9 2.26 (t, J 2.5 Hz, CH2CCH) and 1.76 (OH); So (67.8 MHz CDC13): 168.1 
(s), 143.0 (d), 125.8 (d), 80.5 (d), 72.2 (s), 61.5 (t), 36.2 (t) and 29.5 (t); m/z (EI): 
153 (15%, M+), 135 (13, M+-H20), 122 (70)ý 108 (95), 99 (96), 96 (30, M+- 
propargylamine), 81 (45), 69 (95), 55 (90, propargylamine), 43 (50) and 41 (100). 
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(E)-N-Propargyl-S-acetoxypent-2-enamide (150). 
0 
nook` ý 
Acetic anhydride (6.8 cm3,71.81 mmol) was added dropwise, over 10 min, to a stirred 
solution of the amide (149) (5 g, 32.64 mmol) and pyridine (5.8 cm3,71.81 mmol) in 
dry CH2C12 (300 cm3) at 0°C. DMAP (20 mg) was added and the mixture was stirred 
overnight while allowing it to warm to room temperature. The mixture was washed 
with 1M HCl (50 cm3), then washed with saturated Na2C03 (50 cm3), and finally 
washed with brine (50m1). The dried solution (MgSO4) was concentrated in vacuo and 
the residue was purified using flash chromatography (3% MeOH in CH2C12) to give 
the amide (5.1 g, 80%) as a colourless oil; (Found: C, 54.4; H, 8.7; N, 2.7%, 
Ci0H13N03 requires C, 54.3; H, 8.3; N, 2.9%); Vmax(cm"1): 3287 (N-H), 1732 (ester 
C=O), 1674 (amide C=O), 1633 (C=C), 1538 (amide dimer) and 974 (trans C=C-H); 
811 (400 MHz CDC13): 6.85 (dt, J 15.4 and 6.9 Hz, COCH: CH), 5.86 (dt, J 15.4 and 
1.5 Hz, COCA,: ), 5.70 (NH), 4.18 (t, J 6.9 Hz, AcOCH2), 4.14 (dd, J 2.6 and 5.3 
Hz, NHCtCCH), 2.53 (app dq, J 1.5 and 6.9 Hz, : CHCJi2CH2), 2.25 (t, J 2.6 Hz, 
CHZCCIJ) and 2.06 (OCR, ); Sc (67.8 MHz CDC13): 170.8 (s), 165.3 (s), 139.9 (d), 
125.1 (d), 79.4 (d), 71.1 (s), 62.4 (t), 30.9 (t), 28.8 (t) and 20.8 (q). 
(E, E). N. (3"tri"n-Butylstannyl)prop-2-enyl-5"acetoxypent"2"enamide 
(151). 
0 
AcO N 
'OON Snßu3 H 
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Copper (I) cyanide (1.65 g, 18.44 mmol) was suspended in dry THE (150 cm3) under 
an atmosphere of nitrogen in a scrupulously dried flask. The mixture was cooled to 
-78°C and n-butyllithium 1.6M in hexanes (24.2 cm3,38.75 mmol) was added 
dropwise, over 15 min, and the mixture was then stirred at 
-78°C for 15 min. Tri-n- 
butyltin hydride (10.41 cm3,38.75 mmol) was added dropwise, over 10 min, and the 
mixture was then stirred for a further 15 min at 
-78°C. A solution of the amide (150) 
(3.6 g, 18.44 mmol) in dry THE (5 cm3) was added dropwise, over 5 min, and the 
mixture was then stirred for 30 i'nin at 
-78°C before being quenched with 10% 
NH3/NH4CI solution (5 cm3). The mixture was allowed to warm to room temperature 
and the solids were filtered off. The filtrate was extracted with ethyl acetate (3 x 50 
cm3) and the extracts were combined. The dried solution (MgSO4) was concentrated in 
vacuo and the was residue purified using flash chromatography (10% ethyl acetate in 
petroleum ether) to give the vinyl stannane (5.6 g, 70%) as a colourless oil; (Found 
MH+(FAB) 488.2182, C22H41NO3Sn requires MH+ 488.2186); Vmax(cm-1): 3277 (N- 
H), 1742 (ester C=O), 1671 (amide C=O), 1630 (C=C), 1547 (amide dimer) and 983 
(trans C=C-H); X, $,, (EtOH)/nm (c): 208 (64 092), 213 (69 538) and 216 (71609); 811 
(400 MHz CDC13): 6.83 (dt, J 15.3 and 6.7 Hz, COCH: CH), 6.13 (dt, J 19 and 1.2 
Hz, SnCJj: ), 5.96 (dt, J 19 and 5.3 Hz, SnCH: Cjj). 5.89 (dt, J 15.3 and 1.5 Hz, 
COCH: ), 5.57 (Nfi), 4.17 (t, J 6.7 Hz, AcOCth), 4.01 (app dt, J 1.1 and 5.3 Hz, 
NHCtCH: ), 2.52 (app dq, J 1.5 and 6.7 Hz, : CHCH2CH2), 2.05 (OCh3), 1.48 
(pent, J 7.1 Hz, SnCH2Cli2CH2), 1.31 (hext, J 7.1, SnCH2CH2CH2CH3) and 0.88 
(t, J 7.1 Hz, SnCjj2CH2CH2Cth); So (67.8 MHz CDC13): 170.8 (s), 165.0 (s), 
143.2 (d), 139.2 (d), 129.8 (d), 125.7 (d), 62.5 (t), 44.7 (t), 31.0 (t), 29.0 (t), 27.4 
(t), 20.6 (q), 13.5 (q) and 9.2 (t); m! z (FAB): 488 (20%, MH+), 430 (100, M+-Bu), 
291 (20, Bu3SnH), 177 (100), 99 (60, M+-HNCH2CH: CHSnBu3) and 55 (16, 
propargylamine). 
98 
(E, E)-N-(3-tri-n-Bu tylstannylprop-2-enyl)-S. hydroxypent-2-enamide 
(132). 
HO N ýýý SnB u3 H 
Potassium carbonate (1.07 g, 7.1 mmol) was added, in one portion, to a stirred 
solution of the acetoxyamide (151) (3.43 g, 7.06 mmol) in wet methanol (30 cm3) at 
0°C and the mixture was then stirred for 1h at room temperature. Brine (30 cm3) was 
added and the mixture was extracted with CH2C12 (3 x 50 em3). The extracts were 
combined and the dried solution (MgSO4) was concentrated in vacuo to leave the 
hydroxyamide (3.2 g, 98%) as a colourless oil; (Found: MH+, 446.2140. 
C20H4ONO2Sn requires MH+, 446.2090); Vma,, (cm-1): 3290 (N-H, O-H), 1670 (amide 
C=0), 1633 (C=C) and 1540 (amide dimer); A, max (EtOH)/nm (e): 202 (85 688) and 
214 (112 119); SI, (270 MHz CDC13): 6.85 (dt, J 15.5 and 6.9 Hz, COCH: C11), 6.11 
(dt, J 18.8 and 1.3 Hz, SnCII: CH), 5.96 (dt, J 18.8 and 9.9 Hz, SnCH: CII), 5.92 
(dt, J 15.5 and 1.3 Hz, COCII: CH), 5.52 (NJjCO), 4.00 (dt, J 1.3 and 6.9 Hz, 
CH2OH), 3.77 (app q, J 6.0 Hz, NHCCH: ), 2.47 (app dq, J 1.3 and 6.9 Hz, 
COCH: CHCH. L), 1.50 (pent, J 6.9 Hz, SnCH2CJi2), 1.30 (hext, J 6.9 Hz, 
SnCH2CH2Chi2) and 0.89 (t, J 6.9 Hz, SnCtCH2CH2Cth); SC (67.8 MHz CDC13): 
165.7 (s), 143.2 (d), 141.1 (d), 130.1 (d), 125.6 (d), 60.7 (t), 44.8 (t), 35.2 (t), 28.9 
(t), 27.2 (t), 13.6 (q) and 9.3 (t); m/z (FAB): 446 (15%, MP), 388 (30, M+-Bu), 291 
(10, Bu3SnH), 274 (15), 235 (25) and 177 (100). 
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(-)-(E, E)-N-(3-tri-n-B utylstannylprop-2-enyl)-S-(N-(9-fluorenyl- 
methoxy carbonyl)-(S)-prolinoyloxypent-2-enamide (216). 
O0 
FmocN '' ON/ SnBu3 
DCC (1.43 g, 6.93 mmol) was added, in one portion, to a suspension of N-Fmoc-L- 
proline (4.67 g, 13.85 mmol) (from Novo Biochem) in dry CH2C12 (50 cm3) at 0°C 
under an atmosphere of nitrogen. The mixture was stirred at this temperature for 30 
min and the hydroxyamide (132) (2.05 g, 4.62 mmol) and DMAP (0.69 g, 4.7 mmol) 
were then added in one portion. The mixture was stirred for 3h and the solid 
precipitate was then filtered off, and the filtrate was concentrated in vacuo. The residue 
was purified using flash chromatography (5% MeOH in CH202) to give the proline 
ester (3.7 g, 90%) as a colourless sticky solid as a mixture of rotamers; (Found: C. 
62.6; H, 7.4; N, 3.5%. C40H56N2O3Sn requires C, 62.9; H, 7.4; N, 3.7%); [aID 
-6.10 (c 1.405 in CHC13); Vm., (cm"1): 3306 (N-H), 1741 (ester C=O), 1701 (amide 
C=O), 1631 (C=C), 1536 (amide dimer), 987 (trans-C=C-H), 739 and 702 (aromatic 
C-H); SH (400 MHz CDC13): 7.75 (t, J 7.2 Hz, 2 H, aromatic CI), 7.61 (t, J 7.2 Hz, 
2 H, aromatic Cu. ), 7.40 (t, J 7.2 Hz, 2 H, aromatic CJj), 7.31 (t, J 7.2 Hz, 2 H, 
aromatic Cif), 6.82 (m, 1 H, COCH: Cji), 6.12 (dt, J 18.5 and 1.2 Hz, SnCjj: ), 5.95 
(dt, J 18.5 and 5.4 Hz, SnCH: CID, 5.87 (dt, J 15.3 and 1.2 Hz, COCH), 5.69 (m, 1 
H, NW, 4.40 (m, 2 H, OC CH), 4.30 (m, 1 H, 02C C JjN), 4.20 (m, 3 H, 
OCH2CJj and OCtCH2), 3.99 (t, J 5.4 Hz, NHC CH: ), 3.50-3.65 (m, 2 H, 
CONCH), 2.52 (app q, J 6.6 Hz, OCH2CH2), 1.80-2.20 (m, 4 H, COCHCH2 and 
CONCH 2C Jj2), 1.46 (pent J 6.6 Hz, SnCH2C 
, 
), 1.29 (hext, J 6.6 Hz, 
SnCH2CH2Cth) and 0.89 (t, J 6.6 Hz, SnC 
, 
CH2CH2Cth); SC (67.8 MHz CDC13): 
172.8 (s), 172.6 (s), 165.8 (s), 165.4 (s), 155.1 (s), 154.8 (s), 144.3 (d), 144.2 (d), 
141.5 (s), 139.1 (d), 138.7 (d), 130.0 (d), 129.7 (d), 128.0 (d), 127.4 (d), 126.6 (d), 
100 
126.5 (d), 125.4 (d), 125.3 (d), 120.3 (d), 67.8 (t), 67.7 (t), 63.3 (t), 60.6 (t), 59.5 
(t), 59.2 (t), 47.5 (d), 47.4 (d), 47.2 (t), 46.8 (t), 45.1 (t), 45.0 (t), 31.3 (t), 31.0 (t), 
29.3 (t), 27.5 (t), 24.7 (t), 23.6 (t), 14.0 (q) and 9.7 (t); m/z (FAB): 714 (100%), 656 
(10), 544 (15), 426 (10), 368 (10), 291 (10, Bu3SnH), 254 (10), 235 (35), 179 (75), 
133 (15), 91 (10) and 73 (20). 
(-)-(E, E)-N-(3. Tri-n-b utylstannylprop-2-enyl-)S. (S)-prolinoyloxypent- 
2-enamide (217). 
00 j 
wo. ý 
"' 0N/ SnBu3 H 
The Fmoc-proline ester (216) (1 g, 1.13 mmol) was added, in one portion, to a 
solution of piperidine (0.4 cm3,4.5 mmol) in acetonitrile (4 cm3) and the solution was 
then stirred at room temperature for 30 min. The mixture was concentrated in vacuo 
and the residue was then purified using flash chromatography (5% MeOH in ethyl 
acetate) to give the proline ester (560 mg, 90%) as a colourless oil; (Found: C, 55.3; H, 
8.85; N, 4.85%. C8H1jN02 requires C, 55.5; H, 8.6; N, 5.2%); [a]D 
-9.20 (c 1.96 
in CHC13); Vma,,. (cm-1): 3286 (N-H), 1731 (ester C=0), 1673 (amide C=O), 1633 
(C=C), 1555 (amide dimer) and 983 (trans C=C-H); X..,, (EtOH)/nm (E): 207 (63 841) 
and 216 (70 148); 811 (400 MHz CDC13): 6.82 (dt, J 15.4 and 6.6 Hz, COCH: CI), 
6.10 (dt, J 19 and 1.3 Hz, SnCJj: CH)9 5.96 (dt, J 19 and 5.4 Hz, SnCH: CJj), 5.87 
(dt, J 15.4 and 1.3 Hz, COCJj: CH), 5.71 (NUCO), 4.22 (t, J 6.6 Hz, C02C112), 3.98 
(app t, J 5.4 Hz, NHCJCH: ), 3.73 (dd, J 5.5 and 8.2 Hz, HNCHCO2), 3.05 (dt, J 
6.4 and 10.0 Hz, HNCL. HCH2), 2.88 (dt, J 6.4 and 10.0 Hz, HNCHjjCH2), 2.53 
(app q, J 6.6 Hz, OCH2CU2CH: ), 2.18 (CH2NIICH), 2.10 (app dq, J 8.2 and 12.6 
Hz, HNCHCJIH), 1.80 (app dq, J 8.2 and 12.6 Hz, HNCHCIJH), 1.74 (m, 2H, 
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HNCH 2C), 1.47 (pent, J 6.6 Hz, SnCH2C th), 1.29 (hext, J 6.6 Hz, 
SnCH2CH2CH2) and 0.88 (t, J 6.6 Hz, SnCH2CH2CH2Cth); Sc (67.8 MHz CDC13): 
174.9 (s), 164.7 (s), 143.3 (d), 138.6 (d), 129.5 (d), 125.8 (d), 62.7 (t), 59.3 (d), 
46.7 (t), 44.6 (t), 30.9 (t), 30.0 (t), 28.7 (t), 26.9 (t), 25.2 (t), 13.4 (q), and 9.1 (t); 
m/z (FAB): 525 (20%), 469 (10), 432 (20), 376 (95), 347 (10), 283 (15), 266 (25), 
229 (45), 172 (100), 134 (15), 118 (25), 97 (55) and 69 (45). 
erythro-2,3-Dibromobutanol (189). 80 
Br 
HO 
Br 
A solution of bromine (60 cm3,1.16 mol) in carbon tetrachloride (50 cm3) was added 
dropwise, over 2 h, to a stirred solution of Ecrotyl alcohol (80 g, 1.11 mol) in carbon 
tetrachloride (500 cm3) at 
-20°C under an atmosphere of nitrogen The mixture was 
stirred for an additional 2h at 
-20°C and then allowed to warm to room temperature. 
The solvent was removed in vacuo and the residue was distilled to give the dibromide 
(206 g, 80%) as a low melting colourless solid, m. p. 35-36°C, b. p. 119°C @ 18 mmHg 
(Lit. 80 m. p. 36°C, b. p. 117°C @ 17 mmHg); Vma,, (cm3): 3361 (O-H), 1450 (C-H) 
and 1065 (C-0); 8H (270 MHz CDC13): 4.32 (m, Cf, BrCH3), 4.22 (m, 
CIIBrCH2OH), 4.05 (t, J2 Hz, CHBrCt) and 1.90 (d, J 6.6 Hz, CHBrC ); 6c 
(67.8 MHz CDC13): 65.8 (t), 61.9 (d), 47,6 (d) and 25.2 (q). 
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(E)-3-Bromo-2-butenol (155)80. 
HO" Br 
n-Butyllithuim 1.6M in hexanes (103 cm3,165.6 mmol) was added slowly to a stirred 
solution of diisopropylamine (22.4 cm3,158.7 mmol) in dry THE (225 cm3) at -20°C 
under an atmosphere of nitrogen The mixture was stirred for 15 min at -20°C and then 
cooled to 
-78°C. A solution of the dibromide (189) (16 g, 69 mmol), in dry THE (25 
cm3), was added dropwise over 2h while maintaining the temperature at -78°C. The 
mixture was stirred at 
-78°C for a further 1h and then allowed to warm to -50°C before 
it was quenched with water (50 cm3). The mixture was allowed to warm room 
temperature, and then iM HCl (200 cm3) was added. The mixture was extracted with 
ethyl acetate (3 x 200 cm3), and the extracts were then combined and washed with 1M 
HCl (200 cm3) and brine. The dried solvent (MgSO4) was concentrated in vacuo and 
the residue was purified using flash chromatography (5% Et20 in CH2C12) to give the 
alcohol (4.3 g, 43%) as a pale yellow oil; Vmax(cm-1): 3329 (0-H) and 1651 (C=C); 
811 (270 MHz CDC13): 6.11 (dt, J 1.3 and 6.9 Hz, HOCH2CII: ), 4.13 (t, J 6.9 Hz, 
C OH), 2.31 (CH3) and 1.38 (t, J 6.9, CH2OU); SC (67.8 MHz CDC13): 130.7 (d), 
123.7 (s), 59.1 (t) and 23.4 (q). 
(E). 3. Bromo-2-butenal (153). 
p' / Br 
Activated manganese dioxide (28.8 g, 0.3312 mol) was added carefully, in one 
portion, to a stirred solution of alcohol (155) (5 g, 33.12 mmol) in dry CH2C12 (150 
103 
cm3) and the mixture was then stirred at room temperature overnight. The mixture was 
filtered through celite and the solvent was then removed carefully in vacuo. The 
residue was purified using flash chromatography (CH2C12) to give the aldehyde (3.4 g, 
70%) as a pale yellow oil (identical to that in ref. 102); Vmax (cm*'): 1700 (aldehyde 
C=O) and 1623 (C=C); ax (EtOH)/nm (c) 284 (18 558); 811 (270 MHz CDC13): 9.80 
(d, J 7.5 Hz, CiO), 6.52 (d, J 7.5 Hz, CHO: CJj) and 2.80 (: CHBrC1b); Sc (67.8 
MHz CDCl3) 186.9 (d), 148.9 (s), 133.3 (d) and 25.0 (q). 
(E, E)-Ethyl 5-bromohexa-2,4-dienoate (201). 
Et42C / 04 Br 
Triethyl phosphonoacetate (6.26 cm3,31.54 mmol) was added dropwise, over 10 min, 
to a stirred suspension of potassium t-butoxide (3.54 g, 31.54 mmol) in dry THE (100 
cm3) at 0°C under an atmosphere of nitrogen. The mixture was stirred at 0°C for 30 
min, then cooled to 
-78°C when the aldehyde (153) (4.7 g, 31.54 mmol) was added 
dropwise over 10 min. The mixture was stirred at -78°C for 2 h, then water (25 cm3) 
was added slowly and the mixture was allowed to warm to room temperature. The 
mixture was extracted with ethyl acetate (3 x 50 cm3) and the extracts were then 
combined and washed with brine. The dried (MgSO4) extracts were concentrated in 
vacuo and the residue was purified using flash chromatography (10% ethyl acetate in 
petroleum ether) to give the ester (4.6 g, 68%) as a pale yellow oil (Found: C, 43.6; H. 
5.2; Br, 36.2%; M+, 217.9913. C8Hi1BrO2 requires C, 43.8; H, 5.1; Br, 36.5%; M+, 
217.9943); Vmax(cm-1): 1714 (C=O), 1626 (C=C) and 975 (trans-C=C-H); ''max 
(EtOH)/nm (e): 272 (35 100); S1, (400 MHz CDC13): 7.34 (dd, J 11.6 and 15.2 Hz, 
COCH: CH.: CH), 6.60 (d, J 11.6 Hz, : CIiCBr(CH3)), 5.82 (d, J 15.2 Hz, 
COC I: CH), 4.22 (q, J 7.1 Hz, OCI12CH3), 2.48 (: CHBr(C113)) and 1.30 (t, J 7.1 
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Hz, CII3CH2O); 8C (67.8 MHz CDC13): 167.8 (s), 137.9 (d), 132.3 (s), 130.3 (d), 
121.5 (d), 60.5 (t), 24.4 (q) and 14.2 (q); Wz (EI) 219 (20%, M+), 173 (29, M+- 
OEt), 139 (15, M+-Br) and 111 (100, M+-OEt, 
-Br). 
(E, E)-S-Bromo-2,4-hexadienol (202). 
HO Br 
Diisobutylaluminium hydride 1M in CH2C12 (196 cm3,195.5 mmol) was added 
dropwise, over 1 h. to a stirred solution of the ester (201) (21 g, 96.77 mmol) in dry 
CH2Cl2 (400 cm3) at 
-78°C under an atmosphere of nitrogen, and the mixture was then 
stirred at 
-78°C for 1 h. The mixture was allowed to warm to room temperature, and 
then methanol (20 cm3) and MgSO4 were added and the mixture was stirred vigorously 
until the aluminium salts had precipitated out. The solid precipitates were filtered off 
(celite) and washed repeatedly with CH2C12. The filtrate and washings were combined 
and concentrated in vacuo to leave the alcohol (17g, 98%) as a colourless oil; (Found: 
M+ 175.9834. C6H9BrO requires Mf 175.9837); Vmax(cm"1): 3382 (0-H), 1652 
(C=C) and 965 (trans 
-C=C-H); , max (EtOH)/nm (E): 239 (5621); 81, (250 MHz 
CDC13): 6.49 (dd, J 1.2 and 14.9 Hz, Cfl: C(CH3)Br), 6.31 (tt, J 1.2 and 14.9 Hz, 
HOCH2CH: Cjj), 5.83 (dt, J 14.9 and 5.3 Hz, HOCH2CII: ), 4.19 (d, J 5.3 Hz, 
HOCH2CH: ), 2.36 (d, J 1.2 Hz, Cth) and 1.57 (OJj); Sc (100 MHz CDC13): 132,7 
(d), 131.2 (d), 125.2 (d), 122.9 (s), 62.5 (t) and 23.6 (q); m/z (EI): 176 (30%, M+), 
97 (100, M+-Br) and 43 (95), which was used without further purification. 
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(E, E)-S-Bromo-2,4-hexadienal (195). 
Br 
Activated manganese dioxide (12.3 g, 141.2 mmol) was carefully added, in one 
portion, to a stirred solution of the alcohol (202) (2.5 g, 14.12 mmol) in dry CH2C12 
(100 cm3) and the mixture was stirred at room temperature overnight. The mixture was 
filtered through celite and the solvent was then removed in vacuo. The residue was 
purified using flash chromatography (CH2C12) to give the aldehyde (1.9 g, 80%) as a 
pale yellow oil; Vm, (cm-1): 1684 (aldehyde C=O), 1617 (C=C) and (trans-C=C"H); 
X,. 
a, 
(EtOH)/nm (c) 284 (18 558); 811 (270 MHz CDC13): 9.6 (d, J 8.1 Hz, CIJO), 
7.20 (dd, J 11.6 and 15.0 Hz, CJj: CHCHO), 6.76 (d, J 11.6 Hz, Cl: CBr(CH3)), 
6.15 (dd, J 15.0 and 8.1 Hz, C: CHCHO) and 2.54 (C3); SC (67.8 MHz CDC13): 
193.2 (d), 144.7 (d), 134.5 (s), 131.3 (d), 130.5 (d) and 24.4 (q). 
N-Methoxy-N-methylacetamide (191). 103 
McO, 
Ný 
Acetyl chloride (4 cm3,56.34 mmol) was added dropwise, over 10 min, to a stirred 
solution of N, O-dimethylhydroxylamine hydrochloride (190) (5 g, 51.25 mmol) and 
triethylamine (15 cm3,107.6 mmol) in dry CH2C12 (100 cm3) at 0°C under an 
atmosphere of nitrogen. The mixture was stirred overnight and was then washed with 
2M HCl (50 cm3), and washed with brine (50 cm3). The dried solution (MgSO4) was 
concentrated in vacuo to give the amide (4.20 g, 80%) as a colourless oil; Vmax(cm"1): 
1664 (amide C=O); 511 (400 MHz CDC13): 3.69 (OCt), 3.18 (NCI) and 2.13 
106 
(COCt); 6c (67.8 MHz CDC13): 171.6 (s), 60.7 (q), 31.6 (q) and 19.5 (q). 
(+/-)-(E)-N-Methoxy-N-methyl-5-bromo-3-hydroxy-4-hexenamide 
(192). 
O OH 
McO, 
N Br 
1 
A solution of potassium hexamethyldisilazane 0.5M in THE (21 cm3,10.50 mmol) 
was addgd dropwise, over 30 min, to a stirred solution of the amide (191) (1.03g, 10 
mmol) in dry THE (100 cm3) at -78°C under an atmosphere of nitrogen. The mixture 
was stirred at 
-78°C for 10 min and then a solution of the aldehyde (153) (1.56 g, 
10.50 mmol), in dry THE (3 cm3), was added dropwise over 5 min. The mixture was 
stirred at 
-78°C for 1h and quenched with saturated NH4C1 solution (5 cm3). Water 
(50 cm3) was added and the mixture was then extracted with ethyl acetate (3 x 50 cm3). 
The extracts were combined and washed with brine, and the dried solution (MgSO4) 
was concentrated in vacuo. The residue was purified using flash chromatography (2% 
MeOH in CH2C12) to give the hydroxyamide (1.4 g, 60%) as an orange oil as a racemic 
mixture: (Found: C. 40.9; H, 6.0; N, 5.9%. C8H14BrNO3 requires C, 40.7; H, 6.0; 
N, 5.9%); Vma,, (cm-1): 3416 (0-H), 1721 (amide C=0), 1653 (C=C) and 989 (trans- 
C=C-H); 8H (250 MHz CDC13): 5.95 (dd, J 1.1 and 8.5 Hz, CHOHCU: ), 4.72 (dt, J 
8.5 and 6.0 Hz, CH2CHOH), 3.88 (01j), 3.68 (OCt), 3.19 (NCt), 2.64 (d, J 6.0 
Hz, COC CH), 2.31 (d, J 1.1 Hz, : C(Ct)Br); SC (67.8 MHz CDC13): 172.8 (s), 
133.2 (d), 124.0 (s), 66.0 (d), 61.5 (q), 38.1 (t), 32.1 (q) and 24.2 (q); in/z (EI): 254 
(100%, M+), 172 (60, M+-Br), 154 (40, M+-Br, 
-H20), 149 (30, aldehyde from retro- 
aldol), 111 (20), 69 (20), 61 (N, O-dimethyl hydroxylamine), 43 (70). 
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(+/-)"(E)-N-Methoxy-N-methyl"5-bromo-3. (methoxy)methoxy-4- 
hexenamide (193). 
O OMOM 
McO"N 
Br 
Chloromethyl methyl ether (1.57 ml, 20.7 mmol) was added in four portions, at 30 
min intervals, to a solution of the hydroxy-amide (192) (580 mg, 2.30 mmol) and 
diisopropylethylamine (0.8 ml, 4.6 mmol) in dry CH2C12 (25 ml) which was heated to 
reflux, under an atmosphere of nitrogen. The mixture was heated for a further 30 min 
and then allowed to cool to room temperature. The mixture was washed with water (20 
ml) and the dried solution (MgSO4) was concentrated in vacuo. The residue was 
purified using flash chromatography (CH2C12) to give the amide (470mg, 70%) as a 
colourless oil; 'Umar( cm-t): 1651 (C=0) and 918 (trans-C=C-H); 81, (400 MHz 
CDC13): 5.79 (dd, J 1.6 and 9.7 Hz, CHORCIj: ), 4.81 (dt, J 5.2 and 9.7 Hz, 
CH2CIIOR), 4.52-4.67 (dd, J 6.8 and 6.8 Hz, OCI322OCH3), 3.71 (NOCt), 3.36 
(OCR), 3.19 (NC}), 2.89 (dd, J8 and 14.8 Hz, COCHHCHOR), 2.52 (dd, J 5.2 
and 14.8 Hz, COCHJICHOR), 2.35 (: CBr(CH3)); Sc (100 MHz CDC13): 170.9 (s), 
131.3 (d), 125.2 (s), 93.7 (t), 68.8 (d), 61.4 (q), 55.5 (q), 37.6 (t), 32.1 (q), 24.1 
(q); m/z EI): 250 (2%), 216 (15, M+-Br), 154 (7, M+-Br, 
-OMOM), 61 (8, MOMO+), 
45 (100, MOM+). 
Ethyl 2-((ethoxyethylidene)amino)acetate (171). 79 
Et0" Noe*4*.. COZEt 
108 
Ethyl acetimidate hydrochloride (169) (50 g, 0.4046 mol) and cold ether (200 cm3) 
were placed in a seperating funnel and a slurry of potassium carbonate (66.2 g, 0.48 
mol), in cold water (100 cm3), was added. The mixture was shaken vigorously for 5 
min and the organic layer was then removed. The aqueous layer was extracted with 
ether (200 cm3) and the organic layers were combined and placed in a clean seperating 
funnel. A solution of glycine ethyl ester hydrochloride (170) (56.4 g, 0.4046 mol), in 
cold water (100 em3), was added to the organic extracts and the mixture was shaken 
vigorously for 15 min. The organic layer was removed and dried (MgSO4), and the 
solvent was carefully removed in vacuo to give the imino ether (44 g, 63%) as a 
colourless oil: Vmax(cm"1): 1748 (ester C=O) and 1682 (C=N); ö (250 MHz CDC13): 
4.16 (q, J7 Hz, CO2CtCH3), 4.08 (q, J7 Hz, CH3C132OC: N), 4.02 (: NCtCO), 
1.89 (CH3), 1.22 (t, J7 Hz, CO2CH2C ) and 1.12 (t, J7 Hz, CtCH2OC: N); Sc 
(100 MHz CDC13): 171.0 (s), 164.7 (s), 80.8 (t), 80.6 (t), 14.1 (q) and 14.0 (q). 
2-Methyloxazole-4-ethylcarboxylate (173). 79 
EtOZCYN 
0 
The imino ether (171) (100 g, 0.578 mol) was added dropwise, over 30 min, to a 
suspension of potassium t-butoxide (71.3 g, 0.6358 mol) in dry THE (150 em3) at 
-20°C under an atmosphere of nitrogen, and ethyl formate (51.4 cm3,0.6358 mol) was 
added dropwise over 30 min. The mixture was stirred at 
-20°C for 2 h, then dry ether 
(300 cm3) was added, and the mixture was stirred at 
-20°C for a further 2 h. The 
mixture was allowed to warm to room temperature and the solvent was then removed in 
vacuo. Hot glacial acetic acid (150 cm3) was added to the residue, and the mixture was 
then heated under reflux until all the solids had dissolved. The mixture was cooled in 
an ice-bath and then basifled cautiously with sodium carbonate. The mixture was 
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diluted with water (150 cm3) and then extracted with ethyl acetate (3 x 200 cm3). The 
organic extracts were combined and washed with brine. The dried solution (MgSO4) 
was concentrated in vacuo and the residue was purified using flash chromatography 
(20% ethyl acetate in petroleum ether) to give the oxazole (66 g, 88%) as a colourless 
. 
(cm-1): 1735 (C=O) and 1592 (cyclic C=N-); 811 (250 MHz CDC13): 8.11 oil; V.,,,, 
(oxazole : Ckj), 4.35 (q, J 7.1 Hz, CH3CO), 2.50 (C) and 1.36 (t, J 7.1 Hz, 
CtCH2O); Sc (67.8 MHz CDC13): 161.5 (s), 160.3 (s), 143.0 (d), 132.6 (s), 60.0 
(t), 13.23 (q) and 12.8 (q). 
4-Hydroxymethyl-2"methyloxazole (184). 29 
N HO 0000 
O 
A solution of diisobutylaluminium hydride 1.5M in hexanes (86 cm3,0.1289 mol) was 
added dropwise, over 1 h, to a stirred solution of the oxazole (173) (10 g, 64.45 
mmol) in dry CH2C12 (200 cm3) at -78°C under an atmosphere of nitrogen and the 
mixture was then stirred at 
-78°C for 3 h. The mixture was allowed to warm to room 
temperature and then methanol (20 cm3) and MgSO4 were added and the mixture stirred 
vigorously until the aluminium salts had precipitated out. The solids were filtered off 
and washed repeatedly with CHZC12. The filtrate and washings were combined and 
concentrated in vacuo and the residue was purified using flash chromatography 
(CH2C12) to give the alcohol (4.8g, 60%) as an off white solid, m. p. 52-53°C (ether); 
(Found: C, 52.8; H, 6.5; N, 12.3%; M+, 113.0477. CSH7NO2 requires C, 53.1; H, 
6.2; N, 12.4%; M+, 113.0477); Vmax(cm-1): 3351 (0-H), 1650 (C=C) and 1580 
(cyclic C=N); 811(250 MHz CDC13): 7.49 (oxazole : CH), 4.56 (d, J 3.8 Hz, C H2011). 
2.64 (t, J 3.8 Hz, OH) and 2.46 (CH3); Sc (67.8 MHz CDC13): 162.0 (s), 140.2 (s), 
134.8 (d), 55.5 (t) and 13.5 (q); m/z (EI): 113 (100%, M+), 112 (99, M+-H), 96 (16, 
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M+-OH), 84 (71), 82 (7, M+-CH2OH), 71(82), 43 (79) and 42 (98). 
4-(tert-Bu tyldimethylsiloxymethyl). 2-methyloxazole (185). 
TBDMSOý N 
0 
A solution of the oxazole (184) (1.2 g, 10.61 mmol), in dry DMF (5 cm3), was added 
dropwise, over 10 min, to a stirred solution of imidazole (0.8 g, 11.67 mmol) and 
chloro-tert-butyldimethylsilane (1.76 g, 11.67 mmol) in dry DMF (15 cm3), at 0°C, 
under an atmosphere of nitrogen. The mixture was stirred overnight and then poured 
into iced water (100 cm3). The mixture was extracted with ether (3 x 50 cm3) and the 
extracts were combined and the dried solution (MgSO4) was concentrated in vacuo to 
give the crude protected oxazole (2.5 g, 96%) as a colourless oil; (Found M+--Me, 
212.1076. Ci 1H21NO2Si requires M+--Me, 212.1064); Vm87, (cm-'): 1582 (cyclic 
C=N) and 838 and 779 (Si-0); Stt (270 MHz CDC13): 7.42 (oxazole : CH), 4.62 
(HOCH), 2.42 (Ct), 0.92 (OSi(C(Cth)3) and 0.11 (OSi(Cli3)2); Sc (67.8 MHz 
CDC13): 161.4 (s), 141.4 (s), 134.6 (d), 58.5 (t), 25.8 (q), 18.3 (s) and 
-5.5 (q); m1z 
(EI): 212 (15%, M+--Me), 170 (100, M+--tBu), 96 (70, M+'-TBDMSO) and 75 (90). 
(+/-)-2-((E, E)-6-Bromo-2-hydroxyhepta-3,5-dienyl). 4. (tert- 
butyldimethyl-siloxymethyl) oxazole (200). 
TBDMSOýN Br 
0 OH 
A solution of n-butyllithium 1.6M in hexanes (3.2 cm3,5.143 mmol) was added 
dropwise, over 5 min, to a stirred solution of the protected oxazole (185) (1.25 g, 
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5.143 mmol) in dry THE (50 cm3), at -78°C, under an atmosphere of nitrogen. The 
mixture was stirred at 
-78°C for 15 min and then the aldehyde (193) (1 g, 5.714 
mmol) was added dropwise, over 1 min, and the mixture was stirred at -78°C for a 
furhter 30 min. The mixture was allowed to warm to room temperature over 30 min 
and was then quenched with saturated NH4CI solution (10 cm3). The mixture was 
extracted with ethyl acetate (3 x 25 cros) and the extracts were combined. The dried 
solution (MgSO4) was concentrated in vacuo and the residue was purified using flash 
chromatography (2% MeOH in CH202) to give the oxazole (884 mg, 38%) as a brown 
oil; (Found: M+, 401.1022. C17H28BrNO3Si requires M+, 401.1022); Vmax(cm-i): 
3356 (0-H), 1646 (C=C), 1568 (cyclic C=N), 969 (trans-C=C-H) and 839 and 779 
(Si-0); SH (270 MHz CDC13): 7.47 (oxazole : CH), 6.42 (dd, J 1.1 and 11.2 Hz, 
: CHCji: CBr), 6.36 (dd, J 11.2 and 14.2 Hz, CHOHCH: C}1), 5.73 (dd, J 6.1 and 
14.2 Hz, CHOHCJj: ), 4.68 (m, CHOH), 4.66 (SiOCH2), 2.95 (m, CtCHOH), 
2.36 (: C(Ct)), 0.92 (OSi(C(CIb)3)) and 0.11 (OSi(Ct)2); so (67.8 MHz CDC13): 
162.8 (s), 140.8 (s), 134.8 (d), 134.3 (d), 131.1 (d), 125.2 (d), 123.5 (s), 69.0 (d), 
58.2 (t), 35.5 (t), 25.7 (q), 23.6 (q), 18.2 (s) and 
-5.4 (q); m/z (CI): 401 (5%, M+), 
344 (40, M+-tBu), 252 (15, M+-TBDMSO), 227 (oxazole portion from retro-aldol), 
170 (50), 95 (85) and 75 (100). 
(+/-). 2-((E, E)-6-Bromo-2-hydroxyhepta-3,5-dienyl). 4- 
hydroxymethyloxazole (203). 
HON Br 
`00ý CI 
0 OH 
A solution of n-butyllithium 2.5M in hexanes (23.1 cm3,60 mmol) was added 
dropwise, over 15 min, to a stirred solution of the hydroxy oxazole (184) (3.23 g, 
28.6 mmol) in dry THE (50 cm3) at 
-78°C under an atmosphere of nitrogen. The 
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mixture was stirred at -78°C for 15 min and then the aldehyde (195) (5 g, 28.6 mmol) 
was added dropwise, over 10 min, and the mixture was stirred at -78°C for a furhter 30 
min. The mixture was allowed to warm to room temperature over 30 min and then 
quenched with saturated NH4C1 solution (10 cm3). The mixture was extracted with 
ethyl acetate (3 x 50 cm3) and the extracts were combined. The dried solution (MgSO4) 
was concentrated in vacuo and the residue was purified using flash chromatography 
(3% MeOH in CH2C12) to give the diol (3 g, 45%) as an orange oil; (Found: C, 45.5; 
H, 4.9; N, 4.7%; M+-H20,269.0052. C8H11N02 requires C, 45.85; H, 4.9; N, 
4.9%; M+-H20,269.0051); Vm. (cm-1): 3384 (O-H), 3156 (0-H), 1647 (C=C), 1565 
(cyclic C=N-), 1318 (0-H) and 968 (trans C=C-H); ? ax (EtOH)/nm (e): 233 (8044) 
and 256 (6794); SH (400 MHz CDC13): 7.53 (oxazole : CI), 6.45 (dd, J 1.2 and 11.1 
Hz, : CHCfi: CBr), 6.38 (dd, J 11.1 and 14.8 Hz, CHOHCH: Cli), 5.74 (dd, J 5.8 and 
14.8 Hz, CHOHCji: ), 4.66 (app q, J 5.8 Hz, CH2CjjOH), 4.56 (HOC112), 3.63 
(OH), 2.96 (m, 2H, Chi 
, 
CHOR), 2.71 (OH) and 2.35 (Ct); Sc (67.8 MHz CDC13): 
162.4 (s), 139.7 (d), 135.2 (d), 134.4 (d), 130.9 (d), 125.0 (d), 123.6 (s), 68.9 (d), 
55.5 (t), 35.8 (t) and 23.5 (q); rn/z (CI): 287 (11%, M+), 270 (37, M+-H20), 208 (18, 
M+-Br), 190 (8, M+-Br, 
-H20), 175 (26, aldehyde from retro aldol), 113 (96, oxazole 
from retro aldol), 95 (100, aldehyde-HBr) and 67 (20). 
(+/-)-2-((E, E)-6-Bromo-2-hydroxyhepta-3,5-dienyl)-4-formyloxazole 
(205). 
0 Br 
0 OH 
Activated manganese dioxide (24.6 g, 260 mrnol) was added carefully, in one portion, 
to a stirred solution of the diol (203) (2 g, 12.98 mmol) in dry C112C12 (150 ml) and 
the mixture was stirred at room temperature overnight. The mixture was filtered 
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through celite and the filtrate concentrated in vacuo. The residue was purified using 
flash chromatography (CH2C12) to give the aldehyde (1.3 g, 70%) as an orange solid, 
m. p. 30-32°C; (Found: M+-H20,266.9670. CtoH11BrN02 requires M+-H20, 
266.9695); Vmax(cm-1): 3382 (0-H), 1694 (aldehyde C=0), 1651 (C=C), 1587 (cyclic 
C=N-) and 968 (trans C=C-H); 811 (400 MHz CDC13): 9.89 (aldehyde Cli), 8.22 
(oxazole : CH), 6.44 (dd, J 1.2 and 11.1 Hz, : CHCU: CBr), 6.37 (dd, J 11.1 and 14.3 
Hz, CHOHCH: CJj), 5.74 (dd, J 5.8 and 14.3 Hz, CHOHCII: ), 4.73 (app q, J 5.8 
Hz, CH2CHOH), 3.32 (CHOIR, 3.05 (m, 2H, Chi CHOH) and 2.33 (Ct); Sc (100 
MHz CDC13): 183.4 (d), 163.5 (s), 145.2 (d), 140.4 (s), 135.8 (d), 130.8 (d), 125.5 
(d), 124.0 (s), 69.0 (d), 35.6 (t) and 23.6 (q); m/z (EI): 204 (100%, M+-HBr), 175 
(25, aldehyde from retro-aldol), 163 (20), 145 (10), 135 (10), 110 (45, oxazole from 
retro-aldol), 82 (25), 65 (60), 54 (40) and 43 (35). 
(+/-)-2-((E, E)-6-Bromo-2-hydroxyhepta-3,5. dienyl)-4-oxazolic acid 
(199). 
HOZC` 
'N Br 
>0000 y 
0 OH 
A solution of 80% sodium chlorite (138 mg, 1.526 mmol) and potassium hydrogen 
orthophosphate (243 mg, 1.785 mmol), in water (1 cm3), was added dropwise, over 2 
min, to a stirred solution of the aldehyde (205) (292 mg, 1.021 mmol) and 2-methyl- 
2-butene (0.541 cm3,5.105 mmol) in t-butanol (10 cm3) at 0°C and the mixture was 
then stirred overnight while allowing to warm to room temperature. The t-butanol was 
removed in vacuo and the residue was partitioned between ethyl acetate (10 cm3) and 5 
M HCl (5 cm3). The mixture was seperated and the aqueous layer was then extracted 
with ethyl acetate (2 x 10 cm3). The extracts were combined and the dried solution 
(MgSO4) was concentrated in vacou to give the acid (270 mg, 80%) as a yellow 
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hydroscopic solid; (Found: M+ 300.9949. Ci1H12BrNO4 requires M+ 300.9950); 
Vm. 
x(cm-1): 3424 (0-H), 1718 (acid C=O), 1653 (C=C) and 1570 (cyclic C=N-); %M lx 
(EtOH)/nm (e): 236 (8010) and 318 (1649); 81-1 (400 MHz CD3OD): 8.40 (oxazole 
: CJ), 6.42 (m, 2 H, CHOHCH: CUCU: ), 5.78 (dd, J 6.1 and 14.4 Hz, CHOHCH: ), 
4.61 (q, J 6.1 Hz, CH2CJIOH), 3.01 (d, J 6.1 Hz, C112CHOH), 2.55 (d, J1 Hz, 
OH) and 2.33 (d, J1 Hz, Cth); Sc (100 MHz CD3OD): 164.6 (s), 163.8 (s), 145.8 
(d), 136.2 (d), 134.4 (s), 132.4 (d), 126.4 (d), 124.4 (s), 70.5 (d), 37.0 (t) and 23.9 
(q); m1z (EI): 301 (5%, M+), 282 (10, M+-H20), 204 (20), 177 (35), 164 (95), 127 
(100), 189 (75), 96 (50), 91 (35) and 80 (40). 
2-Methyloxazole-4"carboxylic acid (186). 79 
HOZCyNO 
Lithium hydroxide (450 mg, 16.22 mmol) was added, in one portion, to a stirred 
solution of ester (173) (1 g, 6.448 mmol) in wet THE (10 em3) and the mixture was 
then stirred overnight at room temperature. 2M HCl (5 cm3) was added and the 
mixture was then extracted with ethyl acetate (3 x 20 cm3). The organic extracts were 
combined and washed with brine (10 cm3). The dried solution (MgSO4) was 
concentrated in vacuo and the crude solid was recrystallised from ether to give the acid 
(490 mg, 60%) as a colourless solid, m. p. 182°C (ether) (Lit. 79 m. p. 184°C); (Found: 
C, 47.4; H, 4.1; N, 11.3%; M+, 127.0278. C8H 11NO2 requires C, 47.3; H, 3.9; N, 
11.0%; M+, 127.0269); vma,, (cm-1): 3436 (O-H), 1718 (acid C=O) and 1587 (cyclic 
C=N-); 8t; (270 MHz CDC13): 8.38 (oxazole : CJ and 2.49 (Ct); So (67.8 MHz 
CDC13): 164.7 (s), 164.1 (s), 146.1 (d), 134.7 (s) and 13.8 (q); rn/z (EI): 127 (90%, 
M+), 110 (30, M+-OH) and 82 (15, M+-C02H). 
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(-)-N-(2-Methyloxazol-4-ylcarbonyl)-(S). proline methyl ester (207). 
McOZC 0 bN'it"4 
O 
DCC (190 mg, 0.9057 mmol) was added, in one portion, to a stirred solution of the 
acid (186) (230 mg, 1.811 mmol) in dry CH2C12 (10 cm3) at 0°C. The mixture was 
stirred at 0°C for 30 min and the L-proline methyl ester (206) (100 mg, 0.6038 mmol 
of L-proline methyl ester hydrochloride was stirred for 15 min with triethylamine 
(0.131 cm3,0.9057 mmol)) in dry CH2C12 (5 cm3) at 0°C under. an atmosphere of 
nitrogen) was then added dropwise over 5 min. DMAP (10 mg) was added and the 
mixture was then stirred overnight while allowing it to warm to room temperature. The 
solid precipitate was filtered off and the filtrate was concentrated in vacuo. The residue 
was then purified using flash chromatography (3% methanol in CH2C12) to give the 
amide (98 mg, 68%) as a colourless oil: (Found: M+, 238.0955. C8H11N02 requires 
M+, 238.0954); [a]D 
-67.40 (c 1.115 in CHC13); Vmlix(cm"1): 1746 (ester C=O), 1622 
(amide C=O) and 1588 (amide dimer); 81; (250 MHz CDC13): 8.13 (0.5 H, oxazole 
: CID, 8.11 (0.5 H, oxazole : C11), 5.28 (dd, J 1.3 and 5.5 Hz, 0.5 H, COCIUNCO), 
4.61 (dd, J 2.5 and 5.5 Hz, 0.5 H, COCLINCO), 4.09 (t, J 6.0 Hz, CONCIH), 3.65- 
3.85 (m, 4 H, CONCH,, and OCR), 2.49 (1.5 H, Cth), 2.39 (1.5 H, Cth) and 
1.80-2.35 (m, 4 H, COCHCtCt); 6c (67.8 MHz CDC13): 172.9 (s), 172.1 (s), 
160.3 (s), 160.0 (s), 142.8 (d), 136.6 (s), 136.4 (s), 59.9 (d), 59.3 (d), 51.7 (q), 
48.2 (t), 46.9 (t), 31.1 (t), 28.1 (t), 24.8 (t), 21.4 (t) and 13.4 (q); m/z (EI): 238 
(15%, M+), 206 (10, Mf-McOH), 179 (75, M+-MeOOC), 128 (20, proline methyl 
ester), 110 (100, M+-proline methyl ester) and 82 (10,2-methyloxazole). 
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N- (2 
-Methyloxazol-4-ylcarb onyl)- (S) -pro line (208). 
H02C ý 
JNJLI> 
Lithium hydroxide (1.6 g, 64.49 mmol) was added, in one portion, to a stirred solution 
of the oxazole (207) (2 g, 12.90 mmol) in wet THE (50 cm3) and the mixture was 
then stirred at room temperature overnight. 2M HC1(10 cm3) was added and the 
mixture was then extracted with ethyl acetate (3 x 50 cm3). The organic extracts were 
combined and the dried solution (MgSO4) was concentrated in vacuo. The residue was 
recrystalized from methanol to give the acid (1.5 g, 85%) as a colourless solid, m. p. 
217-219°C; (Found: M+, 224.0795. CjoH12N204 requires M+, 224.0797); [a]D 
-95.60 (c 0.09 in CHC13); Vmax(cm"1): 3480 (0-H), 1730 (acid C=0) and 1590 
(amide C=0); SH (250 MHz CDC13): 11.40 (COQ), 8.12 (0.5 H, oxazole : CJj), 8.11 
(0.5 H, oxazole : Cl i), 5.27 (d, J 5.5 Hz, 0.5 H, NCIICH2), 4.64 (d, J 5.5 Hz, 0.5 
H, NCJjCH2), 4.04 (app q, J 7.6 Hz, CH2CJIHNCO), 3.71 (m, CH2CjjHNCO), 
2.44 (1.5 H, Cth), 2.36 (1.5 H, CM) and 1.88-2.24 (m, 4 H, CHCt. CtCHZN); 
SC (67.8 MHz CDC13): 175.9 (s), 174.6 (s), 160.9 (s), 160.7 (s), 143.8 (d), 143.6 
(d), 136 3 (s), 136.1 (s), 60.4 (d), 60.2 (d), 49.0 (t), 47.4 (t), 31.2 (t), 28.0 (t), 25.1 
(t), 21.7 (t) and 13.6 (q); m/z (EI): 224 (8%, M+), 179 (40, M+-C02H), 110 (100, M+- 
proline), 82 (10,2-methyloxazole) and 70 (45). 
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(E, E)-N-(2-(6-Bromo-2-hydroxyhepta-3, S-dienyl)oxazol-4. ylcarbonyl)- 
(S)-proline methyl ester (210). 
MeO2C 0 
NIIN Br 
OH 
EDC (67 mg, 0.3507 mmol) was added, in one portion, to a stirred solution of the acid 
(199) (100 mg, 0.2505 mmol) in dry CH2C12 (7 cm3) at 0°C under an atmosphere of 
nitrogen. The mixture was stirred for 30 min and then HOBt (42 mg, 0.3131 mmol) 
and triethylamine (0.039 cm3,0.26 10 mmol) were added, in one portion, followed by 
dropwise addition of the L-proline methyl ester (206) (46 mg, 0.2610 mmol of proline 
methyl ester hydrochloride was stirred with triethylamine (0.039 cm3,0.26 10 mmol) in 
dry CH2C12 (3 cm3) at 0°C under an atmosphere of nitrogen). The mixture was stirred 
overnight at room temperature and then washed with water (10 cm3). The dried 
solution (MgSO4) was concentrated in vacuo and the residue was then purified using 
flash chromatography (3% methanol in CH2C12) to give a mixture of diastereoisomers 
of the amide (85 mg, 64%) as a pale orange oil; (Found: M+, 412.0578. 
C17H21BrN205 requires M+ 412.0584); [a]D -19.30 (c 0.82 in CHC13); Vmax(cm-i): 
3360 (0-H), 1745 (ester C=0), 1617 (amide C=0) and 913 (trans-C=-C-H); 81, (400 
MHz CDC13): 8.18 (m, oxazole : CH), 6.42 (m, 2 H. CHOHCH: CUCIi: ), 5.74 (m, 
CHOHCJI: ), 5.26 (dd, J 2.6 and 8.7 Hz, 0.5 H, COCUN), 5.13 (dd, J 2.6 and 8.7 
Hz, 0.5 H, COCILN), 4.55-4.70 (m, CHZCJ. OHCH: ), 4.08 (app q, J 6.7 Hz, 
CHNCIIH), 3.82 (app dq, J 2.6 and 6.7 Hz, CHNCHLD, 3.75 (1.5 H, OCHS), 3.73 
(1.5 H, OCH3), 3.50 (0Ji), 2.85-3.10 (m, 2 H, CtCHOH), 2.36 (d, J1 Hz, 
C(C )Br) and 1.85-2.35 (m, 4 H, COCHCH2CH2); Sc (67.8 MHz CDC13): 173.7 
(s), 172.5 (s), 161.5 (s), 161.4 (s), 143.7 (d), 143.5 (d), 136.5 (s), 136.4 (s), 133.9 
(d), 125.5 (d), 125.3 (d), 123,8 (s), 69.1 (d), 68.5 (d), 60.5 (d), 59.8 (d), 52.4 (t), 
52.2 (t), 35.7 (t), 35.5 (t), 31.6 (t), 28.5 (t), 25.2 (t), 21.7 (t) and 23.7 (q); m! z (El): 
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412 (25%, M+), 331 (20, M+-HBr), 238 (10, (207) from retro-aldol), 207 (20, 
(207)-OMe), 136 (75), 128 (40, proline-H), 83 (45,2-methyloxazole) and 69 (80, 
oxazole). 
(S)-Proline methoxymethy ester (212). 
MOMOZC 
NH 
Chloromethyl methyl ether (0.82 cm3,10.40 mmol) was added dropwise, over 5 min, 
to a stirred solution of L-proline (1 g, 8.686 mmol) and triethylamine (1.33 cm3,9.923 
mmol) in dry CH2C12 (25 cm3) at room temperature under an atmosphere of nitrogen. 
The mixture was stirred overnight and was then washed with saturated NaHCO3 
solution (10 em3). The dried solution (MgSO4) was concentrated in vacuo to leave the 
crude ester (0.98 g, 90%) as a pale yellow oil: Vm. (cm-1): 3408 (N-H) and 1743 (ester 
C=O); St, (400 MHz CDC13): 5.34 (OCHf, O), 3.40-3.55 (m, 4 H, OCh3 and 
COCJINH), 3.12 (m, 1 H, NHCHH), 2.68 (m, 1 H, NHCIIH), 1.75-2.20 (m, 4 H, 
CHCJC ) and 1.40 (t, J 9.8 Hz, Nil); 6c (67.8 MHz CDC13): 173.4 (s), 89.8 (t), 
63.6 (d), 57.0 (q), 51.3 (t), 28.9 (t) and 23.0 (t). 
(. ). N-(2-Methyloxazol-4-ylcarbonyl)-(S). proline metlioxymetliyl ester 
(213). 
MOMOZC 0 
J-- 
NN 
0 
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EDC (210 mg, 1.1015 mmol) was added, in one portion, to a stirred solution of the 
acid (186) (100 mg, 0.7868 mmol) in dry CH2C12 (10 cm3), at 0°C, under an 
atmosphere of nitrogen. The mixture was stirred for 30 min and then HOBt (133 mg, 
0.9835 mmol) and triethylamine (0.121 cm3,0.8655 mmol) were added, in one 
portion, followed by the addition of the L-proline methyoxymethyl ester (212) (125 
mg, 0.7868 mmol). The mixture was stirred overnight and then washed with water (10 
cm3). The dried solution (MgSO4) was concentrated in vacuo and the residue was then 
purified using flash chromatography (3% MeOH in CH2C12) to give the amide (85 mg, 
64%) as a colourless oil; (Found: M+, 268.1084. C12H16N205 requires M+ 268.1069); 
[a]D 
-42.60 (c 0.865 in CHC13); Vmax(cm-1): 1747 (ester C=O), 1632 (amide C=0) 
and 1588 (amide dimer); 81, (400 MHz CDC13): 8.13 (0.5 H, oxazole : CH), 8.11 (0.5 
H, oxazole : CH), 5.34 (m, 1 H, OCUUHO), 5.26 (m, 1.5 H, OCHIJO and COCUNH), 
4.65 (dd, J 4.1 and 8.4 Hz, 0.5 H, COCHNH), 4.12 (m, 1 H, NHCIIHCH2), 3.70- 
3.90 (m, 1H, NHCHHCH2), 3.46 (1.5 H, OCt), 3.44 (1.5 H, OCR), 2.45 (1.5 
H, Chi), 2.43 (1.5 H, Cth) and 1.80-2.40 (m, 4 H, NHCHCli2Ct2) 8c (67.8 MHz 
CDC13): 172.2 (s), 171.4 (s), 160.5 (s), 160.2 (s), 143.1 (d), 142.9 (d), 136.7 (s), 
136.5 (s), 90.6 (t), 90.4 (t), 60.0 (d), 59.6 (d), 57.2 (q), 48.4 (t), 48.0 (t), 31.2 (t), 
28.3 (t), 25.0 (t), 21.4 (t) and 13.5 (q); m! z (EI): 268 (31%, M+), 207 (100, M+- 
C2H402), 180 (100, M+-MOM02C), 172 (85) and 110 (100,2-methyl-4- 
formyloxazole). 
(E, E). N-(2-(6-Bromo-2-hydroxyhepta-3,5-dienyl)oxazol. 4. ylcarbonyl)- 
(S). proline methoxymethyl ester (214). 
MOMOZC 0 
NIN Br 
ý OH 
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EDC (67 mg, 0.3507 mmol) was added in, one portion, to a stirred solution of the acid 
(199) (100 mg, 0.2505 mmol) in dry CH202 (10 em3), at 0°C, under an atmosphere 
of nitrogen. The mixture was stirred for 30 min and then HOBt (42 mg, 0.3131 mmol) 
and triethylamine (0.039 cm3,0.2610 mmol) were added, in one portion, followed by 
the addition of the L-proline methoxymethyl ester (212) (44 mg, 0.2610 mmol). The 
mixture was stirred overnight at room temperature and then washed with water (10 
cm3). The dried solution (MgSO4) was concentrated in vacuo and the residue was 
purified using flash chromatography (3% MeOH in CH2C12) to give a mixture of 
diastereoisomers of the amide (94 mg, 72%) as a pale orange oil; (Found: M+, 
442.0716. C18H23BrN206 requires M+ 442.0740); [a]D 
-20.40 (c 0.225 in CHC13); 
Vmax(cm-1): 3408 (0-H), 1747 (ester C=0), 1614 (amide C=O), 1586 (amide dimer) 
and 952 (trans-C=C-H); 811(400 MHz CDC13): 8.19 (m, 1 H, oxazole : C. h, 6.44 (m, 
2 H, COHCH: Cf CJj: ), 5.74 (m, 1 H, COHCf : ), 5.18-5.42 (m, 2 H, CH3OCH2O), 
4.63 (m, 1 H, CH2CLLOHCH: ), 4.10 (m, 0.5 H, NCJIHCH2), 3.70-3.90 (m, 0.5 H, 
NCH JjC H2), 3.40 (1.5 H, OCt ), 3.34 (1.5 H, OCt ), 2.85-3.10 (m, 2 H, 
CtCHOH), 2.37 (d, J 0.9 Hz, CH: C(C1)Br) and 1.85-2.30 (m, 4 H, 
CHCIhCH2CH2N); So (67.8 MHz CDC13): 172.5 (s), 171.5 (s), 161.7 (s), 161.4 
(s), 143.7 (d), 143.4 (d), 136.7 (s), 136.5 (s), 134.0 (d), 133.9 (d), 131.0 (d), 125.5 
(d), 125.3 (d), 123.5 (s), 123.4 (s), 91.0 (t), 90.8 (t), 68.6 (d), 68.5 (d), 60.6 (d), 
59.9 (d), 57.6 (q), 48.7 (t), 47.5 (t), 35.9 (t), 35.5 (t), 31.6 (t), 28.5 (t), 25.2 (t), 
23.7 (q) and 21.8 (t); rn/z (EI): 442 (5%, M+), 353 (20, M+-C02MOM), 268 (20), 70 
(20) and 45 (100). 
121 
(-). (E, E)-N-(3-Tri-n-b utylstannylprop-2-enyl)-5-(N'. (2-methyloxazol- 
4-ylcarbonyl)-(S)-prolinoyloxy)pent-2-enamide (209). 
0 0I 0 
N SnBu3 
"/, 
/ 
0 
Method A: 
- 
EDC (60 mg, 0.3151 mmol) was added, in one portion, to a stirred 
solution of the acid (208) (50 mg, 0.2251 mmol) in dry CH2C12 (5 cm3) at 0°C under 
an atmosphere of nitrogen. The mixture was stirred for 30 min and DMAP (34 mg, 
0.2814 mmol) and DMAP. HCI (45 mg, 0.2814 mmol) were then added, in one 
portion, followed by addition of the alcohol (132) (100 mg, 0.2251 mmol). The 
mixture was stirred overnight and then washed with water (10 cm3). The dried 
solution (MgSO4) was concentrated in vacuo and the residue was then purified using 
flash chromatography (2% MeOH in CH2C12) to give the amide (69 mg, 53%) as a 
colourless oil; Method B: 
- 
EDC (50 mg, 0.2586 mmol) was added, in one portion, to a 
stirred solution of the acid (186) (26 mg, 0.2032 mmol) in dry CH2C12 (5 cm3) at 0°C 
under an atmosphere of nitrogen. The mixture was stirred for 30 min and then HOBt 
(31 mg, 0.2309 mmol) and triethylamine (0.036 cm3,0.2586 mmol) were added, in 
one portion, followed by addition of the amine (217) (100 mg, 0.1847 mmol). The 
mixture was stirred overnight and was then washed with water (10 cm3). The dried 
solution (MgSO4) was concentrated in vacuo and the residue was purified using flash 
chromatography (2% MeOH in CH2C12) to give the amide (72 mg, 60%) as a 
colourless oil. Both methods gave identical products by nmr and ir; (Found: C, 55.1; 
H, 7.9; N, 6.4%; Mf 651.2773. C8H11N02 requires C, 55.4; H, 7.6; N, 6.5%; 
M+651.2794); [a1D 
-6.05 (c 2.75 in CHC13); Vma,, (em-1): 3300 (N-H), 1746 (ester 
C=O), 1673 (amide C=O), 1633 (C=C), 1538 (amide dimer), 1180 (C-0) and 982 
(trans-C=C-H); 1ýmax (EtOH)/nm (e): 216 (64 050) and 315 (1710); 821 (400 MHz 
CDC13): 8.09 (0.5 H, oxazole : CHi), 8.04 (0.5 H, oxazole : CH), 6.72-6.82 (m, 111, 
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COCH: Cf ), 6.57 (bt, 0.5 H, Nil), 5.70-6.15 (m, 3 H, COCff : and SnCfl: CJi), 5.32 
(m, 0.5 H, NIA, 4.58 (dd, J 4.5 and 9.0 Hz, 0.5 H, COCUNCO), 4.42 (m, 0.5 H, 
COCIINCO), 4.17 (t, J 6.4 Hz, C&OCO), 4.09 (app t, J 6.4 Hz, : CHC CHZ), 
3.98 (app t, J 5.6 Hz, : CHCN), 3.62-3.82 (m, 2 H, CHNC), 2.52 (m, 1 H, 
COCHC ILH), 2.46 (1.5 H, Cl b), 2.38 (1.5 H, C113), 1.80-2.35 (m, 3 H, 
CHCHUCt), 1.46 (m, 6 H, SnCH2Ct2), 1.28 (m, 6 H, SnCH2CH2Cth) and 0.89 
(m, 15 H. SnCH2CH2CHZCH3); 6c (100 MHz CDCl3): 172.5 (s), 172.1 (s), 165.9 
(s), 160.8 (s), 160.5 (s), 143.9 (d), 143.4 (d), 143.3 (d), 136.9 (s), 136.7 (s), 130.0 
(d), 129.6 (d), 126.4 (d), 126.2 (d), 63.0 (t), 62.8 (t), 60.5 (d), 59.9 (d), 48.8 (t), 
47.4 (t), 44.8 (t), 31.0 (t), 30.8 (t), 30.4 (t), 28.5 (t), 29.0 (t), 27.2 (t), 25.3 (t), 21.7 
(t), 13.8 (q), 13.6 (q) and 9.3 (t); m/z (FAB): 651 (5%, M+), 594 (15, M+-Bu), 538 
(5, M*-4-formyloxazole), 388 (15, M+-N-oxazoloylproline), 291 (10, Bu3SnH) and 
55 (propargylamine). 
(E, E, E, E)-N. (3. Trion 
-b utylstannylprop-2-enyl)-S-(N'-(2-(6-bromo-2. 
hydroxypent-3, S-dienyl)oxazol-4-ylcarbonyl)-(S)-pro linoyloxy)p en t. 2. 
enamide (198). 
O 
NýN%SnBu3 
H 
O0 
ONý Br 
0 OH 
EDC (89 mg, 0.4634 mmol) was added, in one portion, to a stirred solution of the acid 
(199) (100 mg, 0.3310 mmol) in dry CH2C12 (5 cm3), at 0°C, under an atmosphere of 
nitrogen. The mixture was stirred for 30 min and then HOBt (56 mg, 0.4138 mmol) 
and triethylamine (0.051 cm3,0.3641 mmol) were added, in one portion, followed by 
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the addition of the amine (217) (197 mg, 0.3641 mmol). The mixture was stirred 
overnight while allowing it to warm to room temperature and then washed with water 
(10 cm3). The dried solution (MgSO4) was concentrated in vacuo and the residue was 
then purified using flash chromatography (2% McOH in CH2C12) to give a mixture of 
diastereoisomers of the amide (165 mg, 61%) as an orange oil; Vma,, (cm"'): 3420 (0- 
H),, 1744 (ester C=O), 1653 (amide C=O), 1636 (C=C) and 973 (trans-C=C-l ); Xmax 
(EtOH)/nm (E): 217 (60 150), 237 (8150) and 315 1650 (1650); 811 (500 MHz CDCl3): 
8.12 (m, 1 H, oxazole : CJ), 6.74 (m, 1 H, COCH: CIL), 6.46 (m, 1 11, 
Cfl: C(CH3)Br), 6.39 (m, 1 H, CHOHCH: Cli), 6.1 (app ddd, J 1.5,7.0 and 19.0 Hz, 
SnCjj: ), 5.97 (dt, J 19.0 and 3.8 Hz, SnCH: Cfi), 5.86 (app dd, J 1.9 and 15.3 Hz, 
COCJ.: CH), 5.72 (m, 1 H, CHOHCIi: ), 5.29 (dd, J 2.5 and 9.0 Hz, 0.5 II9 
CO CAN), 5.19 (dd, J 2.5 and 9.0 Hz, 0.5 H, COCLLN), 4.60-4.75 (m, 1 11, 
CHZCflOH), 3.90-4.40 (m, 7 H, NCtCH:, : CHCH2CI322O and COCHCUUH), 3.70- 
3.85 (m, 1 H, COCHCHID, 3.02 (m, 2 H, C CHOH), 2.50 (m, 1 H, CONCIJ11), 
2.39 (d, J 1.2 Hz, C&), 2.23 (m, I H, CONCHH. ), 1.85-2.05 (m, 2 1-1, 
CONCH2CH2), 1.78 (Off), 1.51 (pent, J 7.1 Hz, SnCH2CI2), 1.30 (hext J 7.1 Hz, 
SnCH2CH2C ) and 0.89 (t, J 7.1 Hz, SnCtCH2CH2C, ); SC (125 MHz CDC13): 
172.8 (s), 171.8 (s), 165.6 (s), 165.2 (s), 161.5 (s), 161.3 (s), 160.3 (s), 143.6 (d), 
143.1 (d), 139.3 (d), 138.4 (d), 136.6 (s), 136.4 (s), 134.3 (d), 134.2 (d), 131.1 (d), 
131.0 (d), 130.1 (d), 129.6 (d), 125.9 (d), 125.2 (d), 125.1 (d), 125.0 (d), 123.6 (d), 
123.4 (d), 69.0 (d), 68.7 (d), 63.4 (t), 62.7 (t), 60.6 (d), 59.9 (t), 48.6 (t), 44.8 (t), 
44.7 (t), 35.9 (t), 35.8 (t), 31.5 (t), 30.7 (t), 30.4 (t), 28.9 (t), 27.1 (t), 25.2 (t), 23.6 
(q), 21.6 (t), 13.5 (q) and 9.3 (t). 
124 
(E, E, E, E)-N-(7-Ethoxycarbonyl-4-methylhepta-2,4,6. trienyl). S- 
acetoxypent-2-enamide (218). 
0 
Ac0ý'ý/ý/ 
H 
OEt 
A solution of triphenylarsine (5.04 mg, 16.44 tmol) in dry THE (1 cm3) was added 
dropwise, over 5 min, to a stirred solution of iris(benzylideneacetone)dipalladium(0) 
(1.9 mg, 2.06 µmol) in dry THE (12 cm3) at room temperature, under an atmosphere 
of nitrogen, in a scrupulously dried flask. The mixture was stirred for 30 min and a 
solution of the amide (151) (100 mg, 0.2056 mmol), in dry THE (1 cm3), and then a 
solution of the ester (201) (45 mg, 0.2056 mmol), in dry THE (1 cm3), were added 
dropwise. The mixture was heated under reflux for 2h and was then allowed to cooled 
to room temperature. The solvent was removed in vacuo and the residue was then 
purified using flash chromatography (10% ethylacetate in petroleum ether) to give the 
amide (39 mg, 62%) as a pale yellow oil; Vmax(cm-1): 3270 (N-I3), 1742 and 1712 
(ester C=O), 1670 (amide C=O), 1630 (C=C), 1550 (amide dimer) and 980 (trans- 
C=C-H); Xmax (EtOH)/nm (e): 208 (71231) and 304 (60 688); 811 (400 MHz CDCI3): 
7.63 (dd, J 11.8 and 15.3 Hz, COCH: CJICH), 6.83 (dt, J 15.3 and 6.9 Hz, 
COCHCJ, ), 6.26 (d, J 15.6 Hz, NHCH2C H: C I-), 6.14 (d, J 11.8 liz, 
C(CH3): CIJCH: ), 5.90 (m, 3 H, NHCOCU:, COCII: CH and NH2CIIC, j: ), 5.80 
(Nil), 4.24 (m, 4 H, OCtC H3 and AcOCjC H 2), 4.05 (app to J 5.6 I-Iz, 
NHCtCH: ), 2.52 (app dq, J 1.4 and 6.9 Hz, AcOCH2Ct), 2.04 (COCt), 1.96 
(: CHC(Ct): CH) and 1.29 (t, J 7.1 Hz, OCH2Ct); So (67.8 Mllz CDCI3): 170.9 
(s), 167.2 (s), 165.2 (s), 142.6 (s), 140.1 (d), 140.0 (d), 135.7 (d), 128.5 (d), 123.4 
(d), 122.5 (d), 116.5 (d), 62.5 (t), 60.3 (t), 41.4 (t), 31.2 (t), 20.8 (q), 14.2 (q) and 
13.2 (q). 
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(E, E, E, E)-N-(7-Ethoxycarbonyl-4-methylliepta-2,4,6. trlenyl). S- 
hydroxypent-2-enamide (219). 
0 
xoý occ 
0 
A solution of triphenylarsine (5.6 mg, 18 µmol) in dry THE (1 cm3) was added 
dropwise, over 2 min, to a stirred solution of tris(benzylideneacetone)dipalladium(0) 
(2.1 mg, 2.25 itmol) in dry THE (12 cm3) at room temperature, under an atmosphere 
of nitrogen, in a scupulously dried flask. The mixture was stirred for 30 min and a 
solution of the alcohol (132) (100 mg, 0.2251 mmol), in dry THE (1 cm3), and then a 
solution of the ester (201) (49 mg, 0.2251 mmol), in dry THE (1 cm3), were added 
dropwise over 5 min. The mixture was heated under reflux for 2h and was then 
allowed to cooled to room temperature. The solvent was removed in vacuo and the 
residue was then purified using flash chromatography (10% ethylacetate in petroleum 
ether) to give the hydroxyamide (45 mg, 67%) as a pale yellow oil; Vmax(cm"t): 3290 
(0-H and N-H), 1713 (ester C=0), 1660 (amide C=0), 1632 (C=C), 1558 (amide 
dimer) and 975 (trans-C=C-H); Xmax (EtOH)/nm (E): 210 (60 150) and 308 (58 450); 
511(400 MHz CDCI3): 7.64 (dd, J 11.8 and 15.3 Hz, COCH: CLICH), 6.84 (dt, J 15.3 
and 7.1 Hz, COCHCID, 6.25 (d, J 15.3 Hz, NHCH2CH: CJ, ), 6.14 (d, J 11.8 Iiz, 
C(CH3): CfCH: ), 6.05 (t, J 6.1 Hz, Nj-j), 5.90 (m, 3 H, NHCOCf:, COCfl: CE1 and 
NH2CHCH: ), 4.20 (q, J 7.1 Hz, OCtCH3), 4.03 (t, J 5.6 Hz, 110CtCI12), 3.74 
(app t, J 6.1 Hz, NHCJCH: ), 2.43 (app q, J 5.6 lIz, 110CI12C J), 1.95 
(: CHC(C ): CH) and 1.30 (t, J 7.1 Hz, OCH2CH3); SC (67.8 MHz CDCl3): 167.3 
(s), 165.8 (s), 142.7 (s), 141.4 (d), 140.1 (d), 135.6 (d), 128.5 (d), 125.6 (d), 121.3 
(d), 60.9 (t), 60.3 (t), 41.4 (t), 35.3 W. 14.3 (q) and 13.2 (q). 
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(E, E, E, E)-N. (8-hydroxy-4-methyl- 9-(4-hydroxymethyloxazo 1.2-ylnona 
2,4,6-trienyl))-5-hydroxypent-2-enamide (220). 
0 
N HOý ýýý\N OH 
0 OH 
A solution of triphenylarsine (4.25 mg, 13.88 µmol) in dry DMF (1 cm3) was added 
dropwise, over 2 min, to a stirred solution of tris(benzylideneacetone)dipalladium(0) 
(1.59 mg, 1.735 tmol) in dry DMF (7 cm3) at room temperature, under an atmosphere 
of nitrogen, in a scrupulously dried flask. The mixture was stirred for 30 min and a 
solution of the bromide (203) (50 mg, 0.1735 mmol), in dry DMF (1 cm3), and then a 
solution of the stannane (132) (77 mg, 0.1735 mmol), in dry DMF (1 cm3), were 
added dropwise over 2 min. The mixture was heated at 100°C for 18 h and was then 
allowed to cooled to room temperature. The solvent was removed in vacua and the 
residue was then purified using flash chromatography (5% MeOll in CH2C12) to give 
the triol (25 mg, 40%) as a pale sticky yellow solid; vmax(cm-t): 3300 (0-11), 1682 
(amide C=O), 1635 (C=C), 1575 (amide dimer), 1565 (cyclic C=N) and 953 (trans 
C=C-H); 7max (EtOH)/nm (e): 214 (60 050) and 310 (57 320); 81, (500 MIIz CD30D): 
7.69 (oxazole : Cli), 6.78 (dt, J 15.4 and 6.4 Hz, COCH: CJJ, ), 6.62 (ddd, J 1.2,11.2 
and 15.1 Hz, CH2CHOHCII: ), 6.22 (d, J 15.6 Hz, NHCH2CH: Cfl), 6.04 (d, J 15.1 
Hz, : CHC(CH3): Cff), 5.98 (dd, J 1.4 and 15.4 Hz, COCJj: ), 5.75 (dd, J 6.4 and 
15.1 Hz, CHOHCH: CH), 5.72 (dt, J 15.6 and 6.4 Hz, NHCH2CJJ: ), 5.71 (m, Nfl), 
4.62 (app q, J 6.4 Hz, C 3. OH), 4.48 (HOC112C(N): CFi), 3.92 (t, J 6.4 Hz, 
HOCtCH2), 3.64 (app t, J 6.4 Hz, NHCIL), 2.96 (dd, J 1.2 and 6.4 Iiz, 
C&CHOH), 2.39 (app dq, J 1.4 and 6.4 Hz, HOC1112C1i2) and 1.82 (Cth); 8c (100 
MHz CD3OD): 168.2 (s), 164.1 (s), 142.5 (d), 141.8 (s), 139.3 (d), 137.0 (s), 136.2 
(d), 132.2 (d), 131.1 (d), 127.1 (d), 126.3 (d), 125.9 (d), 71.2 (d), 61.6 (t), 57.8 (t), 
42.3 (t), 37.3 (t), 36.3 (t) and 12.8 (q). 
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Virginaimycin model (197). 
0 iLH 
0O oll 
0 NýN 
ý0 
A solution of triphenylarsine (2.12 mg, 7.752 µmol) in dry DMF (I em3) was added 
dropwise, over 2 min, to a stirred solution of tris(benzylideneacetone)dipalladium(0) 
(0.79 mg, 0.969 µmol) in dry DMF (8 cm3) at room temperature, under an atmosphere 
of nitrogen, in a scrupulously dried flask. The mixture was stirred for 30 min and a 
solution of the precursor (198) (80 mg, 0.0969 mmol), in dry DMF (I cm3), was 
added dropwise over 2 min. The mixture was heated at 100°C for 18 h and then 
allowed to cooled to room temperature. The solvent was removed in vacuo and the 
residue was then purified using flash chromatography (5% MeOH in CH2C12) to give a 
mixture of diastereomers of the macrolide (19 mg, 40%) as a pale yellow oil. (The 
product was found to decompose readily at room temperature or over longer periods at 
-20°C); Vmax(cm-1): 3415 (0-H), 1738 (ester C=0), 1666 (amide C=0), 1632 (C=C), 
1552 (amide dimer) and 971 (trans-C=C-H); Xmax (EtOH)/nm (c): 278 (54 078) and 
288 (58 245); 811 (500 MHz CDC13): 8.09 (oxazole : CID), 6.52 (m, 211, COCII: Ci 
and CHOHCH: Cjj), 6.28 (d, J 13.5 Hz, NHCH2CH: Cll), 6.00 (d, J 11,1 Hz, 
CHOHCH: CHCLj: ), 5.80 (d, J 15.4 Hz, COCU: C3), 5.72 (m, 2 H, CIi011Cif: and 
NHCH2Cjj: ), 5.62 (t, J 5.6 Hz, Nei), 4.62-4.74 (m, 3 H, CH2CIhOCOCLLN), 4.16 
(dt, J 3.4 and 4.5 Hz, CH2CIJOH), 3.85-3.95 (m, 3 11, N11CthCH: and 
COCHCLIH), 3.58 (dt, J 2.5 and 8.6 Hz, COCHCHII), 3.16 (dd, J 4.5 and 6.6 Hz, 
CtCHOH), 2.68 (d, J 6.8 Hz, CONCUH), 2.45-2.53 (m, 2 11, OCH2Cth), 2.10 
(m, 1 H. CONCHID, 1.94 (m, 1H, CONC12CIIH), 1.80 (C113) and 1.76 (m, 
CONCH2CHfl); Sc (125 MHz CDC13): 171.4 (s), 165.5 (s), 160.5 (s), 160.3 (s), 
143.1 (d), 139.4 (d), 138.7 (d), 136.6 (s), 135.5 (d), 134.9 (s), 130.3 (d), 126.9 (d), 
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126.6 (d), 124.1 (d), 69.3 (d), 59.6 (d), 49.0 (t), 40.6 (t), 35.7 (t), 33.1 (t), 27.9 (t), 
24.6 (t), 17.5 (t) and 13.6 (q). 
N-Prop ionyl-(4S)-isopropyloxazolidin-2-one (129)020 
O0 
ýýN'J"Noo" 
A solution of n-butyllithium 2.5M in hexanes (16.1 cm3,39.80 mmol) was added 
dropwise, over 20 min, to a stirred solution of (4S)-(-)-isopropyloxazolidin-2-one 
(5.13 g, 39.72 mmol) in dry THE (150 cm3), at 
-78°C, under an atmosphere of 
nitrogen. The mixture was stirred at this temperature for 15 min and propionyl chloride 
(3.5 cm3,39.80 mmol) was then added dropwise over 10 min. The mixture was 
stirred at 
-78°C for 30 min and the reaction then quenched with saturated NIi4CI 
solution (100 cm3). The mixture was extracted with ethyl acetate (3 x 100 em3) and the 
organic extracts were combined and washed with brine. The dried solution (MSSO4) 
was concentrated in vacuo and the residue was then purified using flash 
chromatography (10% ethyl acetate in petroleum ether) to give the oxazolidinone (7.5 
g, 95%) as a colourless oil; Vmax(cm-1): 1778 (urethane C=O) and 1692 (amide C=O); 
511 (270 MHz CDC13): 4.42 (dt, J 8.8 and 3.1 Hz, OC112CII(iPr)), 4.28 (app t, J 8.8 
Hz, OCJjHCH(iPr)), 4.20 (dd, J 3.1 and 8.8 Hz, OCHIjCH(iPr)), 2.94 (q, J 6.9 t 1z, 
COC, j2CH3), 2.38 (dsept, J 3.1 and 6.9 Hz, OCH2CH(CJj(C113)2)N), 1.17 (t, J 6.9 
Hz, COCH2CJ, 3) and 0.89 (dd, J 3.1 and 6.9 Hz, CH(Ci1(Cth)2)); So (67.8 MHz 
CDC13): 174.0 (s), 154.6 (s), 63.3 (t), 58.4 (d), 29.1 (t), 28.3 (d), 17.9 (q), 14.6 (q) 
and 8.4 (q). 
129 
N-((2S)-Methyl-(3R)-hydroxy-4-methylpentanoyl)-(4S)-isopropyl 
oxazolidin-2-one (16). 20 
OH 
A solution of di-n-butylboron triflate 1M in CH2CI2 (17.82 cm3,16.30 mmol) was 
added dropwise, over 10 min, to a stirred solution of the oxazolidinone (129) (3 g, 
16.20 mmol) in dry CH2C12 (60 cm3), at 0°C, under an atmosphere of nitrogen. 
Diisopropylethylamine (3.4 cm3,16.40 mmol) was added dropwise, over 5 min, and 
the mixture was then stirred at 0°C for 30 min. The mixture was cooled to -78°C and 
stirred for a further 30 min and then isobutyraldehyde (1.62 em3,16.30 mmol) was 
added dropwise over 5 min. After stirring at -78°C for 30 min the mixture was allowed 
to warm to room temperature and stirred for 1.5 h. The mixture was cooled to 0°C and 
then quenched with a mixture of methanol (80 cm3) and pH 7 buffered water (40 cm3) 
and was then stirred for 1h at 0°C with 30% hydrogen peroxide (40 em3). The 
mixture was extracted with ether (3 x 100 cm3) and then washed with brine. The dried 
solution (MgSO4) was concentrated in vacuo and the colourless residue was then 
purified using flash chromatography (10% ethyl acetate in petroleum ether). The 
resulting solid was recrystallized (diethyl ether) to give the hydroxyoxazolidinone (3.4 
g, 80%) as colourless crystalline solid as one diastereomer, m. p. 86°C (Lit. 20 m. p. 
85°C); [aID +27.7° (c 3.90 in CHC13) (Lit. 20 
-8.22 (c 4.70 in CHHC13))VmAx(cm'1): 
3472 (0-H), 1779 (urethane C=O) and 1692 (amide C=O); 811(400 MHz CDC13): 4.47 
(dt, J 3.2 and 8.9 Hz, OCH2CH(iPr)), 4.29 (app t, J 8.9 Hz, OCjil1C11(, Pr)), 4.22 
(dd, J 3.2 and 8.9 Hz, OCHIICH(PPr)), 3.97 (dq, J 2.0 and 6.9 Hz, COCji(C113)), 
3.51 (app dt, J 2.0 and 6.9 Hz, CJjOH(iPr)), 3.05 (d, J 3.0 Hz, CHOi(iPr)), 2.35 
(dsept, J 3.2 and 6.9 Hz, OCH2CH(CJj(CH3)2)N), 1.70 (dsept, J 2.0 and 6.9 Hz., 
CHOH(CJj(CH3)2)), 1.23 (d, J 6.9 Hz, COCH(CJj3)), 1.02 (d, J 6.9 
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Hz, OCH2CH(CH(Cth)CH3)N), 0.92 (d, J 6.9 Hz, OCH2CH(CH(CH3)Clb)N) and 
0.90 (app dd, J 2.0 and 6.9 Hz, CHOH(CH(C )2)); SC (67.8 Ml-Hz CDC13): 178.3 
(s), 153.5 (s), 76.5 (d), 63.4 (t), 58.3 (d), 39.5 (d), 30.7 (d), 28.4 (d), 19.4 (q), 19.0 
(q), 18.0 (q), 14.8 (q) and 10.4 (q). 
(2S)-Methyl. (3R)-hydroxy-4-methylpe, itanal (18). 20 
OH 
A solution of the hydroxyoxazolidinone (16) (3.47 g, 14.40 mmol) in dry THE (2 
cm3) was added dropwise, over 5 min, to a stirred solution of sodium bis(2- 
methoxyethoxy) aluminium hydride 3.4M in toluene (5.1 cm3,14.60 mmol) in dry 
THE (100 cm3) under an atmosphere of nitrogen. The mixture was cooled to 
-78°C 
and then stirred for 30 min. The mixture was allowed to warm to 
-50°C and stirred for 
a further 1 h. After quenching the reaction with a mixture of ethyl acetate (20 cm3) and 
methanol (5 em3), the solution was poured into a mixture of 2M HCI (60 cm3) and 
ether (120 cm3) at 
-20°C and stirred for 15 min. The organic layer was decanted from 
the resultant gel and the gel was then washed with ether (2 x 50 em3) at 
-20°C. The 
ether washings were combined and the dried solution (K2CO3) concentrated in vºacuo to 
leave a colourless oil (3.4 g). The aldehyde was carried through crude without further 
purification; Vm. (em-I): 3474 (0-H) and 1716 (aldehyde C=O); 81, (400 MFiz CDCI3): 
9.65 (d, J 6.9 Hz, C, JO), 3.28 (app dt, J 2.0 and 6.91-1z, CUGH(iPr)), 2.51 (m, 111, 
OHCCII(CH3)), 1.72 (dsept, J 2.0 and 6.9 Hz, Cjj(CH3)2), 1.40 (d, J 5.5 IIz, Oji), 
1.11 (d, J 6.9 Hz, CH(Ct)) and 0.93 (app dd, J 4.0 and 6.9 liz, Ci1(CJj3)2); SG 
(67.8 MHz CDC13): 201.8 (d), 79.2 (d), 30.8 (d), 19.6 (q), 14.1 (q) and 13.9 (q), 
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(E)-Ethyl-(4R)-methyl- (5R)-hydroxy. 6"metliyl-2. heptenoate (127). 20 
0 oli 
Et0 
ý 
~'''' 
Triethyl phosphonoacetate (2.86 cm3,14.50 mmol) was added dropwise, over 10 min, 
to a stirred suspension of potassium t-butoxide (1.54 g, 14.40 mmol) in dry THE (100 
cm3), at 0°C, under an atmosphere of nitrogen. The mixture was stirred at this 
temperature for 30 min and was then cooled to 
-78°C. The crude aldehyde (18) (14.40 
mmol based on starting hydroxy oxazolidinone) was added dropwise, over 10 min, and 
the mixture was stirred for 3h while allowing to warm to room temperature. The 
reaction was quenched with saturated NH4C1 solution (5 em3), the mixture was then 
diluted with ethyl acetate (100 cm3) and washed with water (3 x 50 em3). The dried 
organic layer (MgSO4) was concentrated in vacuo and the residue was then purified 
using flash chromatography (10% ethyl acetate in petroleum ether) to give the 
hydroxyester (1.6 g, 60% over 2 steps) as a colourless oil; [aID +18.10 (c 1.89 in 
CHC13) (Lit. 2° +18.97 (c 5.83 in CHC13)); Vm$,, (cm-1): 3476 (0-1-1), 1714 (ester 
C=O), 1650 (C=C), 1369 (0-H) and 989 (trans C=C-H); 81, (400 MHz CDC13): 6.92 
(dd, J 6.8 and 15.8 Hz, COCH: Cf), 5.85 (dd, J 1.2 and 15.8 Hz, COCII: CH), 4.20 
(q, J 7.1 Hz, OC112CH3), 3.28 (app q, J 6.8 Hz, CIIOH(iPr)), 2.50 (app dq, J 1.2 
and 6.8 Hz, : CHCH(CH3)), 1.72 (app oct, J 6.8 Hz, CH(CJi(C113)2)), 1.41 (d, J 5.3 
Hz, CHOH(Pr)), 1.30 (t, J 6.8 Hz, OCH2Ct), 1.11 (d, J 6.81-12, C11(C1)C11011) 
and 0.94 (app dd, J 3.9 and 6.8 Hz, CH(C )2); Sc (67.8 MHz CDC13): 166.6 (s), 
151.8 (d), 120.6 (d), 78.8 (d), 60.1 (t), 39.8 (d), 30.8 (d), 19.6 (q), 16.4 (q) and 
13.9 (q). 
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(E)-Ethyl (4R)-methyl-(5R)-(meth oxy)methoxy-6-methyl-2-heptenoate 
(223). 1 
0 OMOM 
EtO j 
Chloromethyl methyl ether (2 cm3,27 mmol) was added in four portions, at 30 min 
intervals, to a stirred solution of the hydroxyester (127) (634 mg, 3.368 mmol) and 
diisopropylethylamine (1 cm3,5.75 mmol) in dry CH2CI2 (20 ml), at refIux, under an 
atmosphere of nitrogen. The mixture was heated for a further 30 min and was then 
allowed to cool to room temperature before washing with water (20 cm3). The dried 
solution (MgSO4) was concentrated in vacuo and the residue was then purified using 
flash chromatography (10% ethyl acetate in petroleum ether) to give the protected 
hydroxyester (596 mg, 85%) as a colourless oil; (Found: C, 63.6; Ii, 10.3%; lit+- 
OCH3,213.1463. C13H2404 requires C, 63.9; H, 9.9%; M+"0CI13,213.1480); [a]D 
+25.75 (c 1.165 in CHC13); Vmax(cm"l): 2850 (OCHS), 1722 and 1714 (ester C=O) 
and 1650 (C=C); 811 (400 MHz CDC13): 6.97 (dd, J 7.9 and 15.7 IIz, COCII: Cjj), 
5.82 (dd, J 1.2 and 15.7 Hz, COC : CH), 4.63 (OCtOCH3), 4.18 (q, J 7.1 Iiz, 
OCH2CH3), 3.39 (OCt), 3.20 (t, J 5.4 Hz, CIOH(1Pr)), 2.59 (app hext, J 6.9 IIz, 
: CHCH. (CH3)), 1.80 (app oct, J 5.4 Hz, CH(CLi(CH3)2)), 1.29 (t, J 7.1 IIz, 
OCH2CH3), 1.10 (d, J 6.9 Hz, CH(Ct)CHOH) and 0.93 (app dd, J 6.9 and 9.21lz, 
CH(Cji )2); SC (100 MHz CDC13): 166.5 (s), 152,0 (d), 120.4 (d), 98.1 (t), 86.9 
(d), 60.1 (t), 55.9 (q), 39.4 (d), 30.7 (d), 20.0 (q), 17.4 (q), 14.7 (q) and 14.2 (q); 
m/z (EI): 213 (34%, M+-OCHS), 183 (16, M+-OMOM), 141 (80) and 45 
(100, MOMOf). 
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(E)-N-Propargyl-(4R)-methyl- (SR)-(methoxy)methoxy. 6-rnethyl-2- 
heptenamide (224). 
O OMOM 
/% H" 
A solution of trimethylaluminium 2M in CH2C12 (78.35 em3,156.7 mmol) was added 
dropwise, over 30 min, to a stirred solution of propargylamine (10.75 cm3,156.7 
mmol) in dry CH2C12 (250 cm3) at 0°C, under an atmosphere of nitrogen, in a 
scrupulously dried flask. The mixture was stirred at room temperature for 30 min and 
the protected hydroxyester (223) (9.57 g, 39.17 mmol) was added in one portion. 
The mixture was heated under reflux for 3h and then cooled to 0°C before carefully 
quenching with water (50 cm3). The mixture was extracted with CH2CI2 (3 x 100 cm3) 
and the extracts were combined. The dried solution (MgSO4) was concentrated in 
vacuo and the residue was then purified using flash chromatography (3% McOll in 
CH2C12) to give the amide (7.5 g, 80%) as a colourless oil; (Found: C, 66.4; 11,9.3; 
N, 5.4%; M+-OCHS, 222.1506. C14H23N03 requires C, 66.4; H, 9.2; N, 5.5%; Af+- 
OCH3,222.1494); [aID +17.25 (c 1.125 in CHC13); Vmax(cm-1): 3480 (N-I1), 1667 
(amide C=O), 1633 (C=C) and 1537 (amide dimer); 51, (400 MHz CDC13): 6.84 (dd, J 
8.0 and 15.4 Hz, COCH: CJ ), 5.85 (NILCO), 5.80 (dd, J 1.2 and 15.4 Hz, 
COCH.: CH), 4.64 (OCtOCH3), 4.12 (dd, J 1.7 and 2.8 Hz, HCCC ), 3.39 
(O C ), 3.17 (app t, J 5.4 Hz, CJjO R (iPr)), 2.56 (app hext, J 6.7 I ft, 
: CHCJj(CH3)), 2.24 (t, J 2.8 Hz, j. 000H2), 1.79 (app hext, J 6.7 liz, 
CH(CJj(CH3)2)), 1.09 (d, J 6.7 Hz, CH(CTh)CHOH) and 0.91 (app dd, J 5.3 and 
6.7 Hz, CH(Cth)2); So (67.8 MHz CDC13): 165.7 (s), 148.1 (d); 122.1 (d), 98.2 (t), 
87.4 (d), 79.5 (d), 71.3 (s), 55.9 (q), 39.2 (d), 30.6 (d), 28.9 (t), 20.0 (q) and 18.8 
(q); in/z (EI): 222 (95%, M+-OCHS), 192 (45, M+-OMOM), 150 (100), 68 (85) and 45 
(100). 
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(E)-N-Propargyl-(4R)-methyl- (SR)-hydroxy-6. metlxyl-2-heptenarnide 
(225). 
OH 
7%%N 
Bromotrimethylsilane (1.18 cm3,9.172 mmol) was added dropwise, over 5 min, to a 
stirred solution of the MOM ether (224) (581 mg, 2.293 mmol) in dry C112C12 (50 
cm3), at 
-78°C, under an atmosphere of nitrogen. The mixture was stirred at this 
temperature for lh and water (10 cm3) was added and the mixture then allowed to 
warm to room temperature. The mixture was extracted with CH2C12 (50 cm3) and the 
extracts were then combined and washed with brine (2 x 25 cm3). The dried solution 
(MgSO4) was concentrated in vacuo to leave the hydroxyamide (524 mg, 95%) as a 
colourless oil: (Found: M+-isobutyraldehyde, 137.0846 
. 
C121119NO2 requires Af+- 
isobutyraldehyde, 137.0841 ); [Y-)p +19.70 (c 0.355 in CHC13); V, 
m, x(cm-1): 3432 
(N"H and O-H), 1738 (amide C=O), 1242 (O-H) and 966 (trans C=C-I1); Xmax 
(EtOH)/nm (c): 215 (6066); Stt (500 MHz CDC13): 6.84 (dd, J 7.8 and 15.4 IN, 
COCH: CID, 6.05 (NJjCO), 5.85 (dd, J 1.0 and 15.4 Hz, COCII: CH), 4.11 (dd, J 
2.5 and 5.0 Hz, HCCCt), 3.26 (app t, J 6.8 Hz, CJIOH(iPr)), 2.49 (app dq, J 0.8 
and 6.8 Hz, : CHC 
, 
(CH3)), 2.24 (t, J 2.5 Hz, HCCCH2), 2.09 (CHO 
, 
1.71 (app 
oct, J 6.8 Hz, CHOH(Cff (CH3)2), 1.08 (d, J 6.8 Hz, : CHCH(Ct)) and 0.92 (app 
dd, J 3.4 and 6.8 Hz, CHOH(CH(CJb)2); 6c (100 MHz CDC13): 166.1 (s), 148.5 
(d), 122.4 (d), 79.1 (d), 71.4 (s), 39.5 (d), 30.8 (d), 29.9 (t), 19.6 (q), 17.2 (q) and 
13.5 (q); m/z (EI): 181 (15%), 169 (15 ), 137 (30, U+-isobutyraldehyde), 82 (25. Af+- 
isobutyraldehyde, 
-propargylamine), 69 (100) and 55 (30, propargylamine). 
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(E). N-Prop argyl-(4R)-methyl- (5R)-acetoxy-6-methyl-2. h eptenamlde 
(226). 
O OAc 
ýN 
f /Hý 
Acetyl chloride (0.273 cm3,3.723 mmol) was added dropwise, over I min, to a stirred 
solution of the hydroxyamide (225) (524 mg, 2.327 mmol. ) and pyridine (0.309 cm3, 
3.723 mmol. ), in dry CH2C12 (20 cm3), at 0°C. DMAP (10 mg) was added and the 
mixture was then stirred overnight while allowing to warm to room temperature. The 
mixture was washed with 1M HCl (50 cm3), then washed with saturated Na2C03 (50 
cm3), and finally with brine (50m1). The dried solution (MgSO4) was concentrated in 
vacuo and the residue was then purified using flash chromatography (3% McOH in 
CH2CI2) to give the amide (542 mg, 95%) as a colourless oil; (Found: M+-acetic acid, 
192.1395 
. 
C14H21N03 requires M+-acetic acid, 192.1388 ); ["ID +5.50 (c 1.055 in 
CHC13); Vmax(cm-1): 3269 (N-H), 1731 (ester C=O), 1667 (amide C=O), 1632 
(C=C), 1537 (amide dinier) and 985 (trans C=C-H); X.,, (EtOH)/nm (E): 216 (6300); 
Sit (500 MHz CDC13): 6.74 (dd, J 8.1 and 15.4 Hz, COCH: C 
, 
5.82 (dd, J 0.9 and 
15.4 Hz, COCff: CH), 5.64 (NUCO), 4.78 (dd, J 5.0 and 7.0 Hz, CH(CH3)CIJOAc), 
4.12 (dd, J 2.6 and 5.3 Hz, HCCCt), 2.63 (app sext, J 7.0 HIz, : CLICUi(C113)), 
2.25 (t, J 2.6 Hz, JjCCCH2), 2.08 (COCA), 1.87 (app doct, J 1.6 and 5.0 Hz, 
CHOAc(Cfl(CH3)2), 1.03 (d, J 7.0 Hz, : CHCH(C )) and 0,88 (app dd, J 5.0 and 
7.0 Hz, CHOH(CH(Ct)2); SC (100 MHz CDC13): 170.8 (s), 165.4 (s), 145.8 (d), 
123.2 (d), 79.5 (d), 71.2 (s), 38.2 (d), 29.6 (d), 28.9 (t), 20.6 (q), 19.5 (q), 16.1 (q) 
and 15.2 (q); m! z (EI): 251 (3%, M+), 137 (80, M+-Ac, 
-isobutyraldehyde), 69 (85), 
55 (20, propargylamine) and 43 (100, Ac). 
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(E)-N-(3-tri-n-butylstannylprop-2-enyl)-(4R)-methyl. (SR)-acetoxy-6- 
methyl-2-heptenamide (227). 
O OAc 
Bu3Sn isi / ~'''ý 
Copper (I) cyanide (190 mg, 2.123 mmol) was suspended in dry THE (40 cm3), under 
an atmosphere of nitrogen, in a scrupulously dried flask. The mixture was cooled to 
-78°C and a solution of n-butyllithium 1.6M in hexanes (2.53 cm3,4.053 mmol) was 
added dropwise, over 5 min, and the mixture was then stirred at 
-78°C for 15 min. Tri- 
n-butyltin hydride (1.10 cm3,4.053 mmol) was added dropwise, over 5 min, and the 
mixture was then stirred for a further 15 min at 
-78°C. A solution of the amide (226) 
(485 mg, 1.930 mmol) in dry THE (1 cm3) was added dropwise, over 5 min, and the 
mixture was stirred for 30 min at 
-78°C before being quenched with 10% NH3/N114C1 
solution (5 em3). The mixture was allowed to warm to room temperature and the solids 
were filtered off. The filtrate was extracted with ethyl acetate (3 x 25 em3) and the 
extracts were then combined and washed with brine. The dried solution (MgSOW) was 
concentrated in vacuo and the residue was then purified using flash chromatography 
(10% ethyl acetate in petroleum ether) to give the vinyl stannane (711 mg, 70%) as a 
colourless oil; (Found: MH+, 540.2816. C26H49NO3Sn requires MfP, 540.2808); 
["ID +0.75 (c 0.805 in CHC13); Vmax(cm-1): 3275 (N-H), 1744 (ester C=O), 1668 
(amide C=O), 1633 (C=C), 1556 (amide dimer) and 986 (trans C=C-1H); Xm$x 
(EtOH)/nm (E): 214 (12 996); 811 (500 MHz CDC13): 6.69 (dd, J 8.2 and 15.411z, 
COCH: CJ, ), 6.10 (dt, J 19.0 and 1.3 Hz, SnCU: CH), 5.96 (dt, J 19.0 and 5.3 Hz, 
SnCH: Cf), 5.83 (dd, J 0.8 and 15.4 Hz, COCII: CH), 5.68 (t, J 5.3 llz, NUCO), 
4.75 (dd, J 5.0 and 7.4 Hz, CH(CH3)CJjOAc), 3.97 (app dt, J 1.4 and 5.3 Hz, 
: CHCt), 2.60 (app sext, J 7.4 Hz, : CHCJj(CH3)), 2.05 (COCJJ3), 1.86 (app oct, J 
5.0 Hz, CHOAc(CIj(CH3)2), 1.52 (pent, J 7.4 Hz, SnC1i2Cjjz), 1.28 (Sept, J 7.4 
Hz, SnCH2CH2CIj2), 1.03 (d, J 7.4 Hz, : CHCH(CJ )) and 0.88 (app t, J 7.4 Hz, 
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CHOH(CH(C )2) and SnCtCH2CH2CIb); 8c (125 MHz CDC13): 170.9 (s), 
165.4 (s), 145.3 (d), 143.5 (d), 130.3 (d), 123.9 (d), 79.8 (d), 44.9 (t), 38.4 (d), 
29.8 (d), 29.1 (t), 27.3 (t), 20.9 (q), 19.7 (q), 16.4 (q), 15.4 (q), 13.7 (q) and 9.5 (t); 
rn/z (EI): 543 (3%, M+), 486 (20, M+-Bu), 426 (65, M+-Ac, 
-isobutyraldehyde), 291 
(10, Bu3SnH), 69 (100), 55 (10, propargylamine) and 43 (40, Ac). 
(E)-N-(3-tri. n-butylstannylprop-2-enyl)-(4R)-methyl. (SR). hydroxy. 6. 
methyl-2-heptenamide (222). 
0 011 
Bu3Sn N 
Potassium hydroxide (273 mg, 4.867 mmol) was added, in one portion, to a stirred 
solution of the acetoxyamide (227) (563 mg, 0.9733 mmol) in wet methanol (15 cm3) 
and the mixture was then stirred at room temperature for 3 h. Brine (5 ems) was added 
and the mixture was extracted with CH2C12 (3 x 15 cm3) and the extracts then 
combined. The dried solution (MgSO4) was concentrated in vacuo to leave the 
hydroxyamide (4.9g, 98%) as a colourless oil; (Found: C, 57.6; 1.1,9.65; N, 3.1 %; 
M+-Bu, 444.1148. C24H46NO3Sn requires C, 57.5; H, 9.4; N, 2.8%; M+-Bu, 
444.1166); [a]D +14.55 (c 0.275 in CHC13); Vmax(cm-1): 3288 (N"H), 1667 (amide 
C=O), 1632 (C=C), 1557 (amide dimer) and 986 (trans C=C-H); 
, max 
(EtOI-I)/nm (e): 
208 (12 404) and 220 (13 798); 811(500 MHz CDC13): 6.83 (dd, J 7.9 and 15.4 Hz, 
COCH: Cf), 6.13 (dt, J 19.0 and 1.3 Hz, SnCLI: CH), 5.98 (dt, J 19.0 and 5.3 Hz, 
SnCH: CJj), 5.85 (dd, J 1.0 and 15.4 Hz, COCIJ: CH), 5.54 (NIICO), 4.00 (app t, J 
5.3 Hz, : CHCt), 3.28 (app q, J 5.3 Hz, CH(CH3)ClOH), 2.51 (app scxt, J 6.7 
Hz, CJj(CH3)CHOH), 1.75 (app oct, J 6.7 Hz, : CHCII(CI13)), 1.52 (pent, J 6.7 Hz, 
SnCH2CJ), 1.28 (sept, J 6.7 Hz, SnCH2CH2CIU, 1.03 (d, J 6.7 Ilz, 
: CHCH(CIL)) and 0.88 (app t, i 6.7 Hz, CHOH(CI1(CIL3)2) and 
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SnCff 2CH2CH2CH3); Sc (67.8 MHz CDC11): 165.8 (s), 147.5 (d), 143.3 (d), 129.9 
(d), 123.1 (d), 79.0 (d), 39.5 (d), 30.7 (d), 28.9 (t), 27.1 (t), 19.6 (q), 16.9 (q), 13.7 
(q), 13.5 (q) and 9.2 (t); m/z (EI): 444 (5%, M+-Bu), 372 (45, M +- ß u, 
-isobutyraldehyde), 119 (55) and 69 (100). 
N-Trifluoroacetate-(R)-proline (228). 104 
HOZC, 
GNTFA 
Triethylamine (0.581 cm3,4.169 mmol) was added dropwise, over 2 min, to a stirred 
solution of (R)-proline (480 mg, 4.169 mmol) in dry McOH (5 cm3), at room 
temperature, under an atmosphere of nitrogen. Ethyl trifluoroacctate (0.595 cm3,5 
mmol) was added dropwise and the mixture was then stirred overnight at room 
temperature. The solvent was removed in vacuo and the residue was taken up in ethyl 
acetate (10 cm3). The solution was washed with 2M HC1(5 cm3) and the dried solution 
(MgSO4) was conentrated in vacuo to leave a 4: 1 mixture of rotamers of the protected 
proline (752 mg, 86%) as a colourless sticky solid: Vmax(em-1): 3160 (0"H), 1732 
(acid C=0), 1683 (amide C=0) and 1232 and 758 (C-F); 811(400 MHz CDCI3): 4.71 
(d, J 8.9 Hz, 0.2 H, HOZCCHJ, 4.57 (dd, J 3.9 and 8.9 Hz, 0.8 H, H02CCII), 3.84 
(m, I H, CONCL. H), 3.76 (m, 1 H, CONCHID, 2.30 (m, 1 H. COCHC, 1-1) and 
2.05-2.20 (m, 3 H, COCHCHU and COCHCH2Cth); 8c (67.8 MHz CDCI3): 176.2 
(s), 156.6 (q, J 5.8 Hz, 
_COCF3), 116.2 (q, J 24.5 Hz, CO. QF3), 69.0 (d), 59.2 (d), 
48.0 (t), 47.2 (t), 31.5 (t), 28.4 (t), 24.8 (t) and 21.0 (t). 
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(E, E)-N-(3-tri-n-butylstannylprop-2-enyl)-(4R)-methyl. (SR)-(N'- 
trifluoro acetoxy-(R)-prolinoyloxy)-6-methyl-2-heptenamide (229). 
O TFA 
OO 
Bu3Sn ý'' 
DCC (124 mg, 0.5995 mmol) was added, in one portion, to a stirred solution of the 
proline (228) (116 mg, 0.5496 mmol), DMAP (122 mg, 0.9992 mmol), and the 
alcohol (222) (250 mg, 0.4996 mmol) in dry CH2C12 (2 cm3), at 0°C, under an 
atmosphere of nitrogen. The mixture was stirred for 48 h and was then washed with 
water (10 cm3). The dried solution (MgSO4) was concentrated in vacuo and the 
residue was then purified using flash chromatography (2% MeOH in CH201) to give a 
4: 1 mixture of rotamers of the ester (350 mg, 61%) as a colourless oil; (Found: C, 
54.1; H, 7.9; N, 4.4%; MH+, 691.3029. C31H53F3N204Sn requires C, 53.6; H. 7.7; 
N, 4.0%; MH+, 691.3053); vma,, (cm-1): 3210 (N-H), 1747 (ester C=O), 1697 (amide 
C=O), 1634 (C=-C) and 1539 (amide dimer); ý,. (EtOH)/nm (c): 211 (9852); Stt (500 
MHz CDC13): 6.64 (dd, J 6.6 and 15.5 Hz, COCH: Cli), 6.12 (d, J 19 Hz, SnCII: ), 
5.98 (dt, J 19.0 and 5.2 Hz, SnCH: Cj), 5.83 (d, J 15.5 Hz, COCII: C11), 5.72 (t, J 
5.2 Hz, NIB, 4.81 (app t, J 6.6 Hz, CH(CH3)CH QPr)), 4.60 (dd, J 3.6 and 8.7 Hz, 
COCUNCO), 3.99 (app q, J 5.2 Hz, NHCtCH: ), 3.82 (m, COCFHCIIH), 3.74 (m, 
COCHCH 
. 
), 2.66 (app hext, J 6.6 Hz, : CHCII(CH3)), 2.25 (m, CIIN(CO)CIII1), 
2.08 (m, 3 H, CHN(CO)CHJ CII2), 1.92 (app oct, J 6.6 Hz, CH(Cfl(C113)2)), 1.47 
(pent, J 7.4, SnCH2Cfl2), 1.30 (hext, J 7.4 Hz, SnCH2C1-12Cth), 1.04 (d, J 6.6 I ft, 
: CHCH(Ct)), 0.92 (app dd, J 6.6 and 9.2 Hz, CH(CH(Ct)2)) and 0.89 (t, J 7.4 
Hz, SnCthCH2CH2C ); 8C (125 MHz CDC13): 170.4 (s), 165.4 (s), 155.7 (q, J 
6.0 Hz, 
_COCF3), 144.7 (d), 143.4 (d), 130.3 (d), 124.3 (d), 116.0 (q, J 24.7 liz, 
CO. CF3), 81.5 (d), 60.4 (d), 47.1 (t), 44.9 (t), 37.9 (d), 29.8 (t), 29.0 (d), 28.7 (t), 
27.3 (t), 24.9 (t), 19.5 (q), 17.1 (q), 14.3 (q), 13.7 (q) and 9.4 (t); nilz (FAB): 695 
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(85%, MHf), 637 (60, M+-Bu), 426 (75, M+-Bu, 
-TFApro), 291 (15, Bu3SnHH) and 
177 (100). 
(E, E)-N- (3- tri-n- butylstannylprop-2-enyl)-(4R)-methyl. (SR). ((R). 
prolinoyloxy)-6-methyl-2-heptenamide (230). 
OH 
O 
Bu3SnT 
Potassium carbonate (84 mg, 0.6043 mmol) was added, in one portion, to a stirred 
solution of the ester (229) (381 mg, 0.5494 mmol) in wet MeOH (5 cm3) at room 
temperature, and the mixture was stirred overnight. The solvent was removed in vacuo 
and the residue was taken up in ethyl acetate (5 cm3). The solution was washed with 
saturated Na2CO3 (5 cm3) and the dried solution (MgSO4) was concentrated in vacua. 
The residue was purified using flash chromatography (5% MeOH in ethyl acetate) to 
give the amine (301 mg, 95%) as a colourless oil; [a]D +16.20 (c 0.42 in CFIC13); 
Vmax(cm-1): 3300 (N-H), 1738 (ester C=O), 1680 (amide C=O), 1650 (C=C) and 
1570 (amide dimer); Xma,, (EtOH)/nm (e): 210 (10 306); 81, (500 Mliz CDC13): 6.71 
(dd, J 7.8 and 15.4 Hz, COCH: CJ), 6.13 (dt, J 19.0 and 1.0 Hz, SnCJJ: ), 5.97 (dt, J 
19.0 and 5.6 Hz, SnCH: Cf ), 5.84 (dd, J 0.8 and 15.4 Hz, COCII: ), 5.56 (t, J 5.6 
Hz, CON, ), 4.83 (app t, J 6.8 Hz, CJ, O R (1Pr)), 4.00 (app q, J 5.6 l Iz, 
NHCtCH: ), 3.80 (dd, J 5.4 and 8.4 Hz, COCUNIi), 3.09 (dt. J 10.2 and 6.8 liz, 
NHCIIHCH2), 2.92 (dt, J 10.2 and 6.8 Hz, NHCHUCH2), 2.67 (app sext, J 6.8 I iz, 
: CHCJI(CH3)), 2.42 (m, 1H COCHCIJH), 2.15 (m, 1H COCIICHW, 1.89 (app 
oct, J 6.8 Hz, CHOR(CJi(CH3)2)), 1.70-1.82 (m, 2 H, COCHC112C ), 1.49 (pent, 
J 7.2 Hz, SnCH2Cth), 1.31 (hext, J 7.2 Hz, SnCH2CH2Cth), 1.05 (d, J 6.7 liz, 
:CHCH (C ib)) and 0.89 (app t, J 7.2 Hz, SnCILC 1120 I12C 3 and 
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CHOR(CH(C)2)); 8c (125 MHz CDC13): 175.2 (s), 165.3 (s), 145.2 (d), 143.4 
(d), 130.4 (d), 123.9 (d), 80.5 (d), 59.9 (d), 46.9 (t), 44.9 (t), 38.2 (d), 30.5 (t), 29.7 
(d), 29.0 (t), 27.3 (t), 25.4 (t), 19.6 (q), 16.8 (q), 14.7 (q), 13.7 (q) and 9.4 (t); 
(E, E, E, E)-N-(3-Tri-n-butylstannylprop-2-enyl)-(4R)-methyl. (SR)-N'- 
((2-(6-bromo-2-hydroxypent-3,5-dienyl)oxazol-4-ylcarbonyl). (R)- 
prolinoyl oxy)-6-methylhept-2-eitamide (221). 
O 
H/ SnBu3 
, 
p'" 
Al".. 
it 
ONI Br 
0 OH 
EDC (48 mg, 0.2511 mmol) was added, in one portion, to a stirred solution of the acid 
(199) (56 mg; 0.1841 mmol) in dry CH2C12 (5 cm3), at 0°C, under an atmosphere of 
nitrogen. The mixture was stirred for 30 min and then HOBt (29 mg, 0.2093 mmol) 
and triethylamine (0.035 cm3,0.2511 mmol) were added, in one portion, followed by 
the addition of the amine (230) (100 mg, 0.1674 mmol). The mixture was stirred 
overnight and then washed with water (10 cm3). The dried solution (MgSO4) was 
concentrated in vacuo and the residue was then purified using flash chromatography 
(2% MeOH in CH2C12) to give a mixture of diastereoisomers of the amide (165 mg, 
61%) as an orange oil as; Vmax(cm-1): 3293 (N-H, O-H), 1742 (ester C=0), 1668 
(amide C=O), 1631 (C=C), 1548 (amide dimer) and 985 (trans-C=C-11), %max 
(EtOH)/nm (c): 222 (12 098) and 232 (9870); 811 (500 MHz CDC13): 8.14 (m, 111, 
oxazole : CJj), 6.61 (ddd, J 7.6,15.6 and 15.6 Hz, COCH: CJ), 6.35-6.50 (m, 2 I1, 
CHOHCLI: CHCII: C), 6.13 (dd, J 4.2 and 19.0 Hz, SnCH: ), 5.95.6.05 (m, 1 I1, 
S NC H: Cam, 5.97 (d, J 15.6 Hz, COCI,: CH), 5.65-5.75 (m, 2 11, NI I and 
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CHOHCH: CLD, 4.80 (m, 1 H, Cf lOR(iPr)), 4.66 (dd, J 3.8 and 8.0 Hz, COCUN), 
4.10 (m, 1 H, CONCLIH), 3.96 (m, 2 H, CONHCH2), 3.92 (m, 1 H, CONCIIU), 
3.78 (m, 1 H, CH2CEOH), 2.85-3.05 (m, 2 H, CJ12CHOH), 2.64 (hext, J 6.6 Eiz, 
: CHCJj(CH3)), 2.39 (d, J 4.3 Hz, C(C )Br), 2.25-2.30 (m, 2 11, COCHHCJ), 
1.98-2.08 (m, 2 H, COCHCH2CH2), 1.80 (O11), 1.46 (app dpent 
,J2.2 and 8.0 Hiz, 
SnCH2CU2), 1.28 (app dhext, J 2.2 and 8.0 Hz, SnCHZCHZCt), 1.01 (app dd, J 
1.0 and 6.6 Hz, : CHCH(CH3)), 0.93 (app dd, J 2.2 and 6.6 Hz, CH(CH(C, h)2)) and 
0.89 (t, J 8.0 Hz, SnCtCH2CH2CLb); Sc (100'MHz CDC13): 172.7 (s), 171.7 (s), 
165.1 (s), 161.9 (s), 161.8 (s), 160.1 (s), 143.6 (d), 143.5 (d), 143.4 (d), 143.3 (d), 
136.7 (s), 136.6 (s), 134.5 (d), 134.4 (d), 131.3 (d), 131.1 (d), 130.4 (d), 130.2 (d), 
125.2 (d), 125.1 (d), 124.1 (d), 124.0 (d), 123.7 (d), 123.6 (d), 81.2 (d), 81.1 (d), 
69.2 (d), 69.1 (d), 61.2 (d), 61.0 (d), 47.3 (t), 47.2 (t), 45.0 (t), 44.9'(t),, 37.9 (d), 
37.8 (d), 31.6 (t), 30.2 (d), 30.1 (d), 29.0 (t), 27.3 (t), 25.3 (t), 23.8 (q), 23.7 (q), 
21.6 (t), 19.6 (q), 19.5 (q), 17.9 (q), 17.8 (q), 14.3 (q), 14.2 (q), 13.6 (q) and 9.4 (t); 
14,15-Anhydro- 16,37-dihydrovirgin iamycin M2 (7). 
0 
off. 
""" o0 
0 
A solution of triphenylarsine (2.25 mg, 7.352 tmol) in dry DMF (1 cm3) was added 
dropwise, over 2 min, to a stirred solution of tris(benzylideneacetone)dipalladium(0) 
(0.84 mg, 0.919 µmol) in dry DMF (8 cm3) at room temperature, under an atmosphere 
of nitrogen, in a scrupulously dried flask. The mixture was stirred for 30 min and a 
solution of the precursor (221) (81 mg, 0.0919 mmol), in dry DMF (1 cm3), was 
143 
added dropwise over 2 min. The mixture was heated at 100°C for 18 h and was then 
allowed to cooled to room temperature. The solvent was removed in vacuo and the 
residue was purified using flash chromatography (5% MeOH in CH202) to give the 
tinacrolide (21 mg, 40%) as a pale yellow oil as a mixture of diastereomers. (The 
product was found to decompose readily at room temperature or over long periods at 
-20°C); (Found M++Na (Electrospray) 534.2492. C28H37N306 requires M++Na 
534.2580); vmax(cm-1): 3385 (NH and OH), 1741 (ester C=O), 1678 (amide C=O), 
1618 (C=C) and 969 (trans-C=C-H); ' ax (EtOH)/nm (e): 210 (91000) and 278 (84 
850); Sn (500 MHz CDC13): 8.12 (oxazole : CH, 0.6 H), 8.10 (oxazole : CH, 0.4 H), 
6.51 (dd, J 5.3 and 16.1 Hz, 0.6 H, COCH: CH), 6.47 (dd, J 5.3 and 16.1 Hz, 0.4 H, 
COCH: Cl), 6.41 (ddd, J 1.9,11.1 and 15.1 Hz, 0.6 H, CHOHCI.: ), 6.32 (ddd, J 
1.9,11.1 and 15.1 Hz, 0.6 H, CHOHCE: ), 6.24 (d, J 15.1 Hz, CH: CUC(C113)), 
5.98 (app t, J 11.1 Hz, C(CH3): CLLCH: ), 5.77 (dd, J 1.9 and 16.1 Hz, 0.6 11, 
COCJ.: ), 5.75 (dd, J 1.9 and 16.1 Hz, 0.4 H, COCJj: ), 5.66-5.75 (m, NHCH2CI: ), 
5.65 (dd, J 7.1 and 15.1 Hz, CHOHCHi: CH), 5.61 (m, NI J), 4.74 (dd, J 1.9 and 10.3 
Hz, 0.6 H, Cf ('Pr)OR), 4.71 (dd, J 1.9 and 10.3 Hz, 0.4 H. Cf (iPr)OR), 4.67 (dd, 
J1.9and 8.7Hz, 0.6H, COCfl: ), 4.63(dd, J1.9and 8.7Hz, 0.4fig COCU: ), 4.03 
(app pent, J 7.1 Hz, CONCHH), 3.91 (m, 2 H, NHC112CH: ), 3.76 (m, CONCIIID, 
3.67 (ddd, J 1.9 and 7.1 and 11.1 Hz, 0.6 H, CH2CIOH), 3.56 (ddd, J 1.9 and 7.1 
and 11.1 Hz, 0.4 H, CH2CIIOH), 3.04-3.26 (m, C CHOH), 2.72 (m, 
: CHCII(CH3)), 2.06 (m, 2 H, COCHCHi), 1.80-1.98 (m, 3 H, COCHC112CIJ2 and 
CHOR(CJj(CH3)2)), 1.79 (2 H, C(CJb): CH), 1.77 (1 H. C(Cth): C11), 1.08 (d, J 
5.3 Hz, 2 H. : CHCH(C)), 1.07 (d, J 5.3 Hz, 1 H, : CHCH(C)), 0.94 (app t, J 
7.0 Hz, 4 H. CHOR(CH(CHj)2)) and 0.91 (app t, J 7.0 IIz, 2 111 
CHOR(CH(C )2)); 8c (125 MHz CDC13): 171.5 (s), 166.6 (s), 160.5 (s), 160.2 (s), 
145.4 (d), 145.3 (d), 143.2 (d), 138.8 (d), 138.5 (d), 136.8 (s), 135.5 (s), 135.2 (d), 
134.9 (d), 130.3 (d), 129.9 (d), 127.5 (d), 127.0 (d), 124.2 (d), 124.1 (d), 124.0 (d), 
81.7 (d), 81.6 (d), 70.6 (d), 70.7 (d), 59.5 (d), 59.4 (d), 48.9 (t), 48.8 (t), 41.4 (t), 
41.1 (t), 37.0 (d), 36.9 (d), 36.1 (t), 36.0 (t), 28.9 (t), 24.6 (t), 19.9 (q), 18.7 (q), 
144 
13.0 (q), 9.8 (q) and 9.6 (q); m/z (Electrospray): 550 (15%, M++K), 534 (100, 
M++Na) and 512 (20, M++H). 
14,15-An hydro virgin iamycin M2 (6). 98 
O 
". 
IH(O 
J'ý 
N 
Dess-Martin's periodinane (21 mg, 0.05 mmol) was added carefully, in one portion, to 
a stirred solution of the macrocycle (7) (21 mg, 0.04 mmol) in dry CH2C12 (2 em3) 
and the mixture was then stirred at room temperature for 10 min. Dess-Martin's 
periodinane (63 mg, 0.15 mmol) was agian added, in three portions, at 10 min 
intervals, and the mixture was stired for a further 10 min. The mixture was washed 
with sodium thiosulphate solution (5 cm3) and then extracted with ether. The dried 
solution (Na2SO4) was concentrated in vacuo and the residue was then purified using 
flash chromatography (5% MeOH in CH2C12) to give 14,15-anhydrovirginiamycin M2 
(12 mg, 59%) as a pale yellow foam; (Found: M+, 510.2590. C28113ON306 requires 
M+, 510.2604); V. 
ax 
(cm-1): 3448 (N-H), 1738 (ester C=O), 1674 (ketone and amide 
C=O), 1623 (C=C), 1558 (amide dimer) and 978 (trans-C=C-11); 811 (500 MHz 
CDC13): 8.18 (oxazole C-J), 7.57 (dd, J 15.0 and 11.7 Hz, C(CH3): CIHCLI: CHHH), 
6.65 (dd, J 15.7 and 5.7 Hz, CH(CH3)CJ.: CHCO), 6.33 (d, J 15.0 Hz, 
C(CH3): CHCH: CJ, CO), 6.29 (d, J 15.6 Hz, NHCH2CH: Cf, 6.17 (d, J 11.7 Hz, 
C(CH3): CflCH: CH), 5.95 (dt, J 15.6 and 6.2 Hz, NHCH2Cfl: CH), 5.79 (dd, J 15.7 
and 1.6 Hz, CH(CH3)CH: CIICO), 5.68 (t, J 6.1 Hz, N13,4.79 (m, OCfl(1Pr)C11), 
4.14 (dt, J 15.4 and 6.4 Hz, CONHCHHCH: ), 3.93 (CH: CH000JJ2), 3.91-3.76 (m, 
CONHCHfCH: and CONCH), 2.25 (m, CH('Pr)C 
, 
(CH3)), 2.09 (m, 
145 
COCHCIIHCH2), 2.02 (CH: CHC(Ct): CH), 1.95 (m, COCH(Cfi(C[13)2) and 
COCHCHJ. CH2), 1.78 (m, COCHCH2CjIH), 1.65 (m, COCHCH2CHJ3. ), 1.11 
(CH(iPr)CH(CtI )), 0.99 (COCH(CH(C )2)) and 0.96 (COCH(CH(CI13)2)); SC 
(125 MHz CDCl3): 192.9 (s), 170.8 (s), 165.5 (s). 160.1 (s), 158.2 (s), 146.8 (d), 
144.5 (s), 143.8 (d), 139.1 (d), 138.3 (d), 137.3 (s), 128.9 (d), 128.4 (d), 128.3 (d), 
123.4 (d), 81.6 (d), 59.4 (d), 48.9 (t), 42.0 (t), 40.4 (t), 36.9 (d), 29.6 (d), 28.6 (t), 
24.5 (t), 19.7 (q), 18.8 (q), 13.9 (q) and 10.4 (q); m/z (FAB): 510 (100%, M4), 357 
(5), 311 (16), 242 (4), 205 (7), 178 (21), 154 (40), 137 (46) and 95 (48. 
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